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Multidrug resistant tuberculosis (MDR-TB), defined as having resistance to at least the first-
line drugs, isoniazid and rifampicin (RIF), is a global health problem. Mutations in the rpoB 
gene, encoding the β-subunit of RNA polymerase, are implicated in RIF resistance - with the 
S531L and H526Y mutations occurring most frequently. The level of RIF resistance varies 
for strains with identical rpoB mutations, which suggests that other factors play a role in RIF 
resistance. Efflux has been implicated in determining the intrinsic level of RIF resistance. 
Increased expression of the multidrug efflux pump, Rv1258c, following RIF exposure was 
observed in some Mycobacterium tuberculosis MDR clinical isolates and H37Rv RIF mono-
resistant mutants, but not others. The factors influencing the induction of Rv1258c are poorly 
understood. 
 
The aim of this study was to investigate the effects of rpoB mutations on expression of 
Rv1258c and whiB7, a transcriptional regulator of Rv1258c, in M. tuberculosis H37Rv in 
vitro generated RIF resistant mutants, in the absence and presence of RIF. 
 
The promoter region of M. tuberculosis H37Rv Rv1258c was cloned into a position upstream 
of a lacZ gene (encoding β-galactosidase) in multi-copy episomal and integrating vectors. 
Vector functioning and the effect of rpoB mutations on Rv1258c promoter activity were 
initially investigated in the non-pathogenic related species, Mycobacterium smegmatis 
mc
2
155 rpoB mutants and subsequently in M. tuberculosis by doing β-galactosidase assays. 
qRT-PCR was done to investigate the effects of rpoB mutations on native Rv1258c and 
whiB7 gene expression. 
 
Episomal and integrating vectors were functional and the integrating vector system was used 
for subsequent β-galactosidase assays in M. tuberculosis. Rv1258c promoter activity in the 
S531L mutant was approximately 1.5 times less and in the H526Y mutant 1.5 times higher 
than that of the wild-type in M. smegmatis. Similarly, Rv1258c promoter activity in the 
S531L mutant was approximately half and in the H526Y mutant approximately double that of 
the wild-type in M. tuberculosis. A similar trend in Rv1258c and whiB7 expression to those 
observed using β-galactosidase assays were observed when investigating the native Rv1258c 




differences were not significant. Exposure of the M. smegmatis and M. tuberculosis rpoB 
mutants to sub-inhibitory levels of RIF did not affect Rv1258c promoter activity. 
 
Mutations in rpoB had a marginal effect on Rv1258c and whiB7 transcript levels, but showed 
the same trend as that seen for Rv1258c promoter activity. It remains to be determined 
whether these differences are biologically significant. When considering efflux pumps as new 
targets for treatment, possible differences in efflux pumps expression due to different rpoB 































Multi-middel weerstandige tuberkulose (MDR-TB) word gedefinieer as weerstandigheid tot 
ten minste rifampisien (RIF) en isoniasied, wat deel van die eerstelyn anti-tuberkulose 
behandeling vorm. Mutasies in die rpoB geen, wat die β-subeenheid van die RNA polimerase 
enkodeer, word geassosieer met RIF weerstandigheid. S531L en H526Y rpoB mutasies kom 
die algemeenste voor. RIF weerstandigheids vlakke verskil egter tussen isolate met identiese 
rpoB mutasies, wat impliseer dat ander faktore ook „n rol in RIF weerstandigheid speel. „n 
Toename in transkripsie van die Rv1258c geen, wat „n multi-middel effluks pomp enkodeer, 
is waargeneem met blootstelling aan RIF, slegs in sommige M. tuberculosis H37Rv RIF 
mono-weerstandige mutante and MDR kliniese isolate, maar nie in ander nie. Die faktore wat 
die induksie van die Rv1258c effluks pomp beïnvloed is nie goed nagevors nie. 
 
Die studie ondersoek die effek van die rpoB mutasies op die uitdrukking van die Rv1258c en 
whiB7, „n transkripsionele regulator van Rv1258c, gene in M. tuberculosis H37Rv in vitro 
gegenereerde RIF weerstandige mutante, in die teenwoordigheid en afwesigheid van RIF. 
 
Die promotor area van die M. tuberculosis H37Rv Rv1258c geen is in „n posisie stroomop 
van „n lacZ geen, wat vir β-galaktosidase enkodeer, in multi-kopie episomale en 
integreerende vektors ingekloneer. Die funksionaliteit van die vektor en effek van rpoB 
mutasies op Rv1258c promotor aktiwiteit is ondersoek in die naverwante nie-patogeniese 
spesies, M. smegmatis en daarna in M. tuberculosis deur β-galaktosidase essais te doen. qRT-
PCR is gedoen om die effek van rpoB mutasies op die vlak van transkripsie van die 
natuurlike Rv1258c geen en die whiB7 geen te bestudeer.  
 
Beide die episomale en integreerende vektors was funksioneel en daar is besluit om die 
integreerende vektor vir daaropeenvolgende β-galaktosidase essais in M. tuberculosis te 
gebruik. Rv1258c promotor aktiwiteit van die S531L mutant was ongeveer 1.5 keer minder as 
en die van die H526Y mutant 1.5 keer hoër as die van die ongemuteerde bakterië in  
M. smegmatis. Soortgelyk was die Rv1258c promoter aktiwiteit van die S531L mutant 
ongeveer die helfde van en die van H526Y mutant ongeveer dubbel die van die ongemuteerde 





„n Soortgelyke neiging in die vlakke van Rv1258c en whiB7 transkripte van die natuurlike 
geen is gedurende qRT-PCR waargeneem alhoewel die verskille nie beduidend was nie. 
Blootstelling aan sub-inhibitoriese konsentrasies van RIF het geen effek op Rv1258c 
uitdrukking in die M. smegmatis of M. tuberculosis rpoB mutante gehad nie. 
 
Die rpoB mutasies het net „n effense effek op Rv1258c en whiB7 transkrip vlakke in  
M. tuberculosis rpoB mutante, maar transkrip vlakke het „n soortgelyke neiging as die 
Rv1258c promoter aktiwiteit getoon. Of die waargenome verskille biologies betekenisvol is, 
moet nog bepaal word. Indien effluks pompe as teikens vir bahandeling gebruik sou word, 
moet in ag geneem word dat effluks pompe moontlik verskillend uitgedruk word in 
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CHAPTER 1: LITERATURE REVIEW: REGULATION OF MULTIDRUG 
 EFFLUX PUMPS 
 
Currently, drug-resistance in many clinically relevant human pathogens is a major problem 
worldwide. This is because of the adaptation of these pathogens and acquisition of numerous 
mechanisms that make them largely resistant to treatment with antibiotics and a wide range of 
other antimicrobial agents (Grkovic et al., 2002). Adaptation is necessary in order for bacteria 
to survive in the harsh environment that they have been exposed to over many years. Bacteria 
are constantly challenged by exposure to antibiotics, disinfectants and antiseptics that are 
widely used (Grkovic et al., 2001). Pathogenic bacteria will become increasingly resistant to 
these compounds if we do not elucidate and gain a complete understanding of the 
mechanisms of drug resistance as well as regulation and interconnectedness of these 
mechanisms, in order to effectively counteract them. Some mechanisms that are used by 
bacteria to evade the toxic effect of drugs include: drug inactivation and modification, using 
alternate metabolic pathways to overcome the effects of antimicrobial drugs on certain 
pathways, altering or mutating drug target sites and preventing drug entry into the cell by 
using permeability barriers or loss of porins as well as active efflux of drugs (Nikaido, 1998; 
Putman et al., 2000; Grkovic et al., 2002). 
 
Efflux has for long been implicated in drug resistance in bacteria, but has only recently been 
implicated in rifampicin (RIF) (Gupta et al., 2006; Louw et al., 2011), isoniazid (Srivastava 
et al., 2010), ethambutol (Gupta et al., 2006; Srivastava et al., 2010), streptomycin (Gupta et 
al., 2006), ofloxacin (Gupta et al., 2006; Singh et al., 2011), ethidium bromide, novobiocins 
and pyrroles (Balganesh et al., 2010) resistance in Mycobacterium tuberculosis.  
M. tuberculosis is the causative agent of the devastating disease, tuberculosis (TB). The 
development of drug resistance of this pathogen to almost all known antituberculosis drugs 
has necessitated research into the discovery of new drug targets. The finding that efflux 
pumps are involved in drug resistance in M. tuberculosis has lead to efflux pumps being 
considered as targets for drug development. One strategy involves the use of efflux pump 
inhibitors in combination with existing or new drugs as it was shown to increase 
susceptibility to the drugs (Balganesh et al., 2010; Louw et al., 2011; Balganesh et al., 2012). 
 
Efflux pumps are present in gram-positive and gram-negative bacteria. Some of these pumps 




bacterial efflux pumps have three membrane components across the cytoplasmic and outer 
membranes (Nikaido, 1998). Efflux pumps are divided into phylogenetic groups based on 
transport mode, energy source, structure, protein family, distribution of homologues in other 
organisms and substrate specificity (Saier et al., 1998; Putman et al., 2000; Van Bambeke et 
al., 2000). Primary active efflux pumps typically use energy from ATP hydrolysis as energy 
source while secondary active efflux pumps use the electrochemical proton or sodium ion 
gradients across the membrane as energy source (Putman et al., 2000; Van Bambeke et al., 
2000). The ATP binding cassette (ABC) superfamily efflux pumps are primary active efflux 
pumps and are phylogenetically similar based on topology, protein family, energy source and 
distribution of homologues (Saier et al., 1998). 
 
The secondary active efflux pumps are further divided into the major facilitator superfamily 
(MFS), small multidrug resistance (SMR) family, resistance-nodulation-cell division (RND) 
family and the multidrug and toxic compound extrusion (MATE) family based on their 
primary and secondary structures (Putman et al., 2000). The MFS efflux pumps are further 
divided into families based on sequence similarity where members within a family are 
homologous and these phylogenetic families correlate to function (Pao et al., 1998). The 
SMR and RND families are further divided into phylogenetic subfamilies based on their 
function (Saier et al., 1998). The MATE family efflux pumps are the most recently 
categorized (Kurodo & Tsuchiya, 2009). 
 
Some efflux pumps only extrude a specific drug or class of drugs whereas others can extrude 
a wide range of structurally unrelated compounds (multidrug efflux pumps) (Putman et al., 
2000). MDR efflux pumps have been identified in all of the efflux pump families (Pao et al., 
1998; Saier et al., 1998; Van Bambeke et al., 2000; Kurodo & Tsuchiya, 2009). Genes 
encoding multidrug efflux pumps are regulated at both local and global level by prokaryotic 
transcriptional regulators. These regulators are classified into families based on sequence 
similarity, structure and function (Ramos et al., 2005).  
 
Local transcriptional regulation provides regulation of a specific efflux pump adjacent or in 
close proximity the local regulator, thus providing a more confined transcriptional effect 
(Grkovic et al., 2001) while global transcriptional regulation simultaneously alters the 
expression of several genes located at different positions in the genome. This review will 




regulation in various bacteria including mycobacteria. The induction of efflux pumps by 
drugs they export, role of pH, metabolic energy and ions in modulating efflux pump function, 
regulation of efflux pumps by quorum sensing and physiological roles of efflux pumps are 
addressed.  
 
1.1 LOCAL REGULATION OF MULTIDRUG EFFLUX PUMPS 
 
1.1.1 Regulation by the drugs exported via the local regulators 
 
In many cases, multidrug efflux pumps are induced by antibiotics they export. This induction 
occurs via local regulators of the efflux pumps. In this case, drugs interact directly with a 
regulator, which in turn alters expression of the efflux system. Examples of regulation of the 
efflux pump expression by their substrates are present in many bacterial species including 
mycobacteria. As an easy to follow guideline, Table 1.1 summarises the local regulators, 
efflux pumps they regulate and compounds by which they are induced that are discussed in 
this review.  
 
The induction of the smeDEF-encoded efflux pump is implicated in resistance to several 
antibiotics and biocides including triclosan in Stenotrophomonas maltophilia. The SmeT 
repressor regulates smeDEF gene expression (Hernández et al., 2009; Hernández et al., 
2011). In the absence of an inducer, SmeT binds to a 28 bp palindromic sequence that 
includes the promoters of both smeT and smeDEF, preventing transcription of both genes 
(Hernández et al., 2009; Hernández et al. 2011). Two triclosan molecules bind to the SmeT 
repressor (which is a homodimer) and causes stabilization of SmeT in a conformation unable 
to bind to DNA. This prevents binding of SmeT to the smeDEF promoter and de-represses 
smeDEF transcription (Hernández et al., 2009; Hernández et al., 2011). The efflux pump 
substrate is therefore responsible for the induction of efflux pump expression. 
 
The TtgR repressor in Pseudomonas putida regulates ttgABC efflux pump expression, which 
is one of three toluene tolerance operons (ttg) including ttgABC, ttgDEF and ttgGHI present 
in P. putida (Rojas et al., 2003). The ttgR gene is situated adjacent to and divergently 
transcribed from the ttgABC operon (Duque et al., 2001). A ttgR null mutant in which the 
promoters of the ttgR and ttgA genes were still intact showed increased ttgA and ttgR 




well as its own expression (Duque et al., 2001). In the absence of substrates of the TtgABC 
efflux system, the TtgR repressor is bound to a palindromic operator site overlapping both the 
ttgABC and ttgR promoters in the ttgR/ttgABC intergenic region, presumably blocking RNA 
polymerase access to the ttgABC and ttgR promoters (Terán et al., 2003). In the presence of 
chloramphenicol and tetracycline, TtgR dissociates from the operator leaving the promoters 
of ttgABC and ttgR exposed for transcription and induction of both genes occurs. Induction of 
ttgABC and ttgR expression by antibiotics is dose dependent and mediated by the induction of 
the regulator itself. Interestingly, the ttgABC and ttgR genes are expressed at basal levels even 
in the absence of these antibiotics, suggesting that its induction is regulated by other 
molecules and suggesting a possible physiological function (Terán et al., 2003).  
 
The TtgR repressor has two different overlapping drug binding sites. One is broader with 
hydrophobic residues while the other is deeper with polar residues. These different binding 
sites allows for some versatility in binding to ligands, which is why TtgR is able to bind to 
many molecules with dissimilar structures, sizes, shapes and charge. This allows for the 
induction of the ttgABC efflux pump system by a diverse range of molecules including 
antibiotics and plant antimicrobials (phloretin, quercetin and naringenin) (Alguel et al., 
2007).  
 
Interestingly, although the TtgR repressor is a member of the TetR family of repressors, it has 
unique drug binding sites to that of the TetR repressor after which the TetR family of 
regulators are named. TetR binds only to tetracycline, while TtgR binds to multiple 
compounds. Binding of tetracycline to TtgR is distinct in that the position in which it fits into 
the binding site is different to TetR (Alguel et al., 2007). Tetracycline binds to the TetR 
repressor with its amino groups on the inside of the binding pocket and its cyclic ring towards 
the outside of the pocket while it binds to TtgR with its amide groups at the bottom of the 
binding pocket and cyclic rings towards the outside. TtgR also shows strong structure 
similarity to QacR family of transporters in Staphylococcus aureus discussed later (Alguel et 
al., 2007). This indicates how efflux pump regulators, which are classified into the same 
family, do not necessarily display the same ligand binding properties even for the same 
ligand. 
 
TtgV is a repressor encoded in the ttgVW operon, which is adjacent to the divergently 




an increase in expression of ttgGHI and ttgVW, while deletion of ttgW, had no effect on 
ttgGHI and ttgVW expression. TtgV thus acts as a repressor of the ttgGHI and ttgVW genes, 
regulating the pump expression and its own. TtgV binds to the ttgGHI/ttgVW intergenic 
region containing the promoters of both operons (Rojas et al., 2003). In the absence of an 
effector, TtgV binds to the DNA in a tetrameric state and with a high affinity causing bending 
of the operator DNA that presumably blocks RNA polymerase binding to the ttgGHI and 
ttgVW promoters (Guazzaroni et al., 2007). Interestingly, when different mutations were 
introduced in the operator of TtgV, it caused either an increase or decrease in ttgGHI and 
ttgVW expression. Although these mutations have not been observed clinically, it is tempting 
to speculate that undiscovered mutations might occur in the operator regions of efflux pump 
regulators and could lead to an additional level of efflux pump regulation that is clinically 
relevant (Guazzarroni et al., 2004). 
 
The TtgGHI efflux pump in P. putida is induced by aromatic hydrocarbons, antibiotics and 
aliphatic alcohols (Rojas et al., 2003; Guazzaroni et al., 2004). Binding of aliphatic alcohols 
to TtgV causes dissociation of TtgV from the operator in the intergenic region, and exposes 
the promoters of ttgGHI and ttgVW so that transcription can occur (Guazzaroni et al., 2004). 
The tetrameric state of TtgV is maintained in the absence and presence of an inducer 
(Guazzaroni et al., 2007). In contrast to most members of the IclR family of transcriptional 
regulators, TtgV is not as specific in the compounds it binds to and subsequently displays 
multidrug binding properties (Guazzaroni et al., 2007). Although there is a high degree of 
homology (70%) at protein level between the TtgABC and TtgGHI efflux systems, they have 
different substrate specificities (Terán et al., 2003), indicating that minor changes in the 
efflux pumps at protein level can significantly affect substrate binding properties. 
 
The bpeR gene, encoding the BpeR repressor, is divergently transcribed from the  
bpeAB-oprB operon, encoding a multidrug efflux pump in Burkholderia pseudomallei (Chan 
et al., 2004; Chan & Chua, 2005). Overexpression of bpeR results in repression of bpeA 
(Chan & Chua, 2005). Investigation of the MIC for numerous drugs in a bpeAB deletion 
mutant, revealed increased susceptibility to the aminoglycosides gentamicin and streptomycin 
and the macrolide erythromycin relative to the wild-type implicating BpeAB-OprB in export 
of these drugs and a multi-drug resistance phenotype (Chan et al., 2004). Erythromycin 
induces the expression of both bpeAB and bpeR, demonstrating that a substrate of this pump 




In some organisms, the repressor and efflux genes are encoded in the same operon. In S. 
aureus a large multi-resistance plasmid encodes QacR in the same open reading frame as 
qacA, and qacB (encoding a closely related protein to QacA from which QacA is thought to 
have evolved) (Grkovic et al., 2003). In the absence of toxic compounds transported by 
QacA, QacR represses qacA expression by binding to a palindromic sequence, inverted repeat 
1 (IR1) overlapping the qacA promoter (Grkovic et al., 1998). QacA exports several 
chemically distinct antimicrobial compounds. Many dissimilar compounds, including plant 
alkaloids, presumably cause a conformational change in QacR and subsequent release of 
QacR from the promoter region, allowing qacA expression (Grkovic et al., 1998; Grkovic et 
al., 2003).  
 
In Escherichia coli the emrR gene is located upstream of the emrA gene in the emrRAB 
operon. Overexpression of emrR caused decreased expression of the emrRAB operon and 
mutations in emrR caused overexpression of emrRAB, indicating that EmrR is a repressor of 
the emrRAB operon (Lomovskaya et al., 1995). In the absence of inducers, EmrR binds to the 
transcriptional start site of the emrRAB operon and represses emrRAB operon transcription 
(Xiong et al., 2000; Grkovic et al., 2001). Exposure to several structurally unrelated 
compounds that are EmrA substrates including nalidixic acid and carbonyl cyanide m-
chlorophenylhydazone (CCCP), interfered with binding of EmrR to its operator and thus 
caused a EmrR-dependent induction of the emrRAB genes (Xiong et al., 2000).  
 
The acrR gene in E. coli encodes the AcrR repressor and is located 141 bp upstream of and 
divergently transcribed from the acrAB (acridine AB) efflux pump. The AcrB efflux pump is 
responsible for the efflux of different toxic compounds in E. coli (Su et al., 2007). In the 
absence of inducers, AcrR binds to a 28 bp operator, between the acrR and acrAB genes, 
which overlaps with the acrAB promoter, thereby repressing transcription of the efflux pump 
encoding gene acrB (Su et al., 2007). Some of the pump substrates bind to AcrR and cause 
dissociation of AcrR from the promoter region thereby de-repressing the efflux system. AcrR 
can bind to two drugs simultaneously (Su et al., 2007).  
 
Induction of efflux pumps by the compounds they export via the local regulator is dependent 
on the drug concentration. The CmeR transcriptional repressor in Campylobacter jejuni 
belongs to the TetR family and is encoded on the same strand upstream of the cmeABC 




the inverted repeat region between the cmeR and cmeA genes, preventing transcription. 
Mutations in this region caused reduced binding of CmeR, increased expression of cmeABC 
and decreased susceptibility to antibiotics including erythromycin, ciprofloxacin and 
norfloxacin. CmeR is thus a repressor of cmeABC (Lin et al., 2005a). 
 
CmeR is a dimeric molecule consisting of two domains and has a large flexible ligand 
binding pocket. The conformation of CmeR changes when ligands bind to it (Gu et al., 2007). 
Sub-lethal concentrations of most of the antibiotics exported by CmeABC including 
erythromycin and ciprofloxacin, could however not induce the efflux pump expression (Lin 
et al., 2005b). Since induction of some efflux pumps is dose-dependent, higher substrate 
concentrations than those tested may be required for induction (Terán et al., 2003). 
 
In Streptomyces lividans, EbrA, EbrB and EbrC are efflux pumps thought to be involved in 
ethidium bromide resistance, since their overexpression conferred elevated resistance to this 
compound. The ebrS gene encodes a transcriptional regulator of the AcrR family and 
regulates expression of ebrC. The ebrS gene is present upstream of ebrC and is divergently 
transcribed. EbrS represses the transcription of ebrC and itself. Overexpression of ebrS 
therefore leads to increased repression of ebrC, resulting in ethidium bromide sensitivity. 
Conversely, when ebrS was deleted, elevated ethidium bromide resistance was observed due 
to ebrC induction (Lee et al., 2007). Eight drugs, including six known substrates of EbrC 
(tetracycline, nalidixic acid, methyltriphenylphosphonium, proflavin, norfloxacin and 
ethidium bromide) failed to induce ebrC expression, while RIF and calcium chloride induced 
the ebrS promoter resulting in ebrC repression. Calcium ions are hypothesized to bind 
directly to EbrS and prevent self-repression (Lee et al., 2007). 
 
Increased transcription of a pump may be facilitated by enhanced binding of a transcriptional 
activator in the presence of an efflux pump substrate. An example of this is the regulation of 
Bmr, a multidrug transporter in Bacillus subtilis, by the transcriptional activator, BmrR. 
Expression of bmr is induced by two structurally diverse compounds rhodamine 6G and 
tetraphenylphosphonium (TPP) which are exported by Bmr. Dimerised BmrR binds to the 
bmr promoter in the absence of the ligand, but its binding is enhanced in the presence of the 
substrates resulting in induction of bmr (Ahmed et al., 1994). Some aromatic cationic 
compounds also bind to BmrR resulting in induction of bmr expression (Markham et al., 




the induction of the bmr by multiple drugs. When determining the crystal structure of BmrR 
bound to tetraphenylphosphonium, it was established that during formation of a complex of 
the drug and BmrR, the multidrug-binding domain of an alpha helix of BmrR unfolds and 
relocates. Subsequently, this shift causes an internal drug binding pocket to be exposed, to 
which the drug then binds (Zheleznova et al., 1999). This multidrug binding pocket has a 
redundant negative nature and is rigid allowing for some control over which substrates induce 
the expression of the multidrug efflux pump Bmr and which do not (Newberry et al., 2008). 
The binding pocket can also solvate drugs with a range of different conformations, which all 
bind in the same orientation to the binding pocket (Bachas et al., 2011). This illustrates how 
multiple drugs with diverse structures are able induce efflux pump expression through their 
ability to bind to a single transcriptional regulator. 
 
1.1.2 Local regulation of multidrug efflux pumps in mycobacteria 
 
LfrA is a multidrug efflux pump implicated in the efflux of fluoroquinolones, cationic dyes 
and anthracyclines in M. smegmatis (Liu et al., 1996; Buroni et al., 2006). The lfrR gene is 
encoded upstream of lfrA and the genes are co-transcribed from a common promoter. LfrR 
acts as a transcriptional repressor of the lfrRA operon. In the absence of LfrA substrate, LfrR 
binds to the promoter of lfrRA and completely represses transcription of lfrRA (Buroni et al., 
2006). Ciprofloxacin and acriflavine, substrates of the LfrA efflux pump, bind to LfrR and 
cause the release of LfrR from the promoter region of lfrRA and in the process de-represses 
lfrA expression. The drugs themselves thus induced the expression of the lfrA efflux pump, 
which exports them (Buroni et al., 2006). 
 
Crystallographic and calorimetric studies have shown the intrinsic flexibility of the LfrR 
transcriptional repressor in M. smegmatis. This flexibility is thought to provide the protein 
with the ability to bind to many different drugs and undergo conformational changes in order 
to de-repress the efflux pumps (Bellinzoni et al., 2009). Interestingly, two binding reactions 
were shown to occur for LfrR with proflavine and ethidium bromide. Which binding reaction 
occurs, depends on the proflavine/LfrR concentration ratio. The first binding reaction occurs 
with a high affinity while the second binding reaction has a much lower binding affinity. At a 
low molar ratio of ethidium bromide/LfrR, one ethidium bromide molecule binds with high 
affinity and at a high molar ratio the ethidium bromide molecule binds with an even higher 




Table 1.1. Summary of the local regulators and efflux pumps they regulate as well as which drugs induce efflux pump expression via 
interaction with the local regulator.  
Efflux pump system Present in Local regulator Family of 
transcriptional 
regulators 
Efflux pump induced 
specifically via the local 





S. maltophilia SmeT repressor TetR Biocide (trisclosan) (Hernández et al., 




P. putida TtgR repressor 
 
(shows structure 
similarity to QacR 
family of regulators 





tetracycline) and plant 
antimicrobials (phloretin, 
quercetin and naringenin) 
 
(Duque et al., 2001; 
Rojas et al., 2003; 
Terán et al., 2003; 




P. putida TtgV repressor IclR Aliphatic alcohols 
(1-hexanol and 1-
naphthol) and nitrotoluene 
(Rojas et al., 2003; 
Guazzaroni et al., 




B. pseudomallei BpeR repressor TetR Erythromycin (Chan et al., 2004; 
Chan & Chua, 2005) 
qacRAB 
(MFS pump) 
S. aureus QacR repressor TetR Plant alkaloids, 
diamidines, guanidines 
and dyes 
(Grkovic et al., 1998; 
Grkovic et al., 2003) 
emrRAB 
(MFS pump) 




(Lomovskaya et al., 
1995; Xiong et al., 







Table 1.1. Summary of the local regulators and efflux pumps they regulate as well as which drugs induce efflux pump expression via 
interaction with the local regulator (continued). 
Efflux pump system Present in Local regulator Family of 
transcriptional 
regulators 
Efflux pump induced 
specifically via the local 
regulator in the presence 
of 
References 
acrAB E. coli AcrR repressor TetR Ethidium, proflavin and 
rhodamine 6G 

























(Ahmed et al., 1994; 
Markham et al., 1997; 
Zheleznova et al., 
1999; Newberry et al., 




M. smegmatis LfrR repressor TetR Ciprofloxacin, acriflavine, 
proflavine and ethidium 
bromide 
(Buroni et al., 2006; 
Bellinzoni et al., 2009) 
mmr 
(SMR pump) 





the efflux pump is dependent on the concentration of the drug. Higher concentration of drug 
might be needed to induce efflux (Bellinzoni et al., 2009).  
 
The Mmr multidrug efflux pump exports multiple drugs including acriflavine, ethidium 
bromide and erythromycin in M. tuberculosis (De Rossi et al., 1998). The rv3066 gene is 
present immediately downstream of the mmr gene. In the absence of compounds extruded by 
Mmr, Rv3066 is bound to IR1 of the mmr promoter and causes repression of mmr 
transcription. Ethidium bromide binds to the multidrug-binding pocket of the Rv3066 
regulator causing a conformational change and dissociation of the Rv3066 repressor from the 
mmr promoter occurs. There is thus a drug-mediated de-repression of the mmr gene 
expression and transcription of mmr occurs (Bolla et al., 2012). 
 
1.2 GLOBAL TRANSCRIPTIONAL REGULATION OF MULTIDRUG EFFLUX 
PUMPS 
 
Global transcriptional regulators enable bacteria to control the expression of multiple genes 
simultaneously, facilitating a concomitant response to environmental cues such as exposure 
to antibiotics, nutrient starvation and other environmental stresses. 
 
1.2.1 Global transcriptional regulation of efflux in bacteria other than mycobacteria 
 
In addition to regulation of the acrAB efflux system in E. coli by the local regulator AcrR, 
this pump is also regulated by a global regulator, MarA (multiple antibiotic resistance). 
(Cohen et al., 1993). The marA gene encodes the global transcriptional activator, MarA, 
belonging to the XylS/AraC family (Alekshun & Levy, 1997). MarA induces a number of 
genes encoding proteins of diverse functions including genes present in the marRAB operon 
as well as the acrA gene which forms part of the acrAB efflux system discussed earlier 
(Barbosa & Levy, 2000). MarR encodes a local transcriptional repressor of the marRAB 
operon and represses transcription when no inducers are present (Cohen et al., 1993; Seoane 
& Levy, 1995). MarR repression of the marRAB operon is reversed by the presence of 
compounds that are involved in stress response (Seoane & Levy, 1995).  
 
Another example of global regulation of efflux is provided in the regulation of the bmr gene 




also regulated by a global regulator, Mta, which belongs to the MerR family of regulators. 
Mta, like BmrR, binds to the bmr promoter and induces or activates the transcription of bmr. 
It also induces transcription of the blt gene which encodes another multidrug efflux pump, 
Blt. It is not known which compounds bind to Mta to induce it, although Mta has been shown 
to auto-regulate its own expression (Baranova et al., 1999). Mta is thus a global 
transcriptional activator. 
 
The MtrCDE (multiple transferrable resistance) multidrug resistance efflux pump in 
Neisseria gonorrhoeae belongs to the RND family and exports macrolide antibiotics, 
penicillin and other antimicrobials. A local repressor of the TetR family, MtrR and a global 
transcriptional activator belonging to the AraC/XylS-type activators, MtrA, regulate the 
MtrCDE efflux pump system (Hagman & Shafer, 1995; Rouquette et al., 1999; Lee et al., 
2003). The mtrR gene is encoded 250 bp downstream of the mtrCDE operon and is 
divergently transcribed (Hagman & Shafer, 1995). MtrR binds to the region between mtrR 
and mtrC, which includes the mtrCDE and mtrR promoter regions (Lucas et al., 1997). 
Mutations in the MtrR binding region causes increased mtrCDE expression and decreased 
mtrR expression, indicating that MtrR is a repressor of the mtrCDE efflux pump (Lucas et al., 
1997). Mutations in the mtrR gene and its promoter region have also been identified in 
clinical isolates of N. gonorrhoeae and are associated with increased resistance to penicillin, 
erythromycin and azithromycin (Warner et al., 2007). MtrA plays a role in the induction of 
mtrCDE by sub-lethal concentrations of pump substrates. It is not known whether this 
regulation of mtrCDE by MtrA occurs directly or indirectly (Rouquette et al., 1999). The 
mtrCDE efflux pump system is thus positively and negatively regulated by a global activator 
and local repressor as summarized in Fig 1.1.  
 
Interestingly, mtrR mutations, which cause de-repression of the mtrCDE efflux pump system, 
also lead to a significant increased fitness of the mutant bacteria relative to wild-type bacteria 
in a mouse infection model. This increased fitness was maintained throughout the course of 
infection, and was specifically due to de-repression of the MtrCDE efflux pump system 
(Warner et al., 2007). When comparing the relative in vivo fitness of a mtrA mutant with that 
of the wild-type in N. gonorrhoeae, a fitness cost was seen within two days of inoculation (in 
a mouse infection model) in the mtrA mutant compared to the wild-type. Interestingly, 




demonstrating that the expression levels of the mtrCDE efflux system have a significant 
impact on the fitness of N. gonorrhoeae (Warner et al., 2007). 
 
In addition to the role of MtrR as local regulator of the mtrCDE efflux pump, MtrR is also a 
global regulator as it controls the expression of about 70 genes across the genome. MtrR 
indirectly regulates the expression of the farAB-encoded efflux pump via regulation of a local 
regulator, FarR. The farAB (fatty acid resistance) operon consists of the membrane fusion 
protein, FarA, and the cytoplasmic membrane transporter protein, FarB, belonging to the 
MFS superfamily. This efflux pump uses the MtrE protein as the outer membrane channel to 
extrude long-chain antibacterial fatty acids and is required for resistance to antibacterial fatty 
acids (Lee et al., 2003). At the local level, farAB is regulated by transcriptional repressor, 
FarR, which binds directly to the farAB promoter and causes transcriptional repression of the 
efflux system. MtrR binds to the farR promoter, repressing farR expression and causing de-
repression of the farAB efflux system. MtrR therefore not only functions as a negative 
regulator of the mtrCDE efflux system, but also as an indirect positive regulator for farAB 
efflux system (Lee et al., 2003). MtrR and FarR-mediated regulation also extends to genes 
involved in other aspects of metabolism. For example, FarR acts as a transcriptional activator 
of glnA, which encodes glutamine synthetase. MtrR therefore indirectly decreases glnA 
expression by reduced binding of FarR to its promoter. The regulation of mtrCDE and farAB 
by MtrR is illustrated in Fig 1.1. This demonstrates that global regulation often involves a 
cascade of events, which can simultaneously induce or repress the expression of genes with 
diverse functions within the cell (Johnson et al., 2011). 
 
NorA is a MDR efflux pump of the MFS family that exports a variety of drugs such as 
fluoroquinolones, ethidium bromide, cetrimide, benzalkonium chloride, 
tetraphenylphosphonium bromide and acrifavine in S. aureus (Fournier et al., 2000). The 
norR gene is present upstream of norA and overexpression of norR led to increased norA 
expression and increased resistance to quinolones and ethidium bromide. NorR is thus a local 
activator or positive regulator of the norA efflux pump (Truong-Buldoc et al., 2003). The 
arlR-arlS genes encode regulatory genes with ArlR being a possible regulatory protein and 
ArlS a histidine kinase (Fournier et al., 2000). The norA gene expression is negatively 
regulated by the ArlR/S regulator (Fournier et al., 2000). The ArlR/S regulator has its effects 
on norA expression by modulating (decreasing) NorR binding to the norA operator (Truong-




(Luong et al., 2006). MgrA is a global transcriptional regulator that shares homology with 
MarR in E. coli. MgrA activates the transcription of many genes and acts a repressor of many 
others (Luong et al., 2003; Luong et al., 2006). MgrA acts as negative regulator of two other 
efflux systems, norB and tet38 (Truong-Buldoc et al., 2005).  
 
1.2.2 Global transcriptional regulation of efflux in mycobacteria 
 
The MSMEG_2173 global regulator in M. smegmatis belongs to the GntR/FadR family of 
transcription factors. MSMEG_2173 binds to a specific palindromic DNA sequence and 
searching the genome of M. smegmatis for this specific sequence revealed 292 potential 
target genes with binding sites for MSMEG_2173. These genes included a broad range of 
thirty-seven transporter genes and this was confirmed with immunoprecipitation with an 
MSMEG_2173 antibody. Deletion of MSMEG_2173 in M. smegmatis increased expression 
of most of the genes with predicted binding sites. Conversely, overexpression of 
MSMEG_2173 decreased expression of the same genes. This is indicative that 
MSMEG_2173 acts as a negative regulator, repressing the expression of multiple transporter 
genes (Rao et al., 2012). MSMEG_2173 was also implicated in negatively regulating drug 
transporters, since overexpression of MSMEG_2173 caused increased susceptibility to 
isoniazid (MIC of 160 µg/ml). A strain overexpressing MSMEG_2173 grew poorly in 30 
µg/ml isoniazid, while the wild-type strain had a MIC of 200 µg/ml. Deletion of 
MSMEG_2173, increased the MIC for isoniazid to 300 µg/ml and the mutant showed 
enhanced growth in 30 µg/ml isoniazid (Rao et al., 2012).  
 
Lsr2 is a histone-like protein that is highly conserved among mycobacteria and acts as a 
transcriptional repressor of the iniBAC efflux pump. The iniBAC pump is induced by 
isoniazid and ethambutol. The expression of iniBAC promoter was elevated and ethambutol 
resistance increased in a M. smegmatis lsr2 mutant relative to the wild-type. This is indicative 
of a role of Lsr2 repressor in iniBAC expression (Colangeli et al., 2007). Deletion of lsr2 in 
M. smegmatis resulted in increased expression of iniA and other genes involved in cell wall 
and metabolic functions, indicating a role of Lsr2 in repressing a broad range of genes 
including those not involved in efflux (Colangeli et al., 2007). Overexpression the lsr2 gene 
in M. tuberculosis resulted in a down-regulation of the isoniazid-mediated induction of the 
iniBAC genes, indicating the role of Lsr2 in M. tuberculosis gene repression (Colangeli et al., 


























Figure 1.1. Regulation of efflux pumps by MtrA, MtrR and FarR regulators. Solid lines 
represent direct regulation, dashed lines indirect regulation and solid and dashed lines 
together indicate that the mechanism of regulation is unknown. 
 
isoniazid-mediated induction of efpA, another putative efflux pump (Colangeli et al., 2007) 
which is part of the QacA family of transporters and is present in several slow and fast 
growing mycobacterial species (Doran et al., 1997). Thus, Lsr2 has a possible role in the 
global regulation of multiple efflux pump systems as well as other genes not involved in 





















1.2.3 The WhiB family of global transcriptional regulators in M. tuberculosis 
 
The WhiB family of genes in M. tuberculosis is a family of key global transcriptional 
regulators that bind to DNA and interact with proteins causing activation of transcription. 
They are present only in actinomycetes (Geiman et al., 2006; Burian et al., 2012). These 
regulators will be discussed in more detail since they are relevant to the current study.  
M. tuberculosis has seven whib-like genes that are structurally and functionally different, 
making each of the WhiB proteins a distinguished member of the family (Alam et al., 2009). 
Sequence analysis of WhiB proteins revealed four conserved cysteine residues, two of which 
are present in a CXXC motif. WhiB proteins also contain redox-sensitive iron-sulphur 
clusters (Alam et al., 2009), which are versatile cofactors that participate in electron transfer, 
substrate binding or activation, iron or sulphur storage, gene expression regulation and 
enzyme activity (Alam et al., 2007). The seven WhiB proteins in M. tuberculosis are thought 
to have distinct functions, and are involved in physiological processes such as cell division, 
reacting to nutrient starvation, pathogenesis and stress sensing, as well as antibiotic 
resistance. Mutations in the different whiB genes cause distinct phenotypes and the whiB 
mutants react differently to stress conditions (Alam et al., 2009).  
 
The redox potential of WhiB1 matches that of thioredoxin-like proteins, and its ability to 
catalyze the reduction of insulin disulfide demonstrates that it functions as a disulfide 
reductase (Garg et al., 2007). The promoter of whiB1 contains a cAMP receptor protein 
(CRP) binding site. whiB1 expression is regulated by cAMP levels through cAMP-dependent 
binding of CRP. In the presence of cAMP (at high enough levels), CRP binds to the whiB1 
promoter inducing its transcription (Agarwal et al., 2006). WhiB2 has chaperone properties 
as it restored the function of a chemically denatured protein and suppressed the aggregation 
of proteins independent of its redox state and in the absence of ATP in M. tuberculosis 
H37Rv (Konar et al., 2012). WhiB3 maintains the intra-bacterial redox homeostasis by 
regulating virulence lipid anabolism in response to the oxido-reductive stress encountered 
during macrophage infection (Singh et al., 2009).  
 
The apo mWhiB4 protein also shows similarity to thiorodoxin proteins and functions as a 
disulfide reductase following destruction of the iron sulphur (4Fe-4S) cluster in an oxidizing 
environment. It was therefore hypothesized that WhiB4 plays a role in the response to 




stress and induced by antioxidants. Deletion of whiB4 from M. tuberculosis caused changes 
in redox balance, a reduction of the membrane potential, increased in vitro oxidative stress 
resistance and the mutant over-expressed the M. tuberculosis antioxidant system, indicating 
the role of WhiB4 in regulating oxidative stress response in M. tuberculosis. The knockout 
mutant was also hypervirulent indicating a role of WhiB4 in modulating virulence (Chawla et 
al., 2012). 
 
WhiB5 regulates the expression of 58 genes as identified by microarray. A whiB5 null mutant 
was attenuated during infection and could not grow after reactivation. WhiB5 could also play 
a part in immunomodulation since there was a larger inflammatory response observed in mice 
infected with the whiB5 knockout mutant than to those infected with the wild-type. WhiB5 is 
thus important in virulence, immunomodulation and reactivation as well as regulating many 
genes (Casonato et al., 2012).  
 
Geiman et al. (2006) investigated the expression of the whiB-like genes in  
M. tuberculosis following exposure to different stress conditions, including exposure to anti-
tuberculosis drugs. Exposure to isoniazid (INH) increased whiB2 and slightly decreased 
whiB4 expression, while having minimal effects on the rest of the gene family. The 
expression of all of the genes was only minimally affected by ethambutol, except for an 
increased expression of whiB2. Kanamycin caused induction of whiB2, whiB3, whiB6 and 
whiB7. Cycloserine increased the expression of whiB2 and slightly decreased whiB5, whiB6 
and whiB7 expression. Streptomycin caused induction of whiB3, whiB6 and whiB7 and 
repression of whiB2 and whiB5 (Geiman et al., 2006). M. tuberculosis whiB7 was induced by 
subinhibitory concentrations of antibiotics including erythromycin, tetracycline and 
streptomycin in a dose dependent manner and fatty acids which accumulate during host 
infection. Null mutants of whiB7 were hypersusceptible to the aforementioned antibiotics 
(Morris et al., 2005). Microarray analyses, used to identify the genes in the whiB7 regulon, 
showed that initially only whiB7 was induced upon antibiotic exposure making it the primary 
regulator of the genes which were subsequently induced by antibiotic exposure. The genes 
which were induced by antibiotic exposure specifically through whiB7 induction included 
Rv1258c, encoding a multidrug efflux pump, and Rv1473, encoding a putative macrolide 





M. tuberculosis is known to infect and replicate within macrophages. Adams et al. (2011) 
showed that drug tolerant bacteria were present soon after infection and these drug tolerant 
bacteria are able to survive within macrophages. The intracellular environment encountered 
by M. tuberculosis within macrophages induces drug tolerance, which is mediated by the 
induction of efflux pumps. Rv1258c is induced upon macrophage infection and its induction 
mediates RIF tolerance. An Rv1258c knockout mutant of M. tuberculosis showed impaired 
survival in macrophages, indicating the importance of Rv1258c in intracellular growth as 
well as RIF resistance (Adams et al., 2011). WhiB7 thus functions as a global transcriptional 
regulator and plays a role in drug resistance (Morris et al., 2005). 
 
The WhiB7 promoter is conserved across actinomycetes (Burian et al., 2012). Investigation of 
the promoter and structural gene sequence of whiB7 in multidrug resistant and extensively 
drug resistant clinical isolates in M. tuberculosis showed a high degree of sequence 
conservation, indicating the importance of the WhiB7 proteins in M. tuberculosis 
(Arjomandzadegan et al., 2011). Induction of whiB7 by erythromycin was much lower in the 
whiB7 mutant providing evidence that WhiB7 activates its own promoter. Burian et al. 
(2012) investigated the mechanism by which WhiB7 responds to antibiotics and activates 
drug resistance genes. WhiB7 was induced by eighty-six structurally unrelated compounds 
demonstrating that its induction is not due to recognition of common structural motif. Instead, 
redox state was shown to control the level of whiB7 induction, as whiB7 was activated by a 
reduced environment. This shows that WhiB7 links physiology and antibiotic resistance by 
maintaining the redox potential and activating resistance genes at the same time (Burian et 
al., 2012).  
 
A novel regulator in M. tuberculosis, Rv2034, belongs to the ArsR family of regulators. 
Rv2034 auto-regulates its own expression by binding to its own promoter and repressing its 
own expression. A palindromic sequence, representing the Rv2034 binding sequence was 
identified. Inspection of the genome of M. tuberculosis for this sequence identified binding 
sites for Rv2034 in the promoter regions of multiple genes, including whiB7, indicating a 
possible role for Rv2034 in regulation of whiB7 expression. Rv2034 also positively regulates 
the dosR gene that encodes DosR protein that acts as a key regulator of hypoxic response in 
M. tuberculosis (Gao et al., 2012). This indicates how global regulators interact to regulate 





1.3 ROLE OF PH, IONS AND METABOLIC ENERGY IN MODULATION OF  
EFFLUX PUMP EXPRESSION 
 
In addition to regulation of efflux pumps at both local and global level, efflux pumps can also 
be modulated by pH and availability of ions and metabolic energy. The AcrAB-TolC efflux 
system in Salmonella Enteridis serovar typhimurium belongs to the RND family and exports 
ethidium bromide (Amaral et al., 2011). The accumulation of ethidium bromide was shown 
to be less at a low pH (pH 5) as appose to a higher pH (pH 8), suggesting that the efflux 
system was more efficient at a low pH. At a pH of 7.4 or higher, metabolic energy (provided 
in the form of glucose) is necessary for the effective functioning of the efflux pumps in order 
to reduce the amount of ethidium bromide accumulated (Amaral et al., 2011). Ions are also 
important in the functioning of the efflux systems since in the absence of ions, metabolic 
energy was required even at a low pH for the effective functioning of the efflux system 
(Amaral et al., 2011). This could be because there is a high availability of protons (ions) to 
use for antiport (manifesting itself as proton motive force) at a low pH. While at a high pH, 
the metabolism provides the protons needed for antiport and metabolic energy is thus 
required for efflux pump functioning. The pH thus modulates the degree to which metabolic 
energy and ions are needed for efflux pump functioning (Amaral et al., 2011). 
 
The same scenario was true for E. coli where ethidium bromide was extruded more 
effectively at a lower pH (pH 5) as opposed to a higher pH and metabolic energy was needed 
for efflux of the drug at high pH (pH 8) (Martins et al., 2009). It was suggested that two 
different efflux systems in E. coli are activated at a low and high pH respectively. At low pH, 
the efflux systems driven by proton motive force are activated while at high pH the efflux 
systems driven by ATP hydrolysis are activated (Martins et al., 2009). Calcium ions were 
also shown to play a role in efflux in E. coli (Martins et al., 2011). 
 
The expression of norA in E. coli is not only regulated by the local regulator NorR and the 
global regulators ArlR/S and MgrA as discussed earlier, but the expression of norA is also 
iron responsive, more specifically, iron uptake was shown to repress norA expression (Deng 
et al., 2012). Fur (ferric uptake regulator) is a master iron uptake regulator that activates 
genes to ensure iron acquisition and storage under conditions of iron deprivation. A fur 
deletion mutant showed a decreased expression of norA compare to the wild-type strain as 




regulator of norA and demonstrates how the expression of efflux pumps is also regulated by 
the environmental conditions such as iron availability. It was suggested that the physiological 
role of NorA involves siderophores secretion and not drugs secretion, explaining the link 
between the iron levels and norA expression (Deng et al., 2012). 
 
In M. tuberculosis copper ions was shown to cause inhibition of the previously described 
MSMEG_2173 regulator binding to DNA; resulting in the formation of an inactive DNA 
binding protein. There was a decrease in MSMEG_2173/DNA complex with an increase in 
copper concentration. Consequently, copper ions could partially reverse MSMEG_2173 
function (Rao et al., 2012). MSMEG_2173 does however have a higher binding affinity for 
DNA than for copper ions. The MSMEG_2173 regulator can thus in part be regulated by the 
presence of metal ions, a finding that might also be relevant to other global regulators. 
 
1.4 REGULATION OF EFFLUX PUMPS BY QUORUM SENSING 
 
Quorum sensing is the process by which bacteria communicate inter-cellularly by secreting 
chemical signals, which in turn regulate the expression of specific genes in the surrounding 
bacteria (Rahmati et al., 2002). Quorum sensing has been implicated in regulation of efflux 
pump expression. 
 
In the Singapore strain, KHW, of B. pseudomallei, expression of bpeAB-OprB efflux system 
is growth phase dependent as it increases gradually from mid-log growth to stationary phase. 
The regulator of bpeAB-OprB, BpeR, which was discussed above, is induced at early 
stationary phase (Chan & Chua, 2005). Since autoinducers were shown to cause induction of 
the bpeAB efflux system at early exponential phase as opposed to mid-log phase (advancing 
the same level as expression obtained after 24 hours by about 12 hours), it is hypothesized 
that the BpeAB-OprB efflux system might be regulated by quorum sensing in  
B. pseudomallei KHW (Chan & Chua, 2005). SdiA (suppressor of division inhibition) 
regulates cell division in a quorum-sensing dependent manner in E. coli and acts as a 
transcriptional activator. An sdiA null mutant had decreased expression of AcrB protein and 
was less resistant to fluoroquinolones compared to wild-type bacteria. SdiA positively 
regulates the acrAB efflux system since subsequent overproduction of SdiA caused an 
increase in protein levels of AcrA and AcrB and returned quinolone resistance (Rahmati et 




1.5 POSSIBLE ROLE OF EFFLUX IN BIOFILM FORMATION AND QUORUM 
SENSING 
 
Many bacteria form biofilms. Biofilms are complex communities of bacteria that are 
metabolically and spatially structured and encased in an exopolysaccharide matrix and are 
located at a phase interface. These complex structures can consist of a single or multiple 
bacterial species (Mah & O‟Toole, 2001; Nikolaev & Plakunov, 2007). Bacteria that are part 
of a biofilm express different properties than planktonic bacteria and are metabolically 
heterogeneous, grow at different rates, experience different environmental conditions and are 
more resistant to most antimicrobials even when there is no genetic basis for resistance (Mah 
& O‟Toole, 2001; Stewart & Costerton, 2001; Nikolaev & Plakunov, 2007).  
 
When comparing gene expression of E. coli biofilms and planktonic bacteria, many genes 
encoding efflux pumps, known to be involved in efflux of toxic compounds including 
antibiotics, were shown to be highly upregulated during biofilm growth. Efflux pump 
inhibitors also reduce biofilm formation in different bacteria. Combinations of efflux pump 
inhibitors with different mechanisms of action synergistically decreased biofilm formation, 
suggesting that a variety of efflux pumps are involved in biofilm formation (Kvist et al., 
2008). Deletion of the genes encoding a putative efflux pump in a Pseudomonas aeruginosa 
biofilm leads to an increased drug sensitivity only in bacteria growing in a biofilm, but not 
for planktonic bacteria and is thus indicates biofilm specific drug resistance presumably 
brought about by efflux (Zhang & Mah, 2008).  
 
Biofilms form in numerous mycobacterial species including Mycobacterium fortuitum, 
Mycobacterium chelonae Mycobacterium avium, Mycobacterium marinum and M. smegmatis 
(Hall-Stoodley & Lappin-Scott, 1998; Bardouniotis et al., 2003; Yamazaki et al., 2006; 
Nguyen et al., 2010). While M. tuberculosis forms biofilms in vitro, (Ojha et al., 2008) it is 
only speculated that biofilms might form in vivo after escape of the bacteria from 
phagosomes (Ojha & Hatfull, 2012). Biofilm dependent biocide resistance occurs in  
M. fortuitum biofilms (Bardouniotis et al., 2003) and biofilm dependent RIF and isoniazid 
resistance occurs in M. tuberculosis (Ojha et al., 2008). It is tempting to speculate that there 
could possibly be an undiscovered role for efflux pumps in biofilm drug resistance in  





Results of studies to determine the importance of efflux pumps in biofilms drug resistance are 
contradictory. In P. aeruginosa the expression of multidrug efflux pumps, MexAB-OprM and 
MexCD-OprJ, were decreased during biofilm formation in P. aeruginosa (De Kievit et al., 
2001). Hyperexpression of mexCD-oprJ in biofilm forming bacteria did not increase 
antibiotic resistance and in a mexAB-OprM mutant, biofilms still had high level resistance 
compared to planktonic cells indicating that these pumps did not contribute to the innate 
antibiotic resistance of biofilms (De Kievit et al., 2001). MDR efflux pumps that have been 
implicated in drug resistance in planktonic P. aeruginosa, do thus not play a role in biofilm 
drug resistance (De Kievit et al., 2001). However, resistance to ofloxacin, but not 
ciprofloxacin was shown to depend on mexAB-OprM expression in the biofilm, but only at 
low concentrations of ofloxacin (Brooun et al., 2000). A maximal activity of MexAB-OprM 
and MexCD-OprJ were observed at the biofilm substratum (De Kievit et al., 2001).  
 
Efflux pumps also play a role in quorum sensing. The MexEF-OprN efflux pump in  
P. aeruginosa exports 4-hydroxy-2-heptylquinoline (HHQ) which is a 4-hydroxy-2-
alkylquinoline (HAQ) autoinducer and is a Pseudomonas Quinolone Signal (PQS) precursor 
(Lamarche & Déziel, 2011). Autoinducers are homoserine lactones that accumulate in the 
growth medium depending on the cell density. When critical levels are reached, certain genes 
within the bacteria are induced, resulting in a population-wide response (Evans et al., 1998). 
The MexEF-OprN efflux pump thus indirectly plays a role in quorum sensing by efflux of 
PQS that is involved in quorum sensing (Lamarche & Déziel, 2011). The MexAB-OprM 
efflux system extrudes an autoinducer, homoserine lactone autoinducer (PAI-1), which is 
involved in expression of virulence factors in P. aeruginosa. Overexpression of mexAB-oprM 
also causes a decline in autoinducer production. (Evans et al., 1998). 
 
A bpeAB efflux pump mutant in B. pseudomallei KHW was defective in the secretion of acyl-
homoserine lactones (Chan et al., 2007). In a bpeR-overexpressing strain, autoinducer 
production did not occur which shows how the BpeR repressor overexpression can inhibit 
quorum sensing (Chan & Chua, 2005). BpeRAB-OprB was also necessary for siderophore 
and phospholipase C production. The latter two compounds are quorum-sensing-controlled 
virulence factors (Chan & Chua, 2005). Additionally, BpeAB-OprB is also involved in 
biofilm formation as biofilm formation was significantly reduced in a bpeAB deletion mutant 
and in a bpeR-overexpressing strain. The BpeR regulator and BpeAB-OprB efflux pump are 




well as biofilm formation in B. pseudomallei KHW (Chan & Chua, 2005). Interestingly, in 
another strain, B. pseudomallei 1026b, BpeAB-OprB did not play a role in acyl-homoserine 
lactone (ACH) export or influence siderophore production, but was still necessary for biofilm 
formation, indicating the effects of strain genetic background on efflux pump function (Mima 
& Schweizer, 2010).  
 
The above studies show that the role of efflux pumps in autoinducer secretion and quorum-
sensing and proves how important it is to control the expression of multidrug efflux pumps 
since the overexpression might have important physiological implications. A role for efflux 
in quorum sensing in mycobacteria has however not been established. 
 
1.6 THE PHYSIOLOGICAL FUNCTIONS OF EFFLUX PUMPS 
 
While multidrug efflux pumps are important in drug resistance, it is believed that the actual 
function of the efflux pumps are not drug efflux, but that all of these pumps have 
physiological functions, which are in many cases still unknown (Putman et al., 2000; Grkovic 
et al., 2002). This is one reason why the regulation of efflux is so important since 
physiological functions could be affected in the case of incorrect regulation of efflux pumps. 
Some examples of possible physiological functions have been named previously in this 
review and a few are subsequently discussed. 
 
Multidrug efflux pumps extrude a variety of compounds such as detergents, bile salts, organic 
solvents and ionophores and may in the process protect the membrane and energy state of the 
cell (Putman et al., 2000). This is indicative of a physiological role for efflux pumps. The 
expression of cmeABC efflux pump in C. jejuni discussed earlier was significantly increased 
upon addition of numerous bile salts to the media, in a dose and time-dependent manner (Lin 
et al., 2005b). Bile salts were shown to interact and bind to the CmeR repressor increasing 
expression of cmeABC and resistance to multiple antibiotics in the presence of bile salts. It 
was suggested that the CmeABC efflux system‟s primary function is providing bile salt 
resistance as appose to drug resistance (Lin et al., 2005b). Similarly, an efflux system 
originally thought to extrude numerous drugs in Vibrio cholerae was shown to extruded bile 
and renamed, breAB. BreR acts as a negative regulator of breAB expression as well as 




able to disrupt the binding of BreR to the promoter regions and subsequently caused 
induction of the breAB efflux system (Cerda-Maira et al., 2008). 
 
The overexpression of the Blt multidrug transporter of B. subtilis leads to an increased efflux 
of spermidine. The presence of the blt gene, which encodes for spermidine acetyltransferase, 
downstream of the blt multidrug transporter suggests that the physiological role of the Blt 
efflux pump is to extrude spermidine (Putman et al., 2000). 
 
M. bovis BCG strains with disrupted homologue of the gene encoding the Tap efflux pump 
grew slower and stopped growing prematurely in liquid cultures. However, when culturing on 
solid medium, this growth defect was reversed. The bacterial morphology also changed as the 
bacteria became elongated after sub-cultivation in liquid. Disruption of the tap efflux pump 
was found to affect gene expression of 18 genes during stationary phase. These genes 
included those involved in virulence, detoxification, adaptation, intermediary metabolism and 
respiration, conserved hypotheticals and cell wall and cell processing. The Tap efflux pump 
is thus important in many important physiological processes during stationary phase (Ramón-
García et al., 2012). 
 
Since toxic product accumulation is a problem during stationary phase, the authors suggested 
a physiological role of the Tap efflux pump to be the removal of these toxic by-products. 
Examination of the genes up- and down-regulated upon disruption of the tap efflux pump, 
supports their hypothesis. Stress response genes such as Heat shock protein R (HspR) and 
Rv2466c (involved in oxidative stress) were up-regulated. Rv2913c a D-amino acid 
aminohydrolase, was upregulated, which suggests the involvement of the Tap efflux pump in 
clearing the D-amino acids, which are components of cell wall synthesis that accumulates 
during stationary phase. whiB6 was up-regulated even though this gene was previously 
thought to be irrelevant for transition into stationary phase (Ramón-García et al., 2012). 
Genes that were down-regulated included those involved in cell wall synthesis, sugar 
transport, recycling of amino sugars which are important energy source during stationary 
phase, import of sugars needed for mycothiol biosynthesis and sigma E which is essential for 
growth in macrophages. A role of the Tap efflux pump in mycobacterial virulence was also 
suggested since early secretory antigenic target-6 (ESAT-6), which is involved in antigen 





The Tap-like efflux pump in M. fortuitum extrudes tetracyclines and aminoglycosides 
(Ramón-García et al., 2006; Louw et al., 2009). The Tap efflux pump is not only present in 
Mycobacterial clinical isolates, but also in different Mycobacterial species collected from soil 
in grasslands. These species include M. fortuitum, M. alvei and M. septicum. The Tap efflux 
pump was present in only a percentage of tetracycline resistant strains and was also found in 
some tetracycline sensitive strains, demonstrating that the presence of the Tap efflux pump 
does not necessarily cause resistance. It would also suggest that the function of the Tap efflux 
pump is not only drug resistance, but that some clinically relevant pathogenic Mycobacteria 
and soil Mycobacteria, which are exposed to tetracycline present in soil, have adapted in such 
a way as to use the Tap efflux pump to efflux drugs such as tetracyclines (Kyselková et al., 
2012). These studies show the physiological role for the Tap efflux pump in addition to its 
role in drug efflux.  
 
Rv1258c, is a Tap-like efflux pump of the MFS family in M. tuberculosis (a homologue of 
the Tap efflux pump discussed above). Expression of the Rv1258c homologue in  
M. smegmatis, resulted in increased tetracycline resistance and a decrease in the intracellular 
tetracycline levels. This demonstrates that Rv1258c is able to transport tetracycline and is 
implicated in subsequent tetracycline resistance (De Rossi et al., 2002). A knockout mutant 
of Rv1258c in M. tuberculosis H37Rv showed increased susceptibility to gentamicin, 
spectinomycin and amikacin while hyperexpression decreased susceptibility to these drugs 
implicating Rv1258c in their efflux (Balganesh et al., 2012). Rv1258c is also implicated in 
RIF resistance as increased Rv1258c expression was observed following exposure to RIF in 
some MDR M. tuberculosis strains (Siddiqi et al., 2004; Gupta et al., 2006; Jiang et al., 
2008). The Rv1258c efflux pump in M. tuberculosis might also have physiological functions 




Multidrug efflux pumps are regulated by both local and global regulators. The local 
regulators are usually encoded in close proximity to the efflux pump that it regulates. The 
genetic arrangement of these regulators may vary, with some encoded upstream of the pump 
on the opposite strand, while others are present within the same operon as the efflux pump 
encoding gene. Either way, the local regulators regulate not only the efflux pump expression, 




Efflux pumps are often induced by the drugs that they export in a concentration dependent 
manner. This regulation occurs via binding of the drugs to the drug binding domains of the 
efflux pump local regulators that usually cause a conformational change. The conformational 
change in turn alters the regulator‟s affinity for the DNA and can cause either dissociation 
from the efflux pump promoter region resulting in de-repression (in the case of repressor) or 
can enhance binding to the promoter region activating transcription (in the case of activators).  
 
In addition to local regulation, global regulators also regulate efflux pumps and provide the 
bacteria with the ability to control the expression of many sets of genes involved in different 
processes at once. The inclusion of efflux pumps in global regulated genes indicates the 
important contribution these efflux pumps to numerous processes. Efflux pump expression 
can also be modulated by pH, ions (for instance metal ions) and metabolic energy. Molecules 
involved in quorum-sensing have also been shown to regulate the expression of some efflux 
pumps.  
 
Efflux pumps have physiological functions in addition to the drug efflux and it is believed 
that the drug efflux is actually a secondary acquired function of these pumps. This why 
regulation of efflux pumps is so important since accidental export of a needed compound can 
be detrimental to the bacteria. It is important that we gain a more complete understanding of 
the regulation of efflux since it is an important process contributing to drug resistance in 
many clinically relevant pathogenic species. Clearly the regulation of these pumps are 
complex and there are many levels to regulation, but understanding these regulatory 





CHAPTER 2: STUDY RATIONAL, HYPOTHESES, AIMS AND EXPERIMENTAL 
 DESIGN 
 
2.1 STUDY RATIONAL 
 
There were an estimated 8.7 million TB incident cases worldwide during 2011. MDR-TB, 
defined as having resistance to at least the first-line drugs, isoniazid and RIF, is a global 
health problem with 3.7% of new and 20% of previously treated TB cases globally estimated 
to have MDR-TB (World Health Organization (WHO), 2012).  
 
RIF binds to the β-subunit of RNA polymerase forming a stable drug-enzyme complex, 
which causes premature termination of transcription and ultimately causes the death of 
bacteria (Johnson et al., 2006). Central dogma suggests that RIF resistance is mainly 
associated with mutations in the 81 bp region encoding the β-subunit, called the RIF 
resistance determining region (RRDR) (Huitric et al., 2006). Mutations such as single point 
mutations, insertions, deletions and multiple nucleotide changes in the rpoB gene are 
associated with RIF resistance. The S531L and H526Y rpoB mutations occur frequently in 
isolates from all over the world (Ohno et al., 1996; Tracevska et al., 2002; Huitric et al., 
2006; Madania et al., 2012) and are associated with high level RIF resistance (Ohno et al., 
1996; Huitric et al., 2006). 
 
However, there is now growing evidence that efflux is also involved in determining the level 
of RIF resistance since exposure of M. tuberculosis MDR clinical isolates and RIF mono-
resistant isolates to efflux pump inhibitors restored susceptibility to RIF (Louw et al., 2011). 
Also, by using efflux pump inhibitors it was shown that RIF resistance could be mediated by 
an efflux mechanism (Gupta et al., 2006). However, exposure of pan-susceptible strains to 
efflux pump inhibitors did not modulate RIF resistance (Louw et al., 2011).  
 
Several studies have implicated Rv1258c, a multidrug efflux pump, in RIF and other drug 
resistance in M. tuberculosis (Siddiqi et al., 2004; Gupta et al., 2006; Jiang et al., 2008; 
Sharma et al., 2010; Louw et al., 2011). Rv1258c expression was increased upon exposure to 
RIF in an in vitro generated M. tuberculosis H37Rv RIF mono-resistant strain (Sharma et al., 
2010) and some MDR clinical isolates, but not in others (Siddiqi et al., 2004; Gupta et al., 




some strains indicates a possible effect of other SNPs present in the strains on Rv1258c 
expression.  
 
A possible binding site for the global transcriptional regulator, WhiB7, has been identified in 
the promoter of M. tuberculosis Rv1258c (Burian et al., 2012). Rv1258c is regulated by 
WhiB7 and exposure to antibiotics initially increased whiB7 expression followed by a whiB7 
dependent induction of Rv1258c (Morris et al., 2005). 
 
Both rpoB mutations and efflux are thus important in the acquisition of RIF resistance and 
determining the levels of RIF resistance in M. tuberculosis. It is currently still unclear if there 
is a link between the rpoB mutation and expression of efflux pumps implicated in RIF 
resistance. This study will focus on expression of the Rv1258c and whiB7 genes, in different 
rpoB mutants. 
 
2.2 HYPOTHESIS, AIMS AND EXPERIMENTAL DESIGN 
 
Overall aim: 
To determine the effects of rpoB mutations on Rv1258c and whiB7 expression in  
M. tuberculosis.  
 
Hypothesis 1: 
The presence of a rpoB mutation affects the expression of the Rv1258c multidrug efflux 




To monitor and compare Rv1258c expression in in vitro generated M. tuberculosis H37Rv 
RIF mono-resistant rpoB mutants in the absence and presence of RIF. 
 
Experimental design: 
The experimental design is outline in Fig 2.1. Briefly, promoter reporter vectors (episomal 
and integrating) with the M. tuberculosis H37Rv Rv1258c promoter upstream of a lacZ gene 
were constructed and functioning of these vectors tested in M. smegmatis. The effects of rpoB 




using β-galactosidase assays. The promoter activity results obtained during β-galactosidase 
assays were compared to the transcript levels of the native Rv1258c gene using qRT-PCR. 
 
Hypothesis 2: 
The presence of rpoB mutation affects the expression of the whiB7 gene, encoding a 




To monitor whiB7 expression in in vitro generated M. tuberculosis RIF mono-resistant rpoB 
mutants in the absence of RIF using qRT-PCR. 
 
Experimental design: 
The experimental design is outline in Fig 2.1. Briefly, RNA was extracted and qRT-PCR 


















Figure 2.1. Experimental design of this study.  
Clone promoter region of Rv1258c from H37Rv into position 
upstream of a lacZ gene in multi-copy episomal vector 
Modify episomal vectors to obtain integrating vectors 
Investigate functioning of episomal and integrating vectors in  
M. smegmatis using β-galactosidase assays 
Investigate effect of rpoB mutations on Rv1258c expression using 
β-galactosidase assays in M. smegmatis and  
M. tuberculosis rpoB mutants in the absence and presence of RIF 
Compare promoter activity results obtained during β-galactosidase 
assay to the native Rv1258c transcript levels using qRT-PCR 




CHAPTER 3: GENERAL METHODOLOGY 
 
3.1 BACTERIAL STRAINS AND CULTURE CONDITIONS 
 
The bacterial strains used during this study are summarized in Table 3.1. E. coli strain 
XL1Blue was used for all cloning purposes. E. coli was cultured overnight in Luria-Bertani 
(LB) broth, aerobically at 37°C with shaking at 175 rpm or on LB agar at 37°C. The 
following antibiotics were added to the LB broth and agar when necessary for selection: 
kanamycin (50 µg/ml), ampicillin (100 µg/ml) and hygromycin (150 µg/ml) (Sigma-Aldrich). 
When required 5-Bromo-4 Chloro-3 Indolyl β-D-galactosidase (X-gal)  
(40 µg/ml) (Roche Applied Sciences) (which was dissolved in dimethyl sulfoxide (DMSO)) 
was added to the LB agar. 
 
M. smegmatis mc2155 was cultured in Middlebrook 7H9 (Becton, Dickinson and Company) 
supplemented with 2% glucose, 0.85% sodium chloride and 0.05% Tween 80 (subsequently 
called 7H9 GS) aerobically at 37°C with shaking at 175 rpm or on 7H10 Difco Dubos Agar 
Base (Becton, Dickinson and Company) supplemented with 2% glucose and 0.85% sodium 
chloride (subsequently called 7H10 GS) at 37°C. M. smegmatis freezer stocks or single 
colonies were inoculated into a pre-culture, cultured to stationary phase and then sub-cultured 
to an optical density (OD) of 0.02 at 600 nm. The MIC for the M. smegmatis mc2155 wild-
type and rpoB mutant strains were previously determined and are summarized in Table 3.2.  
 
M. tuberculosis was cultured under Biohazard safety three conditions in Middlebrook 7H9 
(Becton, Dikinson and Company) supplemented with 0.2% glycerol, 0.05% Tween 80, 
albumin (0.5 μg/ml), 0.111% glucose and 0.0375% catalase (Sigma-Aldrich) subsequently 
called 7H9 ADC, unless stated otherwise. Culturing of M. tuberculosis on solid medium was 
done on Middlebrook 7H10 Agar Base (Becton, Dickinson and Company) supplemented with 
0.5% glycerol, albumin (0.5 μg/ml), 0.111% glucose and 0.0375% catalase subsequently 
called 7H10 ADC, unless stated otherwise. Liquid culturing was done aerobically at 37°C in 
Greiner bio-one flasks without shaking in secondary airtight containers. M. tuberculosis 
freezer stocks or single colonies were inoculated into a pre-culture, cultured to an OD of 





The cultures were regularly screened for possible contamination by plating on blood agar that 
was checked for growth of contaminants two days after plating and Ziehl-Neelsen (Zn) 
staining. Zn-staining was done according to the protocol outlined by Kent & Kubica (1985). 
Briefly, a small drop of M. tuberculosis was heat fixed to glass slides using fixative and 
heating at 95°C for two hours. The slides were subsequently flooded with Carbol Fuschin, 
heated with a flame and left for 5 min. After rinsing with water, any non-acid fast bacteria 
(contaminants) were destained for 2 minutes (min) using acid-alcohol. After rinsing with 
water, counterstaining was done for 2 min with Methylene blue. Any non-acid fast bacteria 
would stain blue. The slides were rinsed and air dried. The slides were inspected using a light 
microscope under oil immersion lens for any possible contaminants. 
 
The following antibiotics were added to the medium when necessary: kanamycin (50 µg/ml) 
and hygromycin (50 µg/ml) for M. smegmatis and M. tuberculosis and RIF, 10 μg/ml for  
M. smegmatis and 2 μg/ml for M. tuberculosis. RIF (Sigma-Aldrich) was dissolved in 10% 
DMSO (Sigma-Aldrich) to a final concentration of 1 000 µg/ml and was stored in aliquots at 
-80°C for no longer than a month. X-gal was added to a final concentration of 40 µg/ml to 
7H10 GS as required. The vectors and primers used in this study are summarized in Table 3.3 
and Table 3.4 respectively. 
 
3.2 RESTRICTION ENZYME DIGESTS 
 
Restriction enzyme (RE) digests were done in a total volume of 20 µl. The amount of enzyme 
added and incubation time was adjusted appropriately to ensure complete digestion of the 
DNA present in each reaction. Reaction mixes were incubated at 37°C. The amount of DNA 
digested varied and is specified for each digest in the figure titles. 
 
3.3 AGAROSE GEL ELECTROPHORESIS 
 
DNA fragments generated by restriction enzyme digests or PCR were separated by agarose 
gel electrophoresis using a Tris-EDTA buffer system (TAE) (containing Tris buffer  
(40 mM), Na2EDTA (1 mM) and 0.112% glycerol). Electrophoresis was done at 100 V and 
an appropriate DNA ladder was included for sizing of the bands. The DNA was stained using 







For purification of DNA fragments prior to ligation, digested DNA or PCR products were 
separated by electrophoresis and the appropriate bands excised from the gel. The DNA was 
then purified using the Wizard SV Gel and PCR Clean-Up System (Promega) according to 
the manufacturer‟s instructions. 
 
Different ligation kits were used during this study as specified in the subsequent sections. The 
FastLink DNA Ligation kit (Epicentre Biotechnologies) was used according to the 
manufacturer‟s instructions. Briefly, 50 ng vector was added to the insert in a vector:insert 
ratio of 1:5 in a 15 µl ligation mixture containing 1x Fast-Link Ligation Buffer, 1 mM ATP 
and two units (U) Fast-Link DNA Ligase. After incubated for 15 min at room temperature, 
the ligase was inactivated by incubation at 65°C for 15 min. 
 
3.5 PREPARATION OF ELECTROCOMPETENT E. COLI  
 
E. coli was cultured to mid-log growth phase and chilled on ice for 20 min. The bacteria were 
harvested by centrifugation at 3,220 ×g for 15 min at 4°C, the supernatant discarded and 
bacteria washed three times with decreasing volumes of ice-cold 10% glycerol (equal volume 
to culture, followed by half of initial culture volume and 1/20
th
 of the initial culture volume). 
The bacterial pellet was re-suspended in 1/500
th
 the initial culture volume of 10% glycerol, 
snap frozen and stored at -80°C until required. 
 
3.6 ELECTROPORATION OF E. COLI 
 
Electrocompetent cells were thawed on ice. For each transformation, a 40 µl aliquot of 
electrocompetent cells was mixed with 2 µl of the ligation reaction or vector DNA and 
transferred into a Gene Pulser cuvette (Bio-Rad). Electroporation was done using a Bio-Rad 
MicroPulser (Bio-Rad) set to the EC2 setting for E. coli transformations. After 
electroporation, 500 µl LB broth was added and the bacteria were incubated at 37°C for one 
hour to allow expression of the selection marker, before plating on LB agar containing an 





Table 3.1. Bacterial strains used 
Bacterial strain 
 
Vector Description of strain Provided by 
E. coli XL1Blue - - Laboratory collection 
 
M. smegmatis mc2155 wild-type - ept-1 (efficient plasmid transformation) mutant of mc26 (Snapper et al., 1990) 
M. smegmatis mc2155 rpoB S531L - Derivative of wild-type generated by allelic exchange containing TCG531TTG 
mutation at codon 531 of rpoB gene causing S531L amino acid substitution 
Anastasia Koch at 
UCT (unpublished) 
M. smegmatis mc2155 rpoB H526Y - Derivative of wild-type generated by allelic exchange containing CAC526TAC  
mutation at codon 526 of rpoB gene causing H526Y amino acid substitution 
Anastasia Koch at 
UCT (unpublished) 
  
M. smegmatis mc2155 wild-type 
(pJEM15) 
pJEM15 M. smegmatis mc2155 wild-type transformed with pJEM15 vector This study 
M. smegmatis mc2155 wild-type 
(pJEM15promo) 
pJEM15promo M. smegmatis mc2155 wild-type transformed with pJEM15promo vector This study 
M. smegmatis mc2155 rpoB S531L 
(pJEM15) 
pJEM15 M. smegmatis mc2155 rpoB S531L transformed with pJEM15 vector This study 
M. smegmatis mc2155 rpoB S531L 
(pJEM15promo) 
pJEM15promo M. smegmatis mc2155 rpoB S531L transformed with pJEM15promo vector This study 
M. smegmatis mc2155 rpoB H526Y 
(pJEM15) 
pJEM15 M. smegmatis mc2155 rpoB H526Y transformed with pJEM15 vector This study 
M. smegmatis mc2155 rpoB H526Y 
(pJEM15promo) 






Table 3.1. Bacterial strains used (continued) 
Bacterial strain Vector Description of strain Provided by 
M. smegmatis mc2155 wild-type 
attB::pMV306lacZ 
pMV306lacZ M. smegmatis mc2155 wild-type with pMV306lacZ vector integrated into attB 
site of mycobacterial genome 
This study 
M. smegmatis mc2155 wild-type 
attB::pMV306promolacZ 
pMV306promolacZ M. smegmatis mc2155 wild-type with pMV306promolacZ vector integrated into 
attB site of mycobacterial genome 
This study 
M. smegmatis mc2155 rpoB S531L 
attB::pMV306lacZ 
pMV306lacZ M. smegmatis mc2155 rpoB S531L with pMV306lacZ vector integrated into 
attB site of mycobacterial genome 
This study 
M. smegmatis mc2155 rpoB S531L 
attB::pMV306promolacZ 
pMV306promolacZ M. smegmatis mc2155 rpoB S531L with pMV306promolacZ vector integrated 
into attB site of mycobacterial genome 
This study 
M. smegmatis mc2155 rpoB H526Y 
attB::pMV306lacZ 
pMV306lacZ M. smegmatis mc2155 rpoB H526Y with pMV306lacZ vector integrated into 
attB site of mycobacterial genome 
This study 
M. smegmatis mc2155 rpoB H526Y 
attB::pMV306promolacZ 
pMV306promolacZ M. smegmatis mc2155 rpoB H526Y with pMV306promolacZ vector integrated 
into attB site of mycobacterial genome 
This study 
 
M. tuberculosis H37Rv wild-type - H37RvJo (ATCC: 25618) (For comparison of genome with that of other H37Rv 
laboratory strains see Ioerger et al. (2010)) 
(Ioerger et al., 2010)  
M. tuberculosis H37Rv rpoB S531L - Spontaneous in vitro rpoB TCG531TTG mutant causing S531L amino acid 
substitution generated from M. tuberculosis H37Rv wild-type strain and isolated 
by selection on RIF 
This study 
M. tuberculosis H37Rv rpoB H526Y - Spontaneous in vitro rpoB CAC526TAC mutant causing S531L amino acid 
substitution generated from M. tuberculosis H37Rv wild-type strain and isolated 







Table 3.1. Bacterial strains used (continued) 
Bacterial strain Vector Description of strain Provided by 
M. tuberculosis H37Rv wild-type 
(pJEM15promo) 
pJEM15promo M. tuberculosis H37Rv wild-type transformed with pJEM15promo vector This study 
 
M. tuberculosis H37Rv wild-type 
attB::pMV306lacZ 
pMV306lacZ M. tuberculosis H37Rv wild-type with pMV306lacZ vector integrated into attB 
site of mycobacterial genome 
This study 
M. tuberculosis H37Rv wild-type 
attB::pMV306promolacZ 
pMV306promolacZ M. tuberculosis H37Rv wild-type with pMV306promolacZ vector integrated 
into attB site of mycobacterial genome 
This study 
M. tuberculosis H37Rv rpoB S531L 
attB::pMV306lacZ 
pMV306lacZ M. tuberculosis H37Rv rpoB S531L with pMV306lacZ vector integrated into 
attB site of mycobacterial genome 
This study 
M. tuberculosis H37Rv rpoB S531L 
attB::pMV306promolacZ 
pMV306promolacZ M. tuberculosis H37Rv rpoB S531L with pMV306promolacZ vector integrated 
into attB site of mycobacterial genome 
This study 
M. tuberculosis H37Rv rpoB H526Y 
attB::pMV306lacZ 
pMV306lacZ M. tuberculosis H37Rv rpoB H526Y with pMV306lacZ vector integrated into 
attB site of mycobacterial genome  
This study 
M. tuberculosis H37Rv rpoB H526Y 
attB::pMV306promolacZ 
pMV306promolacZ M. tuberculosis H37Rv rpoB H526Y with pMV306promolacZ vector integrated 
into attB site of mycobacterial genome 
This study 
 
Table 3.2. MICs of M. smegmatis mc
2
155 wild-type and rpoB mutants 
Bacterial strain MIC for RIF Method for determining MIC Determined by 
M. smegmatis mc2155 wild-type 2.0 - 3.9 μg/ml Microdilution assay in 7H9 supplemented with 10% oleic acid-dextrose-catalase (OADC) A. Koch at UCT 
M. smegmatis mc2155 rpoB S531L 125 - 250 μg/ml Microdilution assay in 7H9 supplemented with 10% OADC A. Koch at UCT 





3.7 PREPARATION OF ELECTROCOMPETENT M. SMEGMATIS 
 
M. smegmatis was cultured to mid-log phase, and then harvested by centrifugation at  
4°C at 3,220 ×g. The cells were washed four times with decreasing volumes of ice-cold 10% 
glycerol. The bacterial pellet was finally re-suspended in 1/60
th
 of the original volume of cold 
10% glycerol. Electrocompetent M. smegmatis was incubated on ice until used. 
 
3.8 PREPARATION OF ELECTROCOMPETENT M. TUBERCULOSIS 
 
M. tuberculosis was cultured to an OD of approximately 1.00 at 600 nm and then harvested 
by centrifugation at 25°C at 3,220 ×g. The cells were washed two times with decreasing 
volumes of a mixture of 0.05% Tween 80 and 10% glycerol preheated to 37°C. The bacterial 
pellet was finally re-suspended in the volume needed for the amount of electroporations to be 
done (400 µl per electroporation) of the mixture of 0.05% Tween 80 and 10% glycerol. 
Electrocompetent M. tuberculosis was incubated at 37°C before use. 
 
3.9 ELECTROPORATION OF M. SMEGMATIS AND M. TUBERCULOSIS 
 
Electroporations were done at 37°C for M. tuberculosis and 4°C for M. smegmatis by either 
preheating or precooling the cells and cuvettes. A 400 µl aliquot of electrocompetent bacteria 
was mixed with the vector DNA (500 ng) and transferred to a Gene Pulser cuvette (Bio-Rad). 
The vectors used in this study are summarised in Table 3.3. Electroporation was done using a 
Bio-Rad Pulse Controller Plus using the following parameters: 1,000 , 25 µF and 2,500 V. 
After electroporation, 800 µl of liquid media (7H9 GS or 7H9 ADC, for M. smegmatis or  
M. tuberculosis respectively) was added and the bacteria were incubated at 37°C for three 
hours in the case of M. smegmatis or overnight in the case of M. tuberculosis to allow 
expression of the selection markers before plating on 7H10 GS or 7H10 ADC containing the 
appropriate antibiotic. Transformants were selected. 
 
3.10 COLONY PCR 
 
Colony PCR was used to confirm the presence of the Rv1258c promoter region and or lacZ 




transformed with the vectors. For E. coli and M. smegmatis, colonies were picked and 
resuspended in 10 µl nuclease free water. After spotting 2 µl of each suspension on 
appropriate solid media containing antibiotic to maintain the vector, the remaining suspension 
was heated to 100ºC for 5 min to facilitate cell lysis and DNA release. For M. tuberculosis, 
10 ml 7H9 ADC was inoculated with the colony and the culture was allowed to grow for a 
few days. A 200 μl aliquot of this culture was transferred to an eppendorf tube and boiled for 
30 min at 99°C to facilitate cell lysis and to ensure killing of the bacteria. The FastStart Taq 
DNA Polymerase kit (Roche Applied Sciences) was used to perform colony PCR. Each 12.5 
µl PCR reaction mix contained 1× PCR buffer with magnesium chloride (MgCl2) (final 
concentration 2 mM MgCl2), 1× GC-Rich solution, 200 µM of each deoxynucleoside 
triphosphate (dNTP) (Fermentas), 0.5 µM of both the forward and reverse primers, 1 µl cell 
lysates and 1.32 U FastStart Taq DNA Polymerase. The PCR cycling conditions were: initial 
denaturation at 95ºC for 4 min followed by 40 cycles of denaturation at 95ºC for 30 s, 
annealing at the appropriate annealing temperature (Tm) for the primers for 30 s and 
extension at 72ºC for 1 min followed by a final extension at 72ºC for 7 min. The primers used 
in this study are summarised in Table 3.4. Agarose gel electrophoresis was used to determine 
the size of the PCR products. 
 
3.11 PLASMID DNA EXTRACTION 
 
The NucleoBond PC100 Plasmid DNA Purification kit (Macherey-Nagel) was used 
according to the manufacturer‟s instructions for the isolation and purification of the following 
vectors: pJEM15, pJET1.2promo and pMV306promolacZ. The Wizard Plus SV Minipreps 
DNA Purification System (Promega) was used according to manufacturer‟s instructions for 
the isolation and purification of the following vectors: pJEM15promo, pMV306, 
pMV306lacZ and pGEM-T EasyRACE1/2. All DNA concentrations and the quality of the 
DNA (260/280 ratios) was assessed using a NanoDrop ND-1000 spectrophotometer. 
 
3.12 PREPARATION OF WHOLE CELL LYSATES (WCLS) FOR  
M. SMEGMATIS AND M. TUBERCULOSIS 
 
WCLs were prepared from liquid cultures as previously described (Carroll & James, 2008). 
Briefly, M. smegmatis or M. tuberculosis culture (10 ml) was pelleted by centrifugation at  




buffer (pH 8.0) (subsequently called Tris buffer), re-suspended in 1 ml Tris buffer and 
transferred to a 2 ml screw cap tube containing 0.1 mm glass beads (Biospec Inc). The 
bacteria were lysed in a Biospec Bead Beater at speed 6.00 for 30 s in the case of M. 
smegmatis and three times 25 s at speed 5.00 in the case of  
M. tuberculosis. The cellular debris was pelleted by centrifugation at 16,100 ×g for 10 min 
and the supernatant transferred to a sterile 1.5 ml eppendorf tube. For M. smegmatis WCLs, 
the supernatant was clarified by centrifugation at 16,100 ×g for 5 min and transferred to a 
sterile eppendorf tube. For M. tuberculosis, the WCLs were double filter sterilized using 
Acrodisc Syringe Filters (Pall Corporation). The WCLs were stored in two aliquots at -80°C 
until used for the Bradford and β-galactosidase assays. 
 
3.13 PROTEIN CONCENTRATION DETERMINATION 
 
The protein concentrations for the WCLs were determined using Bradford protein 
determination assays (Bradford, 1976). A stock solution containing 8 mg/ml of Bovine serum 
albumin (BSA) in Tris buffer was prepared and stored in aliquots at -20°C. Dilutions of the 
BSA stock were used to generate a standard curve (0.05 - 0.25 mg/ml) for each assay and 
Tris buffer was used as a blank. The assays were done in 96 well microtitre plates (Greiner 
Bio-one) in triplicate. Each assay contained 10 µl BSA dilution or WCL and 200 µl Bradford 
reagent (Bio-Rad), the latter pre-warmed to room temperature. The microtitre plate was 
covered with foil to prevent exposure of the reaction to light and incubated at room 
temperature for 15 min prior to measuring the absorbance at 595 nm using a Bio-Tek 
Synergy HT plate reader (Bio-Tek instruments) and the KCL4 program and Excel was used 
for analysis of the data. Appropriate dilutions of the WCLs were made to ensure the 
concentrations could be determined using the linear range of the standard curve. The protein 
concentration for each WCL was determined using the following formula: 
 
                                                               
                              
                 
 
3.14 β-GALACTOSIDASE ASSAYS 
 
The WCLs were defrosted on ice and diluted in Tris buffer to the same total protein 




determine the appropriate protein concentration to use in the assay for each strain. This is 
required since the amount of β-galactosidase in each sample may vary relative to the amount 
of total protein in the different strains. O-nitrophenyl-β-D-galactopyranoside (ONPG) 
(Sigma-Aldrich) was freshly prepared before each assay by dissolving ONPG in Z-buffer (60 
mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4) to a concentration of  
1.33 mg/ml and it was filter sterilized. The β-galactosidase assays were done in a microtitre 
plates in triplicate and the reaction was initiated by mixing 50 µl ONPG (final concentration 
665 μg/ml) with 50 µl of the WCL dilutions. The microtitre plate was placed in a Bio-Tek 
Synergy HT plate reader (Bio-Tek instruments) within 5 min of adding the ONPG and the 
absorbance at 420 nm was measured every 5 min for 1 hour. The absorbance for the Tris 
buffer was used as blank and subtracted from each reading. The kinetic reads were plotted to 
generate kinetic curves at different protein concentrations of each of the dilutions of the 
WCLs. An appropriate protein concentration and incubation period was selected (refer to 
Addendum B for an explanation of how this was done) and used to calculate the β-
galactosidase activity in Miller units according to the following formula: 
 
β                                        
                                                                  
                                                                              
 
 
3.15 RNA EXTRACTION 
 
3.15.1 RNA extraction using trizol 
 
The trizol method of RNA extraction was used as described previously in (Betts et al., 2002) 
with slight modifications. Briefly, 10 ml of the culture was pelleted by centrifugation at  
3,220 ×g and re-suspended in 1 ml trizol (Applied Biosystems, Ambion). The cell suspension 
was transferred to tubes containing 0.1 mm glass beads and ribolysed in a Biospec Bead 
Beater at speed 6.0 for two 60 s cycles with 60 s cooling intervals in between. After 
centrifugation the supernatant was transferred to a new tube and 120 µl chloroform added. 
Tubes were inverted rapidly for 15 s and periodically inverted for 2 min. After centrifugation 
at 14,000 ×g, the top layer was transferred to a new tube, 200 µl chloroform added and the 
tubes inverted as previously. An equal volume of isopropanol was added and samples were 




washed with 70% ethanol. Centrifugation at 14,000 ×g was used to pellet the RNA, the 
ethanol was removed and the pellet was air-dried. The RNA was re-suspended in 1x DNase I 
buffer (Applied Biosystems, Ambion) and incubated with 4 U of DNase I (Applied 
Biosystems, Ambion) for 1 hour. The RNeasy kit (Qiagen) was used for RNA clean-up 
according to the manufacturer‟s instructions. RNA samples, treated with 350 µl RLT buffer 
(from the RNeasy kit) and 250 µl ethanol, were loaded onto a column and spun down for 15s. 
In order to concentrate RNA, multiple preparations was done from a single culture and all the 
RNA loaded onto a single column. The RNA was eluted in 60 µl nuclease free water. RNA 
(49.2 µl) was added to 1× Turbo DNase buffer (Applied Biosystems, Ambion) and incubated 
with 9.6 U Turbo DNase at 37ºC for 2 hours. Phenol-chloroform extraction of the RNA was 
done and the RNA concentration was determined using a NanoDrop ND-1000 
spectrophotometer. 
 
3.15.2 RNA extraction using FastRNA Pro Blue Kit 
 
The FastRNA Pro Blue kit (Qbiogene) was used for RNA extractions according to the 
manufacturer‟s instructions. M. tuberculosis was cultured to the appropriate OD at 600 nm 
and 10 ml culture pelleted at 3,220 ×g. The supernatant was discarded, the pellet re-
suspended in 1 ml RNApro solution and the re-suspended cells transferred to a 2 ml tube 
containing Lysing Matrix B. The samples were rybolysed five times for 25 s at speed 4.5 and 
the cellular debris pelleted at 12,000 ×g for 15 min at 4°C. The supernatant was transferred to 
an eppendorf tube, 300 µl chloroform added and vortexed for 10 s. After 5 min incubation at 
room temperature to facilitate nucleoprotein dissociation, the phases were separated by 10 
min centrifugation at 12,000 ×g at 4°C. The upper phase was transferred to an eppendorf 
tube. Cold absolute ethanol (500 µl) was added and the samples were vortexed. The sample 
was stored for at least 1 hour at -20°C to precipitate the RNA. The RNA was pelleted by 
centrifugation at 12,000 ×g for 30 min at 4°C. Cold 75% ethanol (500 µl) was added to the 
pellet after removal of the supernatant and the sample was vortexed for 5 s. The ethanol was 
removed and the sample air dried for 5 min at room temperature. Water was added to the 
RNA pellet and the sample was incubated for minimum 5 min at room temperature to 
facilitate RNA re-suspension.  
 
The samples were then treated with DNase I (8 U per 100 µl) in 1× DNase I buffer (Applied 




overnight at 4°C as described below. After the RNA pellet was re-suspended in water, the 
RNA was incubated with Turbo DNase I (2 U) in 1× Turbo DNase buffer (Applied 
Biosystems, Ambion) at 37°C for 30 min. The same amount of U of Turbo DNase I (2 U) 
was added after 30 min of incubation and the sample was incubated for a further 30 min at 
37°C. The enzyme was inactivated by phenol-chloroform extraction and the RNA 
precipitated overnight as described below. After re-suspending the RNA in water, the RNA 
quality (the 260/280 ratio) was assessed and the concentration was determined using a 
NanoDrop ND-1000 spectrophotometer. PCR was done to determine whether the RNA was 
free of genomic DNA as described below. It is important to note that the amount of U of 
DNase I and Turbo DNase I used for the removal of the genomic DNA from the RNA 
samples differed in some instances according to the concentration of the crude RNA 
extraction as determined using the NanoDrop ND-1000 spectrophotometer after the first steps 
of the extraction. 
 
3.15.3 Precipitation of RNA 
 
The volume of the RNA sample was made up with water to a total of 200 µl. An equal 
volume of phenol-chloroform (a 4:1 ratio mixture) was added, vortexed and placed on ice for 
10 min, vortexing every 3 min. After centrifugation at room temperature for 10 min at  
13,000 ×g, to separate the layers, the top layer (150 µl) was transferred to an eppendorf tube. 
This was done to inactivate the DNase I and to remove it from the sample. Sodium acetate 
(0.1× volume) and 100% ethanol (2.5× volume) was added and the sample vortexed. The 
sample was incubated overnight at 4°C, spun down at 13,000 ×g for 30 min at 4°C and the 
pellet washed with 75% ethanol. After centrifugation for at 10,000 ×g for 2 min at room 
temperature, the ethanol was removed and the pellet air dried for 5 min. Water was added and 
the sample incubated at room temperature for at least 5 min to facilitate RNA re-suspension. 
 
3.15.4 PCR to check whether the RNA samples were clean of genomic DNA 
 
PCR was used to assess whether the RNA sample contained any genomic DNA. Each 12.5 µl 
PCR reaction mix contained 1× PCR buffer with MgCl2 (final concentration of 2 mM), 1× 
GC-Rich solution, 200 µM dNTPs, 0.5 µM Rv1258cpF and Rv1258cpR primers, 1 µl RNA 
sample and 1.32 U FastStart Taq DNA polymerase (Roche Applied Sciences). The primers 




amplified as positive control. The PCR cycling conditions were: initial denaturation at 95ºC 
for 4 min followed by 35 cycles of denaturation at 95ºC for 30 s, annealing at 60ºC for 30 s 
and extension at 72ºC for 1 min and a final extension at 72ºC for 7 min. The PCR products 
were analysed using agarose gel electrophoresis. 
 
3.16 STATISTICAL ANALYSES 
 
Unpaired t-tests were used to analyse the significance of differences between datasets and 
were performed in GraphPad Prism 5. The Welch correction was used whenever variance 
within samples was not the same for the samples being compared, in order to correct for 





Table 3.3. Vectors used in this study 
Vector Episomal/ 
Integrating 
Copy number Size 
(bp) 






High (in E. coli) 
  
  2,974  
 
Contains:     
 a β-lactamase gene, bla (ApR), conferring ampicillin resistance 
 a lethal gene, Eco47IR, encoding toxic restriction endonuclease 
Eco47I, modified to contain a multiple cloning site (MCS) 
 The vector is linearized at position 371 providing blunt DNA ends for 











High (in E. coli) 
  
  3,621  
  
pJET1.2 vector containing the 635 bp promoter region upstream of the  
M. tuberculosis Rv1258c gene (amplified by PCR) cloned into the MCS at 
position where linearized 











(over 500 copies in E. coli and 









  9,446  
 
An E. coli-mycobacteria shuttle vector containing: 
 aminoglycoside phosphotransferase gene (aph), which confers 
kanamycin resistance 
 a reporter cassette with a mycobacterial transcriptional terminator 
followed by a MCS allowing promoter and operon fusion to the 
reporter gene 
 β-galactosidase gene (lacZ) devoid of its regulatory sequences 
 an E. coli replicon allowing preparation and manipulation of vector in  
E. coli 
 a mycobacterial replicon allowing expression of the vector in 
mycobacteria 







Table 3.3. Vectors used in this study (continued) 
Vector Episomal/ 
Integrating 
Copy number Size 
(bp) 









(3-10 copies in mycobacteria 




pJEM15 vector containing the 635 bp promoter region upstream of the  
M. tuberculosis Rv1258c gene (from pJET1.2promo) cloned into the MCS 
upstream of the lacZ gene 
















 a hygromycin resistance gene 
 an integrase gene which allows the vector to integrate into the attB site 
of the mycobacterial genome 




Integrating Single copy   7,536  pMV306 vector with the lacZ gene and the MCS of the pJEM15 vector and 









  8,165 
  
pMV306 vector with the promoter region of the M. tuberculosis H37Rv 
Rv1258c gene fused to the lacZ gene and transcriptional terminator 

























 an ampicillin resistance gene, ampR 
 a MCS within the alpha-peptide coding region of the lacZ gene 
encoding β-galactosidase 





Table 3.4. Primers used in this study 
Primer Sequence 
5’ – 3’ 
Tm 
°C 
Initial amplification of Rv1258c promoter region 
pRv1258cpF GGT ACC GAA TAT CGC GGC TGA ATC TA 60.0 
pRv1258cpR GGA TCC CAT TTA GCC AGG GTG AGC AT 62.5 
Sequencing of Rv1258c promoter region in sequencing vector pJET1.2 
pJET1.2For CGA CTC ACT ATA GGG AGA GCG GC NA 
pJET1.2Rev AAG AAC ATC GAT TTT CCA TGG CAG NA 
Used during PCR to check whether transformation of bacteria with the vector systems was successful 
LacZFor CTG GCG TAA TAG CGA AGA GG 55.3 
LacZRev GTT GCA CCA CAG ATG AAA CG 54.7 
Used for the amplification and subsequent sequencing of the rpoB RRDR 
rpoB For TGG TCC GCT TGC ACG AGG GTC AGA 66.3 
rpoB Rev CTC AGG GGT TTC GAT CGG GCA CAT 63.1 
5‟Rapid amplification of cDNA ends (5‟ RACE) primers 
Oligo d(T)-anchor GAC CAC GCG TAT CGA TGT CGA CTT TTT TTT TTT TTT TTV 
V=A, C or G 
NA 
PCR anchor GAC CAC GCG TAT CGA TGT CGA C 59.8 
Control primer neo1/rev CAG GCA TCG CCA TGG GTC AC 61.4 
Control primer neo2/rev GCT GCC TCG TCC TGC AGT TC 61.1 
Control primer neo3/rev GAT TGC ACG CAG GTT CTC CG 59.0 
RACE1 SP1 CAA TAA AGG CCA GGT TGA GGA TCG CC 61.6 
RACE1 SP2 ACT ATC GAG ACG CCA TCA CCC G 60.8 
RACE2 SP1 AGC TGG CGA AAG GGG GAT GT 61.8 
RACE2 SP2 AAC GCC AGG GTT TTC CCA GTC 60.3 
RACE2 SP3 GGG TTT TCC CAG TCA CGA CGT T 59.8 
pGEMTeasyT7 TAA TAC GAC TCA CTA TAG GG NA 
pGEMTeasySP6 TAT TTA GGT GAC ACT ATA G NA 
qRT-PCR primers 
MTB-SigA-RT CTG ACA TGG GGG CCC GCT ACG TTG 66.0 
Rv1258c-RT TGT TGG CTA TCC GCG TTC 55.5 
whiB7-RT GAT CTG TGG TTC GCC GAT AC 55.5 
MTB-SigA-F1 TGC AGT CGG TGC TGG ACA C 60.5 
MTB-SigA-R1 CGC GCA GGA CCT GTG AGC GG 66.0 
Rv1258c-F1 CCC GCG TCT GTA TCA CGT A 56.7 
Rv1258c-R1 CGG TTC TTA CCC TGG GTT TG 55.8 
whiB7-F1 TCG AGC CTT GGT CGA ATA TC 54.2 








The expression of mycobacterial genes in other bacterial systems was initially limited 
because of the inability of regulatory elements in other bacteria to recognise and subsequently 
express mycobacterial genes. This is as a result of the evolutionary distance of the bacterial 
species from mycobacteria (Machowski et al., 2005). In 1985 mycobacterial DNA was 
expressed for the first time in the model organism E. coli. This opened up new possibilities 
for studying mycobacterial gene expression using molecular genetics tools such as protein 
expressing genes and episomal and integrating vectors. Subsequently, shuttle vectors that are 
able to replicate in mycobacteria and can be used to transform mycobacteria were developed, 
creating new research possibilities (Machowski et al., 2005). 
 
Promoter activity assays are frequently used to study gene expression and involve the 
creation of transcriptional fusion of a heterologous promoter to a promoterless reporter gene 
upstream of the gene, allowing for investigating transcriptional regulation upon exposure to 
different environmental conditions (Machowski et al., 2005; Carrol & James, 2008). Reporter 
genes that have been used in mycobacteria include gfp, encoding green fluorescent protein, 
and lacZ, encoding β-galactosidase. The lacZ gene can be used to quantitatively determine 
the promoter activity from WCLs in liquid assays (Machowski et al., 2005; Carrol & James, 
2008).  
 
β-galactosidase is an enzyme that cleaves the colourless substrate ONPG to a yellow 
chromophore with a maximum absorbance at 420 nm. The absorbance increase at 420 nm 
over the assay period is therefore directly proportional to the β-galactosidase concentration 
and the promoter activity. The lacZ reporter is advantageous since the β-galactosidase protein 
is stable and no background β-galactosidase activity is present in mycobacteria. The β-
galactosidase assays also enable the study of promoters with low in vitro activity because of 
its sensitivity (Carrol & James, 2008).  
 
The pJEM series of E. coli-mycobacteria promoter reporter shuttle vectors were designed by 
Timm et al. (1994). In these vectors, an E. coli and mycobacterial replicon are present to 




serves as the reporter gene. A heterologous sequence or promoter can be fused to the amino 
terminus of the lacZ gene without loss of enzymatic activity. The pJEM15 vector contains a 
transcriptional terminator upstream of the MCS. The selectable marker gene, aph, confers 
kanamycin resistance and kanamycin is thus added to the media in order to select for the 
presence of the vector. This episomal vector is a multi-copy vector in E. coli and 
mycobacteria (Timm et al., 1994). 
 
In order to investigate M. tuberculosis H37Rv Rv1258c promoter activity in this study, the 
promoter region of Rv1258c would be cloned into the pJEM15 vector upstream of the lacZ 
gene. Since the pJEM15 vector is a multi-copy vector system, we hypothesized that the 
regulation of Rv1258c promoter could be altered by the multiple copies of the Rv1258c 
promoter present within the cell. In addition, the presence of the selectable drug (kanamycin) 
in the media could also influence the expression of the Rv1258c promoter. We therefore 
sought to improve the pJEM15 reporter system. 
 
The discovery of the gene responsible for the integrating of lysogenic mycobacteriophages 
into the mycobacterial genome has led to the development of integrating vectors. Integrating 
vectors have an int gene encoding integrase, which permits integrating of phage DNA into 
the mycobacterial DNA. An attP site (from a phage) is also present in the integrating vectors 
and recombination of the attP site with the chromosomal attB site in the mycobacterial 
genome leads to integration of the entire vector into the attB site of the chromosome 
(Machowski et al., 2005). Only one copy of the integrating vector can integrate into the 
mycobacterial genome. Integrating vectors must integrate into the mycobacterial genome in 
order to persist since they lack a mycobacterial origin of replication (Dennehy & Williamson, 
2005). Integrating vectors are generally more stably maintained in the mycobacterial genome 
than episomal vectors and less likely to mutate once integrated, probably because only a 
single copy of the vector is present per cell (Dennehy & Williamson, 2005). It may therefore 
be possible to culture transformants in the absence of the selectable drug. The pJEM15 vector 
was therefore modified to integrate into the attB site of the mycobacterial genome. The 
generation of episomal and integrating versions of the reporter vectors containing the  






4.2 METHODOLOGY  
 
4.2.1 Determining the transcriptional start site of Rv1258c 
 
4.2.1.1 5‟ RACE 
 
In order to determine the position of the transcriptional start site of the M. tuberculosis 
Rv1258c gene, 5‟ RACE was done. The principle of 5‟ RACE is summarized in Fig 4.1. 
Briefly, this involves synthesis of cDNA using a gene-specific primer, polyA-tailing of the 
cDNA by recombinant terminal transferase and amplification of the cDNA using an oligo  
d(T)-anchor primer and nested gene specific primer. 
 
The 5‟/3‟ RACE Kit 2
nd
 Generation (Roche Applied Sciences) was used according to the 
manufacturer‟s instructions. This kit contains a control system in the form of a control neo-
RNA (an in vitro transcribed RNA) and three control RNA specific neo-primers which allow 
for testing whether the cDNA synthesis, purification, polyA-tailing and the PCR 
amplification steps are working. The neo-RNA and gene specific control neo-primers are 
added to the RNA sample in the control reaction, but are omitted in the experiment (which 
only contains the RNA of interest). The primers used during 5‟ RACE are summarised in 
Table 3.4. 
 
First-strand cDNA synthesis was done in a total volume of 20 µl. Each reaction contained 1× 
cDNA synthesis buffer, 1 mM dNTPs, 0.625 µM cDNA synthesis reverse transcription 
primer (SP1), the RNA sample and 25 U Transcriptor Reverse Transcriptase. The cDNA was 
subsequently purified using the High Pure PCR Product Purification Kit (Roche Applied 
Sciences) according to the modified protocol provided within the 5‟/3‟ RACE Kit 2
nd
 
Generation kit. A homopolymeric A-tail was added to the 3‟ end of the first-strand cDNA 
using recombinant terminal transferase. Each 25 µl reaction contained 1× Reaction Buffer, 
200 µM dATP, 80 U Terminal Transferase and 19 µl purified cDNA. 
 
PCR amplification of the polyA-tailed cDNA was done in a 50 µl reaction containing 1× 
PCR Reaction Buffer (supplied with Taq DNA Polymerase, Roche Applied Sciences),  
200 µM dNTPs, 0.75 µM oligo dT-anchor primer, 0.25 µM of a second nested gene specific 




The PCR cycling conditions were: initial denaturation at 95ºC for 4 min, 10 cycles of 
denaturation at 95ºC for 30 s, annealing at 55ºC for 30 s and extension at 72ºC for 30 s, 25 
cycles of denaturation at 95ºC for 30 s annealing at 55ºC for 30 s and extension at 72ºC with 
an increase of 20 s in extension time with every cycle and a final extension at 72ºC for 7 min. 























Figure 4.1: Principle of 5’ RACE as summarised in the 5’/3’ RACE 2
nd
 Generation kit. 
 
4.2.1.2 Control reactions of 5‟ RACE 
 
For the control reactions the neo-RNA and gene specific control neo-primers are added to the 
RNA sample in the control reaction before the reverse transcription step. The cDNA control 
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contained an additional 1 ng control RNA and 0.625 µM neo1/rev primer (which bind 
specifically within the control RNA). The cDNA control reaction was also purified and a 
homopolymeric A-tail was added to the 3‟ end of the first-strand control cDNA using 
recombinant terminal transferase as described for the cDNA sample. 
 
PCR amplification of the unpurified and purified control cDNA was done in order to 
determine whether the reverse transcription step was successful. The expected size of the 
product for the control cDNA was 157 bp. Each 50 µl reaction contained 1× PCR Reaction 
Buffer (supplied with the Taq DNA Polymerase, Roche Applied Sciences), 200 µM dNTPs, 
0.25 µM Control primer neo2 and Control primer neo 3, 2.5 U Taq DNA Polymerase and  
1 µl control cDNA. As an extra check, PCR amplification of the unpurified and purified 
cDNA was done. No product was expected for the PCR containing the cDNA sample, as no 
control RNA was present in this sample. 
 
PCR was also done, as a control, to determine whether the polyA-tailing step was successful. 
A product of 293 bp was expected for the polyA-tailed control cDNA. Each 50 µl reaction 
contained 1× PCR Reaction Buffer (supplied with Taq DNA Polymerase, Roche Applied 
Sciences), 200 µM dNTPs, 0.75 µM oligo d(T)-anchor primer, 0.25 µM Control primer neo 
2, 2.5 U Taq DNA Polymerase and 1 µl control cDNA.  
 
4.2.1.3 Cloning of 5‟ RACE product into pGEM-T Easy vector 
 
The RACE PCR products were either purified directly or first separated by electrophoresis 
and then purified from the gel before cloning into pGEM-T Easy. E. coli was transformed 
with the ligation mixture and cultured on LB agar containing ampicillin. White colonies were 
selected and colony PCR was done using the PCR anchor primer (supplied with the 5‟/3‟ 
RACE 2
nd
 Generation kit - Roche Applied Sciences), and nested gene specific primers 
(SP2/SP3). The Central Analytical Facility at Stellenbosch University sequenced the insert 
using the pGEMTeasyT7 and/ or pGEMTeasySP6 primer. 
 
4.2.2 Cloning Rv1258c promoter region into pJET1.2 
 
A 635 bp region directly upstream of the Rv1258c gene of M. tuberculosis H37Rv was 




cutting sites, Asp718 and BamHI respectively (Fig 4.2). This region presumably contained the 
transcriptional start site of Rv1258c and will subsequently be called the promoter region. 
Each 50 µl PCR reaction mix contained 1× Phusion HF Buffer, 1× GC Buffer (from the 
FastStart Taq DNA polymerase kit) (Roche Applied Sciences), 200 µM of each dNTP 
(Fermentas), 0.5 µM pRv1258cpF and pRv1258cpR, 200 ng mycobacterial DNA and 1 U 
Phusion Hot Start DNA Polymerase (Thermo Fisher Scientific, Finnzymes). The PCR 
cycling conditions were as follows: Initial denaturation at 98ºC for 1 min followed by 30 
cycles of denaturation at 98ºC for 10 s, annealing at 60ºC for 30 s and extension at 72ºC for 
30 s and a final extension at 72ºC for 7 min. 
 
The PCR product was purified and ligated into the pJET1.2 vector (Fig 4.2) using the 
FastLink DNA Ligation kit (Epicentre Biotechnologies). After transformation of E. coli with 
the ligation reaction, selection of the transformants was done on LB agar containing 
ampicillin. Colonies containing an insert were inoculated into 5 ml LB broth. Vector DNA 
was extracted using the plasmid DNA extraction kits previously described and the insert 
sequenced using the pJET1.2For and pJET1.2Rev primers to confirm that no mutations were 
introduced during PCR. The resulting vector will subsequently be called pJET1.2promo. 
 
4.2.3 Cloning of Rv1258c promoter region into pJEM15 
 
The promoter region of Rv1258c was subsequently fused to lacZ in pJEM15 in order to create 
a promoter reporter construct (Fig 4.3). pJEM15 and pJET1.2promo were digested with 
Asp718 and BamHI and the DNA fragments were separated by agarose gel electrophoresis 
The appropriate bands were excised and purified. pJEM15 was dephosphorylated using 
Antarctic phosphatase (Biolabs) according to the manufacturer‟s instructions and ligation was 
carried out using the T4 DNA Ligase kit (Promega) overnight at 4°C according to the 
manufacturer‟s instructions. After transformation of E. coli with the ligation reaction, 
transformants were selected on LB agar containing kanamycin. Colony PCR was done to 
confirm the presence of the promoter region. The resulting vector will subsequently be called 
pJEM15promo. 
 
4.2.4 Construction of integrating vectors 
 






















































Figure 4.2. Amplification of the promoter region of Rv1258c from M. tuberculosis 
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were subcloned into the integrating vector pMV306 as follows: pMV306 was digested with 
EcoRV, gel purified and dephosphorylated using rAPID Alkaline Phosphatase (Roche 
Applied Sciences), according to the manufacturer‟s instructions. JEM15 and pJEM15promo 
were digested with PstI and PstI/EcoRI respectively, and the bands containing the lacZ gene 
were gel purified. Blunting of the DNA fragments from the pJEM15 (228.88 ng) and 
pJEM15promo (113.19 ng) vectors were done using the DNA blunting enzyme and 1× 
reaction buffer from the CloneJET PCR Cloning Kit (Fermentas) according to the 
manufacturer‟s instructions. The dephosphorylated vector (50 ng) was added to the blunting 
enzyme mixture and Fast-Link DNA Ligase was used for ligation overnight at 4°C (Fig 4.4 
and Fig 4.5). After transformation of E. coli with the ligation reactions, transformants were 
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Figure 4.4. Cloning of the promoterless lacZ gene from pJEM15 into the integrating 
vector pMV306 to yield pMV306lacZ.  Represents approximate positions since the 
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Figure 4.5. Cloning of the promoter region fused to the lacZ gene into the integrating 
vector pMV306 to yield pMV306promolacZ.  Represents approximate positions since the 
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Promoter reporter vectors (episomal and integrating) with the M. tuberculosis H37Rv 
Rv1258c promoter upstream of a lacZ gene were constructed in order to use for subsequent β-
galactosidase assays. 
 
4.3.1 Determining the transcriptional start site of Rv1258c 
 
It was necessary to determine the position of the transcriptional start site for Rv1258c to 
verify that it is present in the promoter reporter region that would be cloned into the reporter 
vectors. In order to determine the position of the transcriptional start site, 5‟ RACE was done.  
 
M. tuberculosis H37Rv was cultured in Difco Dubos Broth Base (Becton, Dickinson and 
Company) supplemented with 10% Dubos medium albumin to early log phase. Gene specific 
primers RACE1 SP1 and RACE1 SP2 (Table 3.4) that bind within Rv1258c were used for 
reverse transcription during PCR amplification during the first 5‟ RACE experiment. RNA 
was extracted using the trizol extraction method previously described. The results are 
summarised in Fig 4.6 as 5‟ RACE 1. 
 
When examining the PCR product obtained to determine the success of the cDNA synthesis 
step, the expected PCR product was obtained for the control cDNA (Fig 4.6). However, 
contamination of the no template control for the PCR and the cDNA PCR reaction was 
present. Changing all reagents except the primers provided with the kit, did not get rid of the 
contamination in the no template control. This led us to the conclusion that the control 
primers used for this reaction were the source of contamination. When the control primers 
were re-synthesized and the PCR repeated using the newly synthesised control primers, the 
no template control PCR reaction was clean of any contamination (results not shown).  
 
When testing whether the polyA-tailing step worked effectively, no PCR products were 
observed after amplification of the control polyA-tailed cDNA (Fig 4.6). The polyA-tailing 
control step was thus unsuccessful. There was however a product (between 100 and 200 bp in 
size) observed for the PCR amplifying the polyA-tailed cDNA using the oligo d(T)-anchor 

























Figure 4.6. Agarose gel electrophoresis of products obtained during PCR during each 
step of 5’ RACE using gene specific primers for Rv1258c (5’ RACE 1). 
 
This PCR product was cloned into the pGEM-T Easy vector after separation by 
electrophoresis and the presence of the insert in the vector was confirmed by colony PCR 
(Fig 4.7). Some of the colonies were picked and the insert sequenced. The PCR product 
corresponded to 16S rRNA that was amplified presumably because of the high rRNA copy 
number in comparison to a possible low mRNA copy number of Rv1258c transcript. The 
transcriptional start site could thus unexpectedly not be determined during this 5‟ RACE (5‟ 
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Figure 4.7. Agarose gel electrophoresis of the colony PCR product to confirm the 
presence of the 5’ RACE 1 product in the pGEM-T Easy vector. Lane (1) GeneRuler  
100 bp Plus (Fermentas), Lane (2-6) 635 bp product obtained for the colony PCR to check for 
the presence of the 5‟ RACE product in five colonies, (7) no template control (water) for the 
PCR, (8) positive control (purified PCR product) for the PCR. 
 
Since the transcriptional start site could not be determined during this 5‟ RACE experiment, 
another strategy using the Rv1258c promoter reporter vector constructed during this study 
would be followed. 5‟ RACE was repeated using gene specific primers for the lacZ gene to 
determine the position of the transcriptional start site of the Rv1258c promoter region cloned 
into the upstream position of the lacZ gene in the multi-copy vector. Since the copy number 
of the vector is high, enough transcripts of the Rv1258c promoter fused to lacZ might be 
produced, which could prevent unwanted non-specific amplification. The second 5‟ RACE 
experiment (5‟ RACE 2) is discussed in Section 4.3.5 after the vector construction sections. 
 
4.3.2 Cloning of Rv1258c promoter region into pJET1.2 
 
In order to generate a reporter construct expressing the Rv1258c promoter, a 635 bp region 
directly upstream of the M. tuberculosis H37Rv Rv1258c gene presumably containing the 
Rv1258c transcriptional start site and promoter, was amplified by PCR using the pRv1258cF 
and pRv1258cR primers that contained RE cutting sites, Asp718 and BamHI. The expected 
635 bp product was obtained as shown in Fig 4.8 lane 3 and subsequently cloned into the 
pJET1.2 sequencing vector to produce pJET1.2promo. RE mapping of pJET1.2promo was 
used to confirm that the PCR product was successfully cloned into the pJET1.2 vector and 
that it was cloned into the correct position. Digestion of pJET1.2promo with Asp718 and 
BamHI resulted in two bands of 641 bp and 2,980 bp (Fig 4.9A lane 2), while digestion with 
BglII resulted in a 693 bp and a 2,928 bp band (Fig 4.9A lane 3). These were the expected 
sizes as indicated on the vector map shown in Fig 4.9B confirming that the PCR product was 




















cloned into the correct position in the pJET1.2 vector. The PCR product present in 
pJET1.2promo was sequenced and it was confirmed that the 635 bp region upstream of 





Figure 4.8. Agarose gel electrophoresis of the PCR product when amplifying the 635 bp 
region upstream of the M. tuberculosis Rv1258c gene. Lane (1) GeneRuler 1 kbp Plus 




                           
Figure 4.9. (A) Agarose gel electrophoresis of RE mapping of pJET1.2promo. Lane (1) 
GeneRuler 1 kbp Plus DNA Ladder (Fermentas), pJET1.2promo (505.30 ng) digested with 
(2) Asp718 and BamHI and (3) BglII and (4) undigested pJET1.2promo, (B) Vector map of 






















4.3.3 Cloning of Rv1258c promoter region into pJEM15  
 
A reporter vector containing the M. tuberculosis H37Rv Rv1258c promoter region upstream 
of a reporter gene, a lacZ gene, was generated in order to study Rv1258c promoter activity 
using β-galactosidase assays. Rv1258c promoter activity serves as an indication of Rv1258c 
gene expression and would be studied using promoter reporter assays. The Rv1258c promoter 
region from pJET1.2promo was cloned into a position upstream of the lacZ gene in the 
pJEM15 vector. The vector is subsequently called pJEM15promo. Colony PCR (using the 
pRv1258cpF and pRv1258cpR primers) was used to confirm the presence of the 
pJEM15promo vector in the E. coli transformants. A PCR product of 635 bp was observed 
for all the colonies examined, thereby confirming the presence of promoter region and 




Figure 4.10. Agarose gel electrophoresis of the colony PCR product to confirm the 
presence of the promoter region in pJEM15promo. Lane (1) GeneRuler 1 kbp Plus 
(Fermentas), lane (2-10) product obtained for the colony PCR to check for the presence of the 
promoter region in pJEM15promo for nine colonies (11) no template control (water) for the 
PCR. 
 
To confirm the presence of the promoter upstream of the lacZ gene in pJEM15promo, RE 
digests of pJEM15 and pJEM15promo were done and the sizes of the resulting DNA 
fragments examined by agarose gel electrophoresis. The expected sizes of fragments obtained 
for digestion with Asp718 and BamHI were 641 bp and 9,434 bp, for digestion with BglII 
were 3,751 bp and 6,324 bp and for digestion with BamHI and EcoRv were 1,828 bp and  
8,247 bp (Fig 4.11B). The DNA fragments obtained during restriction mapping were all the 
expected sizes (Fig 4.11A). Notice the shift of approximately 641 bp of the second largest 
band in the PstI digested pJEM15promo vector (Fig 4.11A lane 4) in comparison to the 
pJEM15 vector (Fig 4.11A lane 3). There is also an upward shift of approximately 641 bp in 






























comparison to the pJEM15 vector (Fig 4.11A lane 5). Three bands of approximately the sizes 
expected for HindIII digested pJEM15promo were observed during RE mapping (Fig 4.11A 
lane10). The digests thus indicate that the promoter region was successfully cloned into the 
















Figure 4.11. (A) Agarose gel electrophoresis of RE mapping of pJEM15 and 
pJEM15promo. Lane (1) GeneRuler 1 kbp Plus DNA Ladder (Fermentas), pJEM15promo 
(595.10 ng) digested with (2) Asp718 and BamHI, (4) PstI, (6) PstI and EcoRI, (7) BglII, (8) 
BamHI and EcoRv and (9) BamHI and HindIII, pJEM15 (525.48 ng) digested with (3) PstI 



















4.3.4 Construction of integrating vectors 
 
To ensure that the copy number of the episomal vector system does not affect the experiment 
and to improve the vector stability in the absence of the selectable antibiotic, integrating 
vectors were constructed. The pMV306 integrating vector contains an integrase gene that 
enables it to integrate into the attB site of the mycobacterial genome. The promoterless lacZ 
gene from pJEM15 and the promoter fused to the lacZ gene from pJEM15promo 
respectively, were ligated into pMV306 to create the integrating vectors subsequently called 
pMV306lacZ and pMV306promolacZ respectively. Because of blunting of the RE digested 
fragment containing the lacZ gene and the Rv1258c promoter region fused to the lacZ gene, 
the fragment could be inserted in either orientation into the pMV306 vector.  
 
RE mapping was used to determine whether the fragments were correctly cloned into 
pMV306 and to determine the orientation in which the fragments were inserted. The expected 
sizes of fragments obtained for digestion of pMV306lacZ with BglII were approximately 
3,124 bp, 3,023 bp and 1,389 bp for the fragment cloned into the pMV306 in a reverse 
orientation (Fig 4.12B). These fragment sizes were obtained (Fig 4.12A lane 2). The expected 
sizes of fragments obtained for digestion with PstI were approximately 6,783 bp and 753 bp 
(Fig 4.12B) and were obtained for the RE mapping (Fig 4.12A lane 3). The expected sizes of 
fragments obtained for digestion with BamHI were approximately 6,703 bp, 631 bp and 122 
bp and those for Asp718 were approximately 4,375 bp and 3,161 bp (Fig 4.12B lane 4 and  7) 
The DNA fragments obtained during RE mapping were all the expected sizes and were that 
which was expected for the lacZ gene being cloned in a reverse direction into the pMV306 
vector to obtain pMV306lacZ (Fig 4.12). This confirmed that the promoterless lacZ gene was 
correctly cloned into pMV306 in a reverse orientation. 
 
The expected sizes of fragments obtained for digestion of the pMV306promolacZ vector with 
Asp718 were approximately 5,004 bp and 3,161 bp (Fig 4.13A lane 2) and those expected for 
BglII were approximately 3,124 bp, 3,023 bp and 2,018 bp (Fig 4.13A lane 3). The expected 
sizes of fragments obtained for digestion with EcoRv were approximately 8,165 bp  
(Fig 4.13A lane 4) and those for PstI were approximately 7,412 bp and 753 bp (Fig 4.13A 
lane 5) and for HindIII were approximately 7,304 bp, 789 bp and 72 bp (Fig 4.13A lane 6). 




into pMV306 in a reverse orientation (Fig 4.13B). This confirmed that the promoter fused to 





Figure 4.12. (A) Agarose gel electrophoresis of RE mapping of pMV306lacZ. Lane (1 and 
6) GeneRuler 1 kbp Plus DNA Ladder (Fermentas), pMV306lacZ (463.58 ng) digested with 
(2) BglII, (3) PstI, (4) BamHI, and (7) Asp718 and (5) undigested pMV306lacZ, (B) Vector 
map of pMV306lacZ.  Represents approximate positions since the sequence of vector is 
not available. 
 
4.3.5 5’ RACE repeated using constructed vector  
 
Since the 5‟ RACE experiment was previously unsuccessful (see 5‟ RACE 1) it was repeated 
using the pJEM15promo transformed strain and three gene specific primers, which bind to 


































transcript would overcome non-specific amplification. The experimental results are referred 





Figure 4.13. (A) Agarose gel electrophoresis of RE mapping of pMV306promolacZ. Lane 
(1) GeneRuler 1 kbp Plus DNA Ladder (Fermentas), pMV306promolacZ (555.61 ng) 
digested with (2) Asp718 and (3) BglII and (4) EcoRv (5) PstI (6) HindIII and (7) undigested 
pMV306promolacZ, (B) Vector map of pMV306promolacZ.  Represents approximate 
positions since the sequence of vector is not available. 
 
M. tuberculosis H37Rv (pJEM15promo) was cultured to an OD of approximately 0.80 at  
600 nm. RNA was extracted using the RNA ProBlue kit as previously described with a few 
minor alterations: After the treatment with DNase I, the RNA was precipitated and 









































DNase I inactivation reagent from the TURBO DNA-free kit (Applied Biosystems, Ambion) 
was used according to the manufacturer‟s instructions, to inactivate the Turbo DNase. The 
RNA was then precipitated overnight and re-suspended in water.  
Three gene specific primers RACE2 SP1, RACE2 SP2 and RACE2 SP3 which bind within 
the lacZ gene of the pJEM15promo vector (which has the promoter region of Rv1258c cloned 
into an upstream position) was used to determine the position of the Rv1258c transcriptional 
start site using 5‟ RACE. The PCR product obtained after the amplification of polyA-tailed 
cDNA with the oligo d(T)-anchor primer, RACE2 SP2, was re-amplified using a second 
nested primer, RACE2 SP3.  
 
The results for 5‟ RACE 2 are summarized in Fig 4.14. When examining the PCR product to 
determine the success of the cDNA synthesis, the expected PCR product was obtained for the 
control cDNA. The use of re-synthesised control primers as opposed to those included in the 
kit was again required to obtain clean no template controls because of contamination of the 
control primers of the new kit used (Fig 4.14). Amplification of the control cDNA produced 
the expected 157 bp product and no product was obtained upon amplification of the cDNA or 
for the no template control (Fig 4.14). A PCR product of the expected size, 293 bp, was 
observed after amplification of the control polyA-tailed cDNA, confirming that the  
polyA-tailing step was successful. There was however no product observed for the PCR to 
amplify polyA-tailed cDNA (Fig 4.14) and therefore a re-amplification of the latter PCR 
product using the PCR anchor primer and a second nested gene specific primer RACE2 SP3 
was done.  
 
A PCR product of between 100 and 200 bp in size was obtained upon  
re-amplification. Since a smear was observed on the gel surrounding this band (Fig 4.14), we 
decided to purify the PCR product without prior separation using gel electrophoresis in order 
to keep possible rare transcripts since the size of the product obtained for 5‟ RACE2 was 
similar to that of 5‟ RACE1 where 16S rRNA was previously amplified. The purified PCR 
product was cloned into the pGEM-T Easy vector, E. coli was transformed with these vectors 
and the presence of the insert in the vector was confirmed by colony PCR using the PCR 
anchor and the RACE2 SP3 primers (Fig 4.15). 
 
Some of the colonies contained inserts of different sizes (Fig 4.15). Colonies with a range of 




determined to be only six base pairs upstream of the Rv1258c gene start codon (Fig 4.16). 
The sequencing product of the RACE product aligned to a region of the pJEM15promo 
























Figure 4.14. Agarose gel electrophoresis of products obtained during PCR during each 
step of 5’ RACE (5’ RACE 2).  









Purified control cDNA 
PCR amplifying purified cDNA and 
control cDNA using control 
neo2/rev and neo3/for primers 




Expected product sizes  
Lane 1: 100 bp Plus DNA ladder (Fermentas) 
Lane 4: no template control (water) 
Test PCR to see whether polyA-tailing of cDNA was successful: 
PCR amplifying polyA-tailed 
control cDNA using  
oligo d(T)-anchor primer and 






Expected product sizes  
PCR to amplify polyA-tailed cDNA: 
PCR amplifying polyA-tailed cDNA 
using olig dT-anchor primer and 




Lane 1: 100 bp Plus DNA ladder (Fermentas) 
Lane 3: no template control (water) 






Lane 1: 100 bp Plus DNA ladder (Fermentas) 
Lane 3: no template control (water) 
Expected product sizes  
Test PCR to see whether cDNA synthesis was successful: 
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above PCR using PCR anchor 
primer and a second nested gene 
specific primer, SP3 
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Figure 4.15 Agarose gel electrophoresis of the colony PCR product to confirm the 
presence of the 5’ RACE 2 product in the pGEM-T Easy vector using the PCR anchor 
primer and the gene specific primer, RACE2 SP3. Lane (1) and (14) 100 bp Plus 






Figure 4.16. Position of the transcriptional start site relative to the start codon of 
Rv1258c in M. tuberculosis. The position of the -10 Pribnow box and -35 promoter regions 





In order to construct promoter reporter vectors with the promoter region of M. tuberculosis 
H37Rv Rv1258c, it was necessary to determine the position of the transcriptional start site of 
Rv1258c. This would give us an idea of where the promoter is located. After performing 5‟ 
RACE twice, the transcriptional start site was determined to be at a position only six 
nucleotides upstream of the start codon of Rv1258c. In agreement with this finding, the 
transcriptional start site is generally located five to nine base pairs downstream of the -10 
promoter region and the first nucleotide can be any one of the four bases (Newton-Foot & 
Gey van Pittius, 2012). Promoter regions generally have a -10 and -35 promoter region. The  
-10 promoter region is essential for transcription, as the sigma factors need to bind in that 
position. The -35 promoter region is sometimes non-essential for transcription in  





WhiB7 binding site -35 -10 






M. tuberculosis, but promoters lacking this could need addition transcriptional activators in 
order for transcription to be initiated. Promoters are generally a minimum of 40 bp in size, 
but could be as big as 2 kbp (Newton-Foot & Gey van Pittius, 2012). Generally, promoters 
contain binding sites for regulators involved in regulating the expression of the downstream 
gene (Newton-Foot & Gey van Pittius, 2012). The whiB7 gene encodes a global 
transcriptional regulator which also regulates Rv1258c (Morris et al., 2005). Analysis of the 
promoters of genes regulated by WhiB7 led to the identification of whiB7 promoter motifs. 
This promoter motif was identified upstream of Rv1258c at position -39 to -45 upstream of 
the start codon of Rv1258c (Burian et al., 2012). 
 
The position of the transcriptional start site at six nucleotides upstream of the start codon was 
however questioned since there was no apparent ribosome binding site between the start 
codon and the determined transcriptional start site. Ribosome binding sites are generally 
adenosine and guanine rich region of at least four base pairs (Newton-Foot & Gey van Pittius, 
2012). In some cases, the transcriptional start site and the start codon are present close to each 
other and there are no ribosome binding sites between them. The mRNA is leaderless in such 
cases (Newton-Foot & Gey van Pittius, 2012). It could be that the Rv1258c mRNA is 
leaderless and that is why no apparent ribosome binding site is present. Interestingly, another 
group had previously also determined that the transcriptional start site for Rv1258c was only 
a very few base pairs upstream of the gene also using 5‟ RACE, but dismissed these results 
(Villellas, 2012). Although we determined the position of the transcriptional start site, the 
results were not conclusive.  
 
An episomal vector with the promoter region of M. tuberculosis H37Rv Rv1258c upstream of 
a lacZ gene (pJEM15promo) was successfully constructed to be used for studying Rv1258c 
promoter activity using β-galactosidase assays. This episomal vector would need to be 
selected by adding kanamycin to the media and kanamycin could possibly influence Rv1258c 
promoter activity. The episomal vector is also a multi-copy vector and this could influence 
the functioning or binding of transcription factors to the promoter region and thus have an 
impact on promoter activity. We therefore chose to modify the pJEM15 system to integrate 
into the mycobacterial genome at the attB site. RE digests and PCR was used to confirm that 
the vectors were correctly constructed. However, the latter does not prove the utility of the 
vectors in mycobacteria. We therefore needed to determine the functioning of the episomal 




M. smegmatis mc2155, before choosing which vector system to use for subsequent studies in 
M. tuberculosis. Promoter reporter vectors (episomal and integrating), were successfully 
constructed in order to use for investigating M .tuberculosis Rv1258c promoter expression 






CHAPTER 5: INVESTIGATING THE FUNCTIONAL CONSEQUENCES OF THE 
 EPISOMAL AND INTEGRATING VECTOR SYSTEMS AND THE 
 EFFECTS OF RPOB MUTATIONS ON THE M. TUBERCULOSIS 




The episomal and integrating vector functioning was investigated in M. smegmatis mc2155. 
M. smegmatis is a closely related species to M. tuberculosis and has long been used as model 
organism for studying relevant basic cellular processes and gene expression relevant to  
M. tuberculosis. M. smegmatis is a fast-growing non-pathogenic mycobacterial species that is 
present in soil. This makes it ideal to investigate the vector functioning since results would be 
obtained fast (within three to four days) as opposed to one to two weeks if M. tuberculosis 
was used. In addition, working with M. smegmatis does not require working under Biohazard 
safety level three conditions. Vector functioning was thus assessed in M. smegmatis.  
 
Previous studies showed a 79% protein homology between M. smegmatis and M. tuberculosis 
(Wang et al., 2005). This implies that the expressed proteome of M. smegmatis is highly 
relevant to that of M. tuberculosis (Wang et al., 2005). M. smegmatis has many genes 
encoding putative drug efflux pumps that are homologues to those genes encoding pumps 
found in M. tuberculosis (Li et al., 2004). Bioinformatic searches revealed that Rv1258c 
homologue, MSMEG_5033, in M. smegmatis mc2155 is a pseudogene (SmegmaList). When 
aligning parts of Rv1258c with MSMEG_5033, a 67% amino acid residue identity with that of 
Rv1258c was identified based on bioinformatic searches (Li et al., 2004).  
 
Comparison of the rpoB nucleotide sequence of M. tuberculosis and M. smegmatis, revealed 
a high degree of similarity (Hetherington et al., 1995; Kim et al., 1999), which means that  
M. smegmatis can serve as a model for studying the effects of rpoB mutations on  
M. tuberculosis Rv1258c promoter expression using β-galactosidase assays. In addition to 
determining the functional consequences of the vector systems, the effects of rpoB mutations 












Growth curves were generated for all the M. smegmatis mc2155 wild-type and rpoB mutants 
transformed with the episomal and integrating vector systems. The pre-cultures were sub-
cultured into 100 ml 7H9 GS containing the appropriate antibiotics to an OD of 0.02 at  
600 nm. The OD at 600 nm was measured every three hours (representing the doubling time 
of M. smegmatis mc2155) for 30 hours using an Ultrospec 4051 (LKB Biochrom). 
 
5.2.2 Rv1258c promoter activity in the absence of rifampicin 
 
The M. smegmatis wild-type and rpoB mutants harbouring the episomal and integrating 
vectors respectively, were cultured (100 ml) overnight to early log phase. Cultures contained 
the selectable antibiotic kanamycin and hygromycin respectively. WCLs were prepared at 
early log phase and three hours later for non-exposure experiments. The protein concentration 
was determined and the promoter activity was determined using β-galactosidase assays. The 
experiment was done in triplicate and the β-galactosidase activity for the three experiments 
averaged. 
 
5.2.3 Rv1258c promoter activity in response to rifampicin 
 
M. smegmatis mc2155 rpoB mutants harbouring the episomal and integrating vectors 
respectively, were cultured (100 ml) overnight to early log phase. Cultures contained the 
selectable antibiotic kanamycin and hygromycin respectively. Each culture was divided in 
two, one of which was exposed to 10 µg/ml RIF and the other to DMSO (diluent for RIF). 
Exposure to DMSO was done to determine the RIF-specific response. WCLs were prepared 
as previously described after one, three and six hours exposure to RIF. The protein 
concentration was determined and Rv1258c promoter activity was determined using β-
galactosidase assays. The experiment was done in triplicate and the β-galactosidase activity 








The functioning of the episomal and integrating vectors were tested using β-galactosidase 
assays in M. smegmatis in order to determine which vector system would be used for 
subsequent β-galactosidase assays in M. tuberculosis. The effects of rpoB mutations on the 
M. tuberculosis Rv1258c promoter expression was also investigated in M. smegmatis. This 
was done in order to compare the results to those of β-galactosidase assays in  
M. tuberculosis, thereby assessing the use of M. smegmatis as model for investigating the 
expression of the M. tuberculosis Rv1258c promoter. 
 
5.3.1 Growth curve analysis for M. smegmatis 
 
Growth curves were generated for all the M. smegmatis mc2155 wild-type and rpoB mutants 
harbouring the episomal and integrating vector systems. This was done in order to determine 
whether the presence of the vectors influenced the growth of the bacteria and to determine the 
effects of the rpoB mutations on the growth of the M. smegmatis rpoB mutants. The OD at 
which the log growth phase was reached was also determined using the growth curves since 
the WCLs for the β-galactosidase assays would be prepared at early log phase.  
 
When comparing the growth of the same strain harbouring the pJEM15 and pJEM15promo 
vectors respectively, (M. smegmatis mc2155 wild-type (pJEM15) with M. smegmatis mc2155 
wild-type (pJEM15promo)), no differences in the growth were observed (Fig 5.1). 
Comparison of the growth of M. smegmatis mc2155 wild-type and S531L rpoB mutant 
harbouring the pJEM15promo vectors, showed (p<0.05) differences in growth at 18 
(p=0.0395), 21 (p=0.0048) and 24 (p=0.0387) hours of growth (representing the log growth 
phase) (Fig 5.1). Similarly the growth of M. smegmatis mc2155 wild-type and H526Y rpoB 
mutant harbouring the pJEM15promo vectors, was significantly (p<0.05) different at 18 
(p=0.0235), 21 (p=0.0017) and 24 (p=0.0069) hours of growth (representing the log growth 
phase) (Fig 5.1). A significant difference in growth was also present at 24 hours (p=0.0150) 
between the M. smegmatis mc2155 S531L and H526Y rpoB mutants (Fig 5.1). In general, the 
mutants tended to grow slower than the wild-type strains. All the strains were in early log 






Figure 5.1. Growth curve for M. smegmatis mc
2
155 wild-type and S531L and H526Y 
rpoB mutants transformed with the episomal vectors, cultured in 7H9 GS containing  
50 µg/ml kanamycin. The graph represents the average of three independent experiments 
and error bars represent standard deviation. Statistically significant difference in growth are 
not indicated on the graph but are discussed in the text. 
 
Similarly, when comparing the growth of the same strain transformed with either the 
pMV306lacZ or pMV306promolacZ vectors, (for example M. smegmatis mc2155 wild-type 
attB::pMV306lacZ with M. smegmatis mc2155 wild-type attB::pMV306promolacZ) no 
differences in the growth were observed (Fig 5.2). Significant differences in growth were 
observed between the M. smegmatis mc2155 wild-type and rpoB S531L mutant strains 
harbouring the pMV306promolacZ vector at 15 (p=0.0276) and 18 (p=0.0183) hours of 
growth. There was also a significant difference in the growth of M. smegmatis mc2155 wild-
type and H526Y rpoB mutant harbouring the pMV306promolacZ vector at 18 hours 
(p=0.0413) of growth (Fig 5.2). There were no significant differences in growth between the 
two rpoB mutants. All the strains were in early log growth phase at an OD of approximately 
0.50 to 0.70 at 600 nm. 
 
5.3.2 Rv1258c promoter activity in the absence of rifampicin 
 
Rv1258c promoter activity was investigated using the episomal vector system and the 




and to determine which system should be used for subsequent β-galactosidase assays in  
M. tuberculosis. The effect of rpoB mutations on Rv1258c promoter activity in  
M. smegmatis was also investigated. M. smegmatis was cultured overnight until early log 
phase (an OD between 0.50 and 0.70 as determined during growth curve analyses) and WCLs 
were prepared at early log phase and three hours later. An example of a kinetic curve 
generated for β-galactosidase assays is given in Addendum B. The β-galactosidase activity 
was determined for a range of different WCL protein concentrations. An appropriate protein 
concentration and reaction incubation period was selected (refer to Addendum B for an 
explanation of how this was done). The final protein concentration of WCLs used for the 
calculation of the β-galactosidase activity was 9.6 μg/ml for the episomal vector system and 
153.6 μg/ml for the integrating vector system. The absorbance reading for the enzymatic 
reaction at 35 min exposure of the enzyme (β-galactosidase) to the substrate ONPG was 
chosen to calculate the β-galactosidase activity. 
 
 
Figure 5.2. Growth curve for M. smegmatis mc
2
155 wild-type and S531L and H526Y 
mutants harbouring the integrating vectors in 7H9 GS containing 50 µg/ml hygromycin. 
The graph represents the average of three independent experiments and error bars represent 
standard deviation. Statistically significant difference in growth are not indicated on the 
graph but are discussed in the text. 
 
The β-galactosidase activity of the strains transformed with pJEM15 and pMV306lacZ 
vectors indicates the background activity in the absence of the promoter. This background 




expected as there is a transcriptional terminator and no promoter present upstream of the lacZ 
gene in the pJEM15 and pMV306lacZ vectors. This proves that the transcriptional terminator 
is functional in both vector systems and that background activity will not affect the 
experimental results in either of the vector systems. 
 
The M. tuberculosis H37Rv Rv1258c promoter activity in M. smegmatis mc2155 rpoB S531L 
(pJEM15promo) was approximately half that of the M. smegmatis mc2155 wild-type 
(pJEM15promo) (Fig 5.3), while the Rv1258c promoter activity in M. smegmatis mc2155 
rpoB S531L attB::pMV306promolacZ was significantly lower at approximately 1.45 times 
less than that of the M. smegmatis mc2155 wild-type attB::pMV306promolacZ (Fig 5.4). The 
results obtained with the episomal and integrating vector systems were thus comparable. 
 
The M. tuberculosis H37Rv Rv1258c promoter activity in M. smegmatis mc2155 rpoB 
H526Y (pJEM15promo) was not significantly different to that of the M. smegmatis mc2155 
wild-type (pJEM15promo) even though a slight upward trend was observed in M. smegmatis 
mc
2
155 rpoB H526Y (pJEM15promo) (Fig 5.3). However, the M. tuberculosis H37Rv 
Rv1258c promoter activity in M. smegmatis mc2155 rpoB H526Y attB::pMV306promolacZ 
was significantly different at approximately 1.5 times higher than that of M. smegmatis 
mc
2
155 wild-type attB::pMV306promolacZ (Fig 5.4).  
 
5.3.3 Rv1258c promoter activity in response to rifampicin 
 
The effect of RIF on Rv1258c promoter activity was investigated in M. smegmatis. To do 
this, the M. smegmatis S351L and H526Y rpoB mutants harbouring either the episomal or 
integrating vector systems were cultured to early log phase, split into two and exposed to RIF 
(10 μg/ml) or DMSO (diluent of RIF). The protein concentrations of WCLs were determined 
and β-galactosidase assays done. RIF did not affect Rv1258c promoter activity in either of the 
mutants transformed with the pJEM15promolacZ (Fig 5.5) or pMV306promolacZ (Fig 5.6) 
vector systems at one, three or six hours of RIF exposure. RIF also did not affect the 
background Rv1258c promoter activity, in other words the β-galactosidase activity in the 







Figure 5.3. β-galactosidase activity for the M. smegmatis mc
2
155 wild-type and S531L 
and H526Y rpoB mutants harbouring the episomal vectors at (A) early log phase and 
(B) three hours later. The value represents the average of three independent experiments 
and error bars represent standard deviation. Significant differences in Rv1258c promoter 





















Figure 5.4. β-galactosidase activity for the M. smegmatis mc
2
155 wild-type and S531L 
and H526Y rpoB mutants harbouring the integrating vectors at (A) early log phase and 
(B) three hours later. The value represents the average of three independent experiments 
and error bars represent standard deviation. Significant differences in Rv1258c promoter 



















Figure 5.5. Effect of RIF on the Rv1258c promoter activity after 1, 3 and 6 hours of RIF 
(10 µg/ml) exposure for the rpoB mutants harbouring the pJEM15promo vector. The 
unexposed culture was exposed to DMSO (the diluent of RIF). The β-galactosidase values 




Figure 5.6. Effect of RIF on the Rv1258c promoter activity after 1, 3 and 6 hours of RIF 
(10 µg/ml) exposure for the rpoB mutants harbouring the pMV306promolacZ vector. 
The unexposed culture was exposed to DMSO (the diluent of RIF). The β-galactosidase 







No difference was observed between the growth of the M. smegmatis mc2155 strains 
transformed with the promoterless and promoter region containing vectors for either the 
episomal or integrating vector systems, indicating that expression of lacZ in these strains does 
not alter growth. The rpoB mutations affect the growth of the strains in comparison to the 
wild-type. The growth of the mutants was significantly slower than that of the wild-type 
during log phase. It has been shown before that the S531L and H526Y rpoB mutations lead to 
a slight fitness cost in in vitro generated M. tuberculosis rpoB mutants in comparison to the 
wild-type (Gagneux, 2009). The rpoB mutations did not have any extreme deleterious effect 
on the growth of the mutants and the mutants could still be cultured in a comparable number 
of hours to that of the wild-type. 
 
Investigation of the Rv1258c promoter activity in the S531L and H526Y mutants revealed 
that the M. tuberculosis H37Rv promoter activity in the S531L mutant was significantly 
lower than that of the wild-type and this difference was observed for both the episomal 
(pJEM15promo) and integrating vector (pMV306promolacZ) transformed strains. However 
there was only a slight upward trend in the M. tuberculosis H37Rv promoter activity of the 
H526Y mutant in comparison to that of the wild-type in the pJEM15promo transformed 
strains whereas there was a significant almost 1.5 fold higher promoter activity in the H526Y 
mutant in comparison to the wild-type in the strains transformed with pMV306promolacZ 
vector. This suggests that having multiple copies of the Rv1258c promoter in the bacterium 
could influence the regulation of the Rv1258c promoter expression and we therefore chose to 
use the integrating vectors for the study in M. tuberculosis since there is only one copy of the 
vector per genome and this more accurately reflects the natural system. The integrating vector 
also has the advantage of being maintained more stably allowing the study to possibly be 
done in the absence of the selectable drug (Dennehy & Williamson, 2005).  
 
When determining the effects of the rpoB mutations on M. tuberculosis Rv1258c promoter 
activity in M. smegmatis, the rpoB mutation affected Rv1258c promoter activity differently 
with a higher activity in the H526Y mutant and lower activity in the S531L mutant. 
Mutations in the rpoB gene have been shown to alter transcriptional pausing and termination 
(Yanofsky & Horn, 1981) and DNA supercoiling (Drlica et al., 1988) and cause defects in 




Jin, 1997) and in the process alter gene expression. In B. subtilis, each rpoB mutation 
differentially affected gene expression and had their own unique effect on growth rate in 
various media, substrate utilization patterns, the expression of competence for transformation, 
sporulation frequency, sporulation efficiency, spore resistance to heat and chemicals and 
germination (Maughan et al., 2004; Perkins & Nicholson, 2008; Moeller et al., 2012). 
Mutations in rpoB also affect antibiotic production in S. lividans and S. coelicolor (Hu & 
Ochi, 2001; Hu et al., 2002). Some of these effects of rpoB mutations might also be present 
in other bacteria including M. smegmatis, together with other unknown effects since the 
effects of rpoB mutations on mycobacterial gene expression has not been studied extensively. 
Structural changes in RNA polymerase might occur as a result of rpoB mutations which may 
influence the binding to or interaction of RNA polymerase with transcription factors resulting 
in altered expression of Rv1258c. Differences in Rv1258c promoter activity were therefore 
not unexpected since gene expression could be influenced by rpoB mutations. 
 
Investigation of the effects of RIF (10 μg/ml) on Rv1258c promoter activity in M. smegmatis 
using the reporter systems developed, revealed that RIF did not affect the promoter activity. 
The induction of Rv1258c in only some MDR clinical isolates and a H37Rv RIF mono-
resistant mutant of M. tuberculosis, but not in others was observed following RIF exposure 
(Siddiqi et al., 2004; Gupta et al., 2006; Jiang et al., 2008; Louw et al., 2011). The lack of 
induction in this study may be due to several reasons. Firstly, induction upon RIF exposure 
might depend on the strain used and therefore be a phenotype of that specific strain as 
suggested by the aforementioned studies in M. tuberculosis. Secondly, the concentration of 
the RIF used (10 μg/ml) might not have been high enough to induce Rv1258c efflux pump 
expression in the rpoB mutants with such a high RIF MIC (125 -200 μg/ml). A RIF 
concentration of 10 µg/ml was chosen since it was higher than the RIF MIC for the wild-type 
strain, but this may not be sufficient. M. smegmatis has intrinsic resistance to RIF and two 
mechanisms have been implicated in this resistance. One mechanism is the inactivation of 
RIF by rybosylation that occurs in M. smegmatis, but not M. tuberculosis. Cloning of the 
gene that is responsible for rybosylation into a related organism, conferred low-level RIF 
resistance and disruption of the gene in M. smegmatis increased susceptibility to RIF. This 






MsRbpA is a protein that is present in M. smegmatis and has homologues in other 
actinomycetes including M. tuberculosis (RbpA), M. leprae and Streptomyces coelicolor 
(Newell et al., 2006; Dey et al., 2010). This protein was shown to interact with and bind to 
the RNA polymerase in M. smegmatis and S. coelicolor. It was suggested that the MsRbpA 
protein (from M. smegmatis) and RbpA (from S. coelicolor) might protect or modify the 
RNA polymerase thereby preventing the effects of RIF (Newell et al., 2006; Dey et al., 
2010). Overexpression of MsRbpA in M. smegmatis increased RIF resistance in otherwise 
RIF sensitive strains, while deletion of the S. coelicolor homologue rbpA, increased its 
sensitivity to RIF and rbpA was essential for growth. The MsRbpA protein and its homologue 
RbpA is thus involved in low-level RIF resistance in M. smegmatis and S. coelicolor.  
M. tuberculosis RbpA was suggested to act as a transcriptional activator by affecting the 
RNA polymerase structure and in the process increasing its affinity for the sigma factor A 
thereby facilitating transcription even in the presence of RIF. RbpA thus indirectly 
contributes to the RIF resistance in M. tuberculosis as well (Hu et al., 2012). The intrinsic 
resistance of M. smegmatis may therefore mean that a much higher RIF concentration is 
required to induce Rv1258c expression. 
 
Thirdly, although M. smegmatis is a useful model organism its utility may be limited due to 
differences between this fast-growing non-pathogenic organism and M. tuberculosis. Since 
the Rv1258c homologue in M. smegmatis, MSMEG_5033, is a pseudogene the regulation of 
Rv1258c may not be conserved in this organism and therefore the expression of the Rv1258c 
promoter in M. smegmatis might not be representative of expression of the Rv1258c promoter 
in M. tuberculosis. In addition, the slight differences in the RNA polymerase of M. smegmatis 
may alter its effect on the M. tuberculosis promoter. In conclusion, while the analysis of the 
M. tuberculosis Rv1258c promoter activity in M. smegmatis was useful to evaluate the 
functionality of the episomal and integrating vectors for the subsequent promoter reporter 
studies in M. tuberculosis and providing an idea of what could be expected in  





CHAPTER 6: EFFECT OF RPOB MUTATIONS ON RV1258C PROMOTER 




RNA polymerase can regulate gene expression not only at the gene‟s promoter operator site, 
but also at their transcriptional termination site or attenuator. Mutations in rpoB have been 
shown to affect transcriptional termination negatively (Yanofsky & Horn, 1981). Expression 
of the tryptophan (trp) operon in E. coli in rpoB mutants was altered because the mutations 
somehow influenced RpoB‟s recognition of the transcriptional terminator and caused either 
increased or decreased expression of trp (Yanofsky & Horn, 1981). Mutations in rpoB, 
causing amino acid substitutions not associated with RIF resistance in E. coli was also shown 
to alter transcriptional pausing and termination (Landick et al., 1990). This indicates how 
rpoB mutations affect the expression of genes through its effect of transcriptional 
termination.  
 
Mutations in rpoB do not only affect transcription by influencing transcriptional termination, 
but also by altering DNA supercoiling (Drlica et al., 1988). In bacteria, DNA supercoiling is 
controlled by DNA gyrase, causing negative supercoils, and DNA topoisomerase, which 
modulates negative supercoiling by gyrase. DNA supercoiling affects transcription. 
Mutations in gyrB cause DNA relaxation. Mutations in the rpoB gene caused a reduced DNA 
relaxation in the gyrB mutant, indicating how RNA polymerase can alter DNA supercoiling 
and thus possibly also transcription (Drlica et al., 1988). 
 
Mutations in rpoB caused defective transcription of the gene encoding the sigma subunit of 
RNA polymerase in E. coli (Zhou & Jin, 1997). Since sigma factors bind to the core of RNA 
polymerase consisting of three subunits including the β-subunit, and this complex then 
recognizes and binds to specific promoter, transcription of other genes would presumably 
also be influenced by defective transcription of the gene encoding the sigma factor and thus 
by rpoB mutations (Zhou & Jin, 1997).  
 
Similarly to M. tuberculosis, numerous mutations in rpoB have been identified which lead to 
RIF resitance in B. subtilis spores as well as vegetative cells. The S487L mutation 




mutation in B. subtilis spores (Nicholson & Maughan, 2002). Besides from the RIF resistance 
phenotype associated with the rpoB mutations in B. subtilis, each rpoB mutation differentially 
affected gene expression and had their own unique effect on growth rate in various media, 
substrate utilization patterns, the expression of competence for transformation, sporulation 
frequency, sporulation efficiency, spore resistance to heat and chemicals and germination 
(Maughan et al., 2004; Perkins & Nicholson, 2008; Moeller et al., 2012).  
 
In S. lividans, rpoB mutations are also associated with RIF resistance. S. lividans produces 
antibiotics including actinorhodin (Act), undecylprodigiosin (Red), methylenomycin and 
calcium-dependent antibiotic (CDA). Act, Red and CDA biosynthesis are induced in the 
presence of rpoB mutations depending on the position of the rpoB mutation and the amino 
acid substitution caused (Hu et al., 2002). Mutations in rpoB enhanced Act production in  
S. coelicolor. Interestingly, the presence of other mutations conferring streptomycin and 
gentamicin resistance respectively also increase the production of Act and a combination of 
mutations conferring resistance to all three drugs have an additive effect on Act production 
(Hu & Ochi, 2001). The rpoB mutations thus affect transcription of numerous genes involved 
in many different processes. 
 
It is tempting to speculate that the effects of rpoB mutations are not limited to those 
discussed, but are also felt at many other levels in bacteria, as it forms part of RNA 
polymerase that is responsible for transcription and gene regulation. In line with this 
argument, rpoB mutations in M. tuberculosis are generally associated with a fitness cost 
under certain conditions, depending on the rpoB mutation and strain (Mariam et al., 2004; 
Gagneux, 2009). However, the S531L and H526Y mutations were associated with a low 
fitness cost in in vitro generated rpoB mutants under the conditions tested (Gagneux, 2009).  
 
RIF binds to RpoB and forms a stable drug-enzyme complex and directly blocks the RNA 
transcript elongation when the transcript is just two to three nucleotides long, thereby 
inhibiting gene transcription (Campbell et al., 2001; Johnson et al., 2006). The effects of RIF 
on Rv1258c expression in some strains lead us to hypothesise that the rpoB mutations present 









6.2.1 Selection of spontaneous M. tuberculosis H37Rv rpoB mutants 
 
M. tuberculosis H37Rv spontaneous in vitro rpoB mutants were selected as described by 
(Morlock et al., 2000), which is an adaptation of the fluctuation test originally designed by 
Luria & Delbrück (1943). According to the Morlock et al. (2000) method, a M. tuberculosis 
H37Rv starter culture was cultured to an OD of approximately 0.80 and diluted 100 000 
times in 7H9 supplemented with 10% OADC (Sigma-Aldrich) (7H9 OADC) to 
approximately 10
3
 colony forming units (CFU)/ml. It was pre-determined that the 
concentration of the culture would be approximately 10
8
 CFU/ml at a culture OD of 0.80 at 
600 nm. Aliquots (5 ml) of this low density culture was aliquoted into 100 flasks. These 
cultures were incubated at 37°C for 28 days with daily shaking, allowing the cultures to reach 
a high density in order to obtain spontaneous RIF resistance mutations. The 5 ml cultures 
were then transferred into 50 ml conical tubes and pelleted by centrifugation at 3,220 ×g for  
3 min. The supernatant was discarded and the pellet was re-suspended in 0.5% Tween 80. 
After centrifugation at 3,220 ×g for 3 min at room temperature, the pellet resuspended in 1.0 
ml of the supernatant. A 100 µl aliquot was then plated onto 7H10 supplemented with 10% 
OADC containing 2 µg/ml RIF in order to select for RIF resistant mutants. After four weeks 
incubation at 37°C, two colonies were picked from each plate and inoculated into 7H9 ADC. 
Stocks were prepared for each of the 200 cultures and an aliquot of each culture (200 µl) was 
boiled to be used for PCR.  
 
A 437 bp region containing the RRDR was amplified using the rpoBFor and rpoBRev 
primers (Table 3.4). The HotStarTaq DNA Polymerase kit (Qiagen) was used. Each 25 µl 
reaction contained 1x PCR buffer, 400 µM dNTPs, 1 mM MgCl2, 0.5 µM rpoFor and 
rpoBRev, 0.75 U HotStarTaq DNA Polymerase and 2 µl of boiled culture. The run protocol 
was as follows: initial denaturation and enzyme activation at 95°C, followed by three sets of 
2 cycles each of denaturing at 94°C, elongation at 72°C, 71°C and 70°C respectively and 
annealing at 72°C, followed by 40 cycles of denaturation at 94 °C, annealing at 69°C and 
elongation at 72°C, followed by a final 10 min elongation at 72°C. The PCR product (5 µl) 
was loaded onto a gel to determine whether amplification was successful. The PCR product 




rpoBFor primer in order to determine whether mutations occurred within the rpoB gene and if 
so, which mutations.  
 
6.2.2 Determining the MIC for the rpoB mutants 
 
The MIC for the M. tuberculosis H37Rv rpoB mutants was determined using the automated 
BACTEC MGIT 960 instrument (BD Biosciences) according to the manufacturer‟s 
instructions. M. tuberculosis freezer stocks (200 µl) were inoculated into MGIT tubes 
supplemented with 10% OADC. The culture was incubated in the MGIT instrument at 37°C 
until a positive growth reading was reached, then incubated for a further two days at 37°C. A 
1:100 dilution of the culture in sterile saline was prepared and 500 µl of this dilution was 
inoculated into a new MGIT tube. This MGIT culture would serve as the growth control. The 
undiluted MGIT culture (500 µl) was inoculated into MGIT tubes containing a range of RIF 
concentrations (50 – 200 µg/ml). The MGIT cultures were placed in a BACTEC MGIT 960 
instrument and EpiCentre (version 5.75A) TBeXist software (BD Bioscience) was used to 
monitor the culture growth for approximately 14 days and to analyse the data generated by 
the MGIT 960 instrument. 
 
6.2.3 β-galactosidase assays to determine loss of integrating vector  
 
M. tuberculosis H37Rv wild-type and rpoB mutant strains were transformed with the 
integrating vector systems. Pre-cultures of M. tuberculosis H37Rv wild-type and rpoB mutant 
strains transformed with the integrating vector systems were cultured in 7H9 ADC containing 
the selectable antibiotic, hygromycin. The pre-cultures were sub-cultured into 7H9 ADC 
containing no hygromycin to a starting OD of 0.05 at 600 nm. WCLs were prepared as 
previously described at early log growth phase and after further one and seven days. The 
protein concentrations of the WCLs were determined and β-galactosidase assays done as 
previously described. 
 
6.2.4 Growth curve analysis of transformed M. tuberculosis  
 
Growth curves were generated for all the M. tuberculosis H37Rv wild-type and mutant 
strains harbouring the integrating vectors. Pre-cultures were cultured in 7H9 ADC containing 




7H9 ADC not containing any selectable drug to an OD of 0.05 at 600 nm. The OD at 600 nm 
was measured every day for 14 days using a Novaspec II visible spectrophotometer (LKB). 
The same M. tuberculosis cultures that were used for the β-galactosidase non-exposure 
experiments were used for the growth curves (in other words, the culture volume gradually 
decreased as volumes of the culture were removed for WCL preparation and RNA 
extraction). 
 
6.2.5 Promoter activity in the absence of rifampicin 
 
The effect of rpoB mutations on Rv1258c expression was determined by comparing Rv1258c 
expression in M. tuberculosis H37Rv wild-type attB::pMV306promolacZ, M. tuberculosis 
H37Rv rpoB S531L attB::pMV306promolacZ and M. tuberculosis H37Rv rpoB H526Y 
attB::pMV306promolacZ. The background expression level of lacZ was also determined in 
the strains transformed with the pMV306lacZ vector. Pre-cultures were cultured in 7H9 ADC 
containing the appropriate selectable drug, hygromycin. The pre-cultures were sub-cultured 
into 80 ml 7H9 ADC not containing any selectable drug to an OD of 0.05 at 600 nm. At an 
OD between 0.6 to 0.75 WCLs were prepared (0 hours) as well as 24 hours later (24 hours) 
later. The protein concentrations of the WCLs were determined and β-galactosidase assays 
done.  
 
6.2.6 Promoter activity in response to rifampicin 
 
Each pre-culture of M. tuberculosis H37Rv S531L and H526Y rpoB mutants harbouring the 
integrating vectors were sub-cultured into two separate 80 ml cultures. After culturing to 
early log-phase, one of the two cultures for each strain was exposed to RIF (2 μg/ml) while 
the other culture was exposed to DMSO (diluent of RIF). Exposure to DMSO was done to 
determine the RIF-specific response. The secondary container for the RIF exposed cultures 
was covered with tinfoil in order to prevent any light from entering since RIF is light 
sensitive. WCLs were prepared for both the exposed and unexposed cultures after 1, 2 and 24 
hours of RIF exposure. The protein concentrations of the WCLs were determined and 








The effect of rpoB mutations on Rv1258c expression was investigated using β-galactosidase 
assays in M. tuberculosis rpoB mutants in the absence and presence of RIF.  
 
6.3.1 Selection of spontaneous M. tuberculosis H37Rv rpoB mutants 
 
M. tuberculosis H37Rv spontaneous in vitro rpoB mutants were selected in order to compare 
the influence of rpoB mutations on Rv1258c expression in mutants which presumably only 
have a SNP in rpoB. A range of rpoB mutations were present among the 94 mutant colonies 
picked and the mutations as well as their distribution are indicated in Fig 6.1. The mutation 
that occurred most frequently are the H526Y (27.7%) mutation followed by the H526R 
(23.4%) and H526D (17%) mutations. S531L mutants occurred at a frequency of 9.6%. 
 
 
Figure 6.1. The frequency of spontaneous in vitro generated rpoB mutants. 
 
6.3.2 Determining the MIC for the rpoB mutants 
 
A S531L and H526Y rpoB mutant was chosen from the library of mutants generated. The 




subsequent studies with the level of RIF resistance observed for the mutants. The growth 
units (GU) of the RIF exposed MGIT cultures were compared to that of the growth control. 
At the time at which the growth control reached a GU of above 400, the GU of the drug 
containing tubes were compared and if the latter was more than or equal to 100, the strain 
would be considered resistant at that specific drug concentration. If the GU at a drug 
concentration was less than 100, incubation was prolonged for another 7 days, until the 
growth control reaches a GU of more than 400. If the GU was still less than 100 after 7 days, 
the strain was considered as sensitive to that drug concentration. If the GU increased to 400 
within 7 days, the strain was considered intermediately resistant at the specific drug 
concentration.  
 
The growth control for the S531L mutant only started to come up at 12 days and 22 hours, 
and had not reached a GU of above 400 yet at this time point (Fig 6.2). The GU of the drug 
containing cultures were however still compared to that of the growth control at this stage, 
since it is not advisable to go beyond 14 days when examining the MIC using this system. At 
this point, the GU for the 50 µg/ml and 100 µg/ml RIF exposed cultures were above 400, 
indicating that the S531L mutant was resistant at these RIF concentrations. After 12 days and 
22 hours of exposure, the GU of the 150 µg/ml RIF exposed culture started to increase  
(Fig 6.2). The S531L mutant was thus resistant to 100 µg/ml RIF, and intermediately resistant 




Figure 6.2. MGIT 960 eXIST Plot of GU measured over days for the S531L mutant. The 
light blue line represents 50 µg/ml RIF, dark grey line represents 100 µg/ml, maroon line 





and 200 µg/ml. From Fig 6.3 it can be seen that the GU was more than 400 for the 50 µg/ml, 
100 µg/ml, 150 µg/ml and 200 µg/ml H526Y RIF exposed culture at the time when the 
growth control reached a GU above 400. This means that the H526Y mutant was resistant to 
all these RIF concentrations and has a MIC of equal to or above 200 µg/ml. 
 
6.3.3 β-galactosidase assays to determine loss of integrating vector  
 
Since integrating vectors systems are more stable than episomal vectors, the vector may be 
maintained in the absence of the selectable antibiotic, hygromycin. In order to assess the 




Figure 6.3. MGIT 960 eXIST Plot of GU measured over days for the H526Y mutant. 
The light blue line represents 50 µg/ml RIF, dark grey line represents 100 µg/ml, maroon line 
represents 150 µg/ml, green line represents 200 µg/ml and the dark blue line represents the 
growth control. 
 
Rv1258c promoter activity was compared between M. tuberculosis H37Rv 
attB::pMV306promolacZ cultured in the absence and presence of hygromycin. WCLs were 
prepared and β-galactosidase assays done in order to monitor the loss of the integrating 
vector when culturing in the absence of hygromycin. Rv1258c promoter expression levels 
were monitored using β-galactosidase assays and served as an indicator of the presence of the 
integrating vector and thus of the loss of integrating vector. The Rv1258c promoter 
expression levels were comparable in the cultures exposed to hygromycin and those that were 





(Fig 6.4). There was only a slightly lower expression of Rv1258c promoter in the absence as 
compared to in the presence of hygromycin after 7 days of culturing (Fig 6.4).  
 
However, only one experiment was done. The results obtained for this experiment suggested 
that there was no loss of integrating vector when culturing was done in the absence of the 
selectable antibiotic, hygromycin, on day 0 and 1. The culturing of M. tuberculosis 
transformed with the integrating vector was subsequently done in the presence of hygromycin 
for the pre-culture and upon sub-culturing in the absence of hygromycin. 
 
 
Figure 6.4. Comparison of Rv1258c promoter activity in the absence and presence of 
hygromycin, to monitor the loss of the pMV306promolacZ vector. Day 0 represents the 
OD of between 0.60 and 0.70 (early log phase) at which point WCLs for β-galactosidase 
assays would be prepared. Day 1 and Day 7 represent 1 and 7 days thereafter. The β-
galactosidase values represent only one experiment. 
 
6.3.4 Growth curve analysis of transformed M. tuberculosis  
 
Growth curves were generated for the M. tuberculosis wild-type and rpoB mutants 
harbouring the integrating vectors. This was done in order to determine if the presence of the 
vectors influenced the growth of the bacteria, the effects of the rpoB mutations on the growth 
of the M. tuberculosis rpoB mutant and the OD at which the log growth phase was reached 
(since the WCLs for the β-galactosidase assays would be prepared at early log phase). No 




although the H526Y mutant tended to grow slower than the wild-type and S531L mutant 
tended to grow faster than the wild-type during log growth phase. The cultures entered log 
phase at an OD of approximately 0.60 to 0.75. 
 
6.3.5 Promoter activity in the absence of rifampicin 
 
The effect of rpoB mutations on Rv1258c expression was determined by comparing Rv1258c 
promoter activity in M. tuberculosis H37Rv wild-type and S531L and H526Y rpoB mutants 
harbouring the integrating vectors at early log growth phase as well as 24 hours thereafter. 
 
Figure 6.5. Growth curves for M. tuberculosis wild-type and rpoB mutants harbouring 
the integrating vectors. Pre-cultures were cultured in the presence of hygromycin and 
hygromycin was omitted upon sub-culturing. The values represent the average of three 
independent experiments and error bars represent standard deviation. 
 
Rv1258c promoter activity of the strains transformed with pMV306lacZ indicates the 
background activity in the absence of a promoter. This background activity was negligible 
(Fig 6.6) as expected since there is a transcriptional terminator upstream of the lacZ gene in 
the pMV306lacZ vector. Rv1258c promoter activity in the integrating vector transformed 
S531L mutant was significantly lower at approximately half of that of the wild-type, while 
Rv1258c promoter activity in the H526Y mutant was significantly higher at approximately 
double that of wild-type. There was an approximately four fold difference in Rv1258c 




early log phase culture (0 hours) (at culture OD of between 0.6 and 0.75) and 24 hours 
thereafter, were comparable (Fig 6.6). 
 
 
Figure 6.6. β-galactosidase activity of the M. tuberculosis H37Rv wild-type and S531L 
and H526Y rpoB mutants harbouring integrating vectors at (A) early log phase (0 
hours) and (B) 24 hours thereafter (24 hours). The β-galactosidase value represents the 
average of three independent experiments and error bars represent standard deviation. 
Significant differences in Rv1258c promoter expression are indicated by p<0.05 (*), p<0.01 



















6.3.6 Promoter activity in response to rifampicin 
 
In order to determine the effect of RIF on Rv1258c expression, M. tuberculosis S531L and 
H526Y rpoB mutants harbouring the integrating vectors were cultured to early log phase and 
exposed to 2 μg/ml RIF. WCLs were prepared after 1, 2 and 24 hours of RIF exposure and 
Rv1258c expression examined using β-galactosidase assays. RIF did not affect Rv1258c 
promoter activity in the either of the rpoB mutants at 1, 2 or 24 hours of RIF exposure. As 
expected, RIF did not affect the expression of the promoterless integrating vector, 
pMV306lacZ at 1, 2 or 24 hours of exposure (results not shown). 
 
 
Figure 6.7. Effect of RIF on the Rv1258c promoter activity after 1, 2 and 24 hours of 
RIF (10 µg/ml) exposure for rpoB mutants harbouring the pMV306promolacZ vector. 
The unexposed culture was exposed to DMSO (diluent of RIF). The β-galactosidase values 





The M. tuberculosis H37Rv rpoB mutations which occurred most frequently in this study 
were the H526Y (27.7%) mutation followed by the H526R (23.4%) and H526D (17%) 




observed that the H526Y mutation occurred more frequently than the S531L mutant in 
another smaller in-house library of another strain of M. tuberculosis H37Rv rpoB mutants. In 
fact, no S531L mutant could be found among the rpoB mutants in the previous library while 
multiple H526Y mutants were present. Huitric et al. (2006) investigated the frequencies of 
spontaneous rpoB mutations in the RRDR in vitro in M. tuberculosis with a Beijing and non-
Beijing genotype and observed the S531L mutation most frequently, followed by the H526Y 
mutation. The S531L, D516V and H526D mutations were the most frequently occurring rpoB 
mutations in Latvian isolates of MDR M. tuberculosis (Tracevska et al., 2002). In Syrian  
M. tuberculosis clinical isolates the S531L mutation also occurred most frequently (Madania 
et al., 2012). Interestingly, from the above studies the S531L mutant appears to occur more 
frequently in the clinical setting than the H526Y mutant. This is hypothesized to be due to the 
lower fitness cost associated with the S531L mutation which had no fitness cost in some 
clinical isolates (Gagneux, 2009). The S531L mutant was also associated with the lowest 
fitness cost in laboratory derived mutants of two different pan-susceptible M. tuberculosis 
strains (Gagneux, 2009). The fitness cost for the H526Y mutant was also low in the 
laboratory derived mutant, but not as low as the S531L mutant (Gagneux, 2009).  
 
It is not clear why the mutation distribution in this study differed from previous observations. 
The fitness cost associated with the rpoB mutation was determined to be dependent not only 
on the type of rpoB mutation, but also on the strains genetic background (Gagneux, 2009). 
This could explain why the distribution of rpoB mutants was different in this study. There 
may also have been a bias in the colony selection. No novel mutations were discovered as all 
the mutations observed had been recorded before (Telenti et al., 1993). Interestingly, for the 
integrating vector transformed strains, the H526Y mutant had a tendency to grow slower than 
the wild-type indicating a slight fitness cost under culturing conditions. The S531L mutant 
tended to grow faster than the wild-type although there were no real differences in the growth 
of the wild-type and S531L and H526Y rpoB mutants (Fig 6.5). This seems contradicting to 
the frequency of the mutants since fitness cost in terms of growth of the S531L mutant 
seemed to be lower than that of the H526Y mutant. This could be because of different growth 
conditions on 7H10 OADC media containing RIF (2 µg/ml) during selection of mutants and 
in 7H9 ADC in the absence of RIF when culturing the mutants. 
 
The RIF MIC for the S531L and H526Y mutants were between 150 and 200 μg/ml and equal 




mutations are associated with high-level resistance in M. tuberculosis clinical isolates with a 
Beijing and non-Beijing genotype (Huitric et al., 2006), in M. tuberculosis clinical isolates 
from Western Japan (Ohno et al., 1996) and in clinical isolates from Poland (Zaczek et al., 
2009). The H526Y mutation was associated with high level resistance in the M. tuberculosis 
clinical isolates from Western Japan, as these mutations were not frequently observed in the 
other two studies (Ohno et al., 1996). Even though the H526Y mutant occurred much less 
frequently in the clinical setting, possibly due to a slight fitness cost in the human host, it was 
still associated with high-level RIF resistance. Bahrmand et al. (2009) also showed that 
multiple rpoB mutations correlated specifically with codons 531 and 526 and are associated 
with high level RIF resistance in secondary infection cases. 
 
It was determined that the integrating vector was stably maintained in the absence of the 
selectable antibiotic, hygromycin for the duration of the culturing that would be done for 
subsequent β-galactosidase assays. This eliminates hygromycin as a possible factor 
influencing Rv1258c promoter activity. Rv1258c expression differs significantly between 
different rpoB mutants. The Rv1258c promoter activity for the S531L mutant was 
approximately half of that of the wild-type while the promoter activity for the H526Y mutant 
was approximately double that of the wild-type. Mutations in the rpoB gene has been shown 
to alter transcriptional termination (Yanofsky & Horn, 1981) and DNA supercoiling (Drlica 
et al., 1988) and cause defects in transcription the sigma subunit of RNA polymerase in  
E. coli (Zhou & Jin, 1997) and in the process alter gene expression.. Besides from the RIF 
resistance phenotype associated with the rpoB mutations in B. subtilis, each rpoB mutation 
differentially affected gene expression and had their own unique effect on phenotype 
(Maughan et al., 2004; Perkins & Nicholson, 2008; Moeller et al., 2012). The rpoB mutations 
also affected antibiotic production in S. lividans and S. coelicolor (Hu & Ochi, 2001; Hu et 
al., 2002). Some of these affects might also be present in other bacteria including M. 
tuberculosis together with other unknown effects of rpoB mutations on gene expression (as 
this has not been studied extensively in M. tuberculosis). The mutation in rpoB could change 
the structure of the RNA polymerase that in turn could changes the binding of the RNA 
polymerase to the promoter regions. It is possible that binding of RNA polymerase to 
different transcription factors involved in the expression of Rv1258c are influenced to a 
different extent by the S531L and H526Y mutations causing differential expression of the 





The MIC for the H526Y mutant was slightly higher than that of the S531L mutant while the 
expression levels of Rv1258c was much higher (approximately four times) in the H526Y 
mutant than that observed for the S531L mutant. It is therefore possible that Rv1258c could 
be a contributor to the higher MIC observed in the H526Y mutant. In,  
C. jejuni ciprofloxacin, nalidoxic acid and enrofloxacin resistance was associated with gyrA 
mutations as well as the expression of the cmeABC gene encoding an efflux pump. Upon 
inactivation of the CmeABC efflux pump there were differences in the fold reduction in 
ciprofloxacin, nalidoxic acid and enrofloxacin resistance between different gyrA mutants. 
Interestingly, there were also differences in the fold reduction in ciprofloxacin MIC in 
isolates with the same gyrA mutations. This indicates that not only the mutations themselves 
play a role in the level of efflux pump expression and contribution to the MIC, but other 
mutations in the genome might also influences the expression levels of efflux pumps (Luo et 
al., 2003).  
 
The contribution of efflux to fluoroquinolone resistance for different ofloxacin resistant 
clinical isolates of M. tuberculosis with different gyrA mutations conferring ofloxacin 
resistance was investigated by Singh et al. (2011). The fold decrease in MIC for ofloxacin 
was investigated in the presence of efflux pump inhibitors. The contribution of efflux to the 
level of resistance differed between different gyrA mutants, suggesting that there may be 
differential efflux pump expression in different gyrA mutants. However, there were also 
differences observed in the MIC in the presence of efflux pump inhibitors between clinical 
isolates with the same gyrA mutations, indicating that other mechanisms are also involved  
(Singh et al., 2011). These studies support the hypothesis that efflux pumps contribute to 
resistance in the presence of mutations in target genes. It is therefore plausible to suggest that 
the differential expression of Rv1258c observed in this study for the S531L and H526Y 
mutants may have an influence on the MIC for RIF in these strains. It is possible that efflux 
might contribute to a different extent to RIF resistance associated with the S531L and H526Y 
mutants. 
 
Although it was assumed that the only mutations present in the in vitro generated mutants 
were the rpoB mutations, there is always a possibility that other mutations could have 
occurred concurrently elsewhere in the genome during the selection, culturing and 
transformation of the rpoB mutants. It has been observed in our group that random single 




makes this assumption flawed in some ways. It was for this reason that sub-culturing was 
minimalized during the preparation of the tranformants. Whole genome sequencing would 
need to be done in order to prove that no other mutations had occurred which could possibly 
be implicated in the different Rv1258c promoter activity levels. However, had spontaneous 
mutants occurred which influenced the results of this study; it is highly unlikely that the same 
spontaneous mutations occurred in both the M. smegmatis and M. tuberculosis mutants and 
transformants. The results obtained for both M. smegmatis and M. tuberculosis were highly 
comparable and it is for this reason highly unlikely that some spontaneous SNP other than the 
SNP in rpoB, occurring elsewhere in the genome, is the cause of the differences in Rv1258c 
expression levels in the S531L and H526Y mutants. 
 
Exposure of the S531L and H526Y mutants to critical concentration of RIF did not affect 
Rv1258c expression in either of the rpoB mutants. Increased expression of Rv1258c was 
previously observed in an in vitro generated M. tuberculosis H37Rv RIF mono-resistant 
mutant (Sharma et al., 2010). It is important to note that there were significant differences 
between the aforementioned study and this study. 
 
In the Sharma et al. (2010) study, a M. tuberculosis H37Rv spontaneous RIF resistant mutant 
was selected on 2 μg/ml RIF and the MIC for the RIF resistant strain was determined to be 
128 μg/ml. The MIC for the sensitive parental strain was determined to be 0.25 μg/ml. The 
sensitive strain and the RIF resistant strain were cultured in the presence of RIF at a 
concentration of one fourth of their respective RIF MIC until mid-log phase, whereas in this 
study the mutants were cultured to early log phase and RIF added at that stage. Therefore the 
concentration of RIF to which the resistant mutant was exposed to was higher and the 
duration of exposure to RIF longer as compared to the current study. 
 
It is possible that in this study, the time allowed for exposure to RIF was not sufficient to 
induce Rv1258c expression. However, in a study done to determine the rate of accumulation 
of RIF (C
14
 at 2 μg/ml) by M. tuberculosis, a steady state concentration of 154 μg/ml RIF was 
reached in the cells after only one to 2 min of RIF exposure. This steady state concentration 
was maintained over the next 20 min (Piddock et al., 2000). This suggests that the RIF would 
have been present in the cells within minutes of exposure. It seems unlikely that the bacteria 
would only induce efflux pump expression after several days of exposure to a foreign 




exposure might be too late to counter any negative effects that RIF might have even on RIF 
resistant strains. It has been suggested that the efflux pumps might serve as one of the first 
mechanisms of resistance and provide the bacteria with sufficient time to acquire drug 
resistance mutations, which presumably is an immediate response. This however may not be 
the case in strains already containing a RIF resistance mutation. It is thus still unclear why 
Rv1258c promoter expression was not upregulated in this study after hours of RIF exposure 
or why it was upregulated in the Sharma et al. (2010) study after days of RIF exposure. 
 
It was previously shown that there was an increase in the concentration of RIF accumulated 
within the cells upon exposure to an increased concentration of RIF (C
14
) in M. tuberculosis 
(Piddock et al., 2000). Thus, it is possible that the accumulated RIF at 2 μg/ml RIF was not 
sufficient to induce Rv1258c expression, possibly because of the high RIF MIC for the 
mutants used in this study. In M. tuberculosis MDR clinical isolates efflux pump inhibitors 
reserpine and verapamil restored RIF susceptibility. However, in RIF pan-susceptible  
M. tuberculosis clinical isolates the RIF resistance was not changed by the addition of efflux 
pump inhibitors reserpine and verapamil. This suggests that efflux pumps which are active in 
the resistant strains (and are targeted by reserpine and verapamil) are not active in the pan-
susceptible strain (Louw et al. 2011). This indicates a possible role of the level of RIF a strain 
is able to tolerate (RIF pan-susceptible versus RIF resistant) in the induction of pumps, since 
the mechanism may be related to the toxic effects of RIF on the cell. It would be interesting 
to observe the effects of adding a concentration of RIF of approximately one fourth of the 
MIC for the S531L and H526Y mutants and observing whether Rv1258c is induced. We 
chose to use 2 µg/ml in this study since it is a clinically relevant concentration while one 
fourth of the MIC of the mutants is not since such high concentrations of RIF would never be 
reached in a clinical setting. However, it was suggested that RIF is rapidly removed by efflux 
from the cell upon RIF exposure and that a high RIF concentration (higher than critical 
concentration of 2 µg/ml) is thus needed for binding of the mutant RpoB to RIF to occur and 
thus for RIF to have its effects (Louw et al., 2011).  
 
Several studies using clinical isolates of M. tuberculosis showed induction of Rv1258c 
following exposure to RIF. Gupta et al. (2006) showed that Rv1258c expression was 
increased to the same extent upon exposure to RIF (1 μg/ml), isoniazid, streptomycin, 
ofloxacin and ethambutol in clinical isolates. These isolates were cultured to early log phase 




expression was assessed (Gupta et al., 2006). Unfortunately, the RIF MICs for the strains 
used were not provided in the article. 
 
Rv1258c expression was also increased upon exposure to RIF and ofloxacin in the  
M. tuberculosis clinical isolate ICC154. ICC154 is resistant to RIF (MIC equal to 40 μg/ml), 
ofloxacin (MIC equal to 4 μg/ml), isoniazid (MIC equal to 2 μg/ml) and minomycin (MIC 
equal to 2μg/ml). The isolate was cultured in the presence of sub-lethal concentrations of one 
fourth the MIC for RIF and ofloxacin respectively. RNA was extracted and Rv1258c 
expression examined. There was a 10 fold increase in Rv1258c expression in the presence of 
RIF and six fold increase in the presence of ofloxacin (Siddiqi et al., 2004). Rv1258c 
expression was also increased upon RIF and INH exposure in the M. tuberculosis multidrug-
resistant strain 1499. The 1499 strain harboured mutations in rpoB (S531L) and katG genes 
and had a MIC of 6.4 μg/ml for RIF and 102.4 μg/ml for INH (Jiang et al., 2008). The strain 
was also cultured in the presence of one fourth of the RIF and INH MIC respectively. 
Rv1258c expression was increased three fold in the presence of RIF and six fold in the 
presence of INH (Jiang et al., 2008). 
 
Another possible explanation for the lack of upregulation following RIF exposure is that it is 
related to differences in the MIC of the isolates. However, upon knocking out the Rv1258c 
gene in M. tuberculosis H37Rv RIF resistant strain, there was no decrease in MIC observed 
for the knockout when compared to that of the wild-type strain (Villellas, 2012). This 
indicates that Rv1258c was not contributing to the MIC for RIF in the particular H37Rv RIF 
resistant strain used in that study. In the aforementioned Siddiqi et al. (2004) and Jiang et al. 
(2008) studies, where up-regulation was observed, the MICs were relatively low at 40 μg/ml 
and 6.4 μg/ml respectively. Furthermore, Rv1258c was shown to only be upregulated in 
Beijing strains with low level RIF resistance and not those with high resistance level RIF 
resistance (Louw et al., 2011). It is therefore possible that the concentration of RIF which a 
strain can tolerate affects the ability of RIF to induce Rv1258c expression. This would 
suggest induction of Rv1258c is due to a general stress response to the presence of the 
“foreign” RIF molecule. Strains with a higher RIF MIC would therefore require a higher RIF 
concentration to induce this stress response. This hypothesis is supported by the observation 
by Gupta et al. (2006) that several drugs were able to induce this Rv1258c, presumably by a 




constitutive expression of Rv1258c, which cannot be further induced in response to RIF 
exposure. 
 
Interestingly, the Tap efflux pump (an Rv1258c homologue) in M. bovis was shown to fulfil 
physiological functions during stationary growth (Ramón-García et al., 2012). Kyselková et 
al. (2012) compared the presence of tetracycline resistance and tetracycline resistance genes 
including the gene encoding the Tap efflux pump, in soil mycobacteria to that of the 
clinically resistant mycobacteria. The Tap efflux pump was shown to be present in both soil 
mycobacteria and clinically relevant mycobacteria and was present in both drug resistant and 
non-resistant mycobacterial species indicating a possible role of Tap in intrinsic tetracycline 
resistance (Kyselková et al., 2012). These studies suggest a physiological role of Rv1258c in  
M. tuberculosis. Overexpression of MFS efflux pumps for which the energy source is 
provided by a proton gradient, could cause the accidental loss of important metabolites and 
loss of membrane potential, which could ultimately lead to cell death (Nikaido, 1998; 
Grkovic et al., 2002). These are reasons why the expression of Rv1258c would need to be 
tightly regulated and could explain why further upregulation of Rv1258c following exposure 
to a low RIF concentration in a strain which has a high MIC does not occur. 
 
It is also possible that the strains in which upregulation is observed share a common, 
unknown mechanism which is responsible for regulating Rv1258c expression in response to 
RIF, not present in the strains used in this study or in other strains in which upregulation was 
not observed. It would be of interest to whole genome sequence both H37Rv strains, the one 
used in this study and the one used in the Sharma et al. (2010) study, which could have 
different SNPs elsewhere in the genome to see which SNPs are present and could possibly 
help explain why these two H37Rv strains responded differently to exposure to RIF. The 
upregulation in Rv1258c expression in some genetically clustered strains, but not in others 
could be explained by other SNPs present in the strains. 
 
When examining the genes upregulated upon exposure to critical concentration (2 μg/ml) of 
RIF, Rv1258c expression was upregulated in strains with a low copy clade genotype which 
have both low and high levels of RIF resistance respectively and in strains with a Beijing 
genotype and low level RIF resistance (Louw et al., 2011). However, Rv1258c expression 
was not upregulated upon RIF exposure in the strains with a Beijing genotype and high level 




expression, you would expect to see difference in the expression in the absence of RIF as 
well as differences in the response of the strains to the exposure to RIF in terms of Rv1258c 
expression. The other SNPs present in the strains could possibly explain why Rv1258c was 
not upregulated upon exposure to RIF in this study while it was upregulated in another M. 
tuberculosis H37Rv strain upon exposure to RIF in the Sharma et al. (2010) study and in the 
multidrug resistant clinical isolates.  
 
The presence of rpoB mutations affects Rv1258c promoter expression in M. tuberculosis with 
a lower expression observed in the S531L mutant and higher expression in the H526Y 





CHAPTER 7: DO β-GALACTOSIDASE ASSAYS REPRESENT RV1258C 
 TRANSCRIPT LEVELS AND WHAT IS THE EFFECT OF RPOB 




Promoter activity assays are a convenient way for determining conditions which influence 
gene expression. We wanted to determine whether Rv1258c promoter activity observed using 
the promoter reporter assays correlated to the transcript levels of the native intact Rv1258c 
gene. qRT-PCR to determine the native Rv1258c gene transcript levels in the wild-type and 
rpoB mutants of M. tuberculosis was done. 
 
Comparison of gene expression between samples by qRT-PCR requires a reference gene to 
which expression is normalized, to correct for variation in the amount of RNA in each 
sample. The sigma factor A (sigA) gene was chosen as a reference gene because the  
M. tuberculosis SigA is presumably the principal sigma factor, as the sigA homologue of  
M. smegmatis has been determined to be indispensable (Gomez et al., 1998). It has also been 
shown that the sigA gene is constitutively expressed under most of the conditions tested by 
Manganelli et al. (1999). The sigA gene has also been used before in the literature as a 
housekeeping gene in studies which examined Rv1258c expression with qRT-PCR (Sharma 
et al., 2010) and the gene encoding the Tap efflux pump (a Rv1258c homologue) in M. bovis 
BCG (Ramón-García et al., 2012). Other genes such as Rv1437 (encoding phosphoglycerate 
kinase) and 16S rRNA have also been used as housekeeping genes when studying Rv1258c 
expression (Siddiqi et al., 2004; Jiang et al., 2008). Also, the sigA gene has been used as 
housekeeping gene before to study differences in gene expression between M. tuberculosis 
wild-type and a rpoB mutant strain (Bisson et al., 2012). The sigA gene has also been used 
before in the literature as housekeeping gene when investigating whiB7 expression (Morris et 
al., 2005; Geiman et al., 2006). 
 
As a second aim of the project we wanted to determine the effects of the rpoB mutations on 
the expression of whiB7. As discussed in the literature review, whiB7 encodes a global 
transcriptional regulator (WhiB7). The expression of Rv1258c was found to be dependent on 




whiB7 gene expression was induced in the presence of drugs such as kanamycin, cycloserine 




7.2.1 RNA extraction and RNA concentration determination 
 
During preparation of WCLs for the β-galactosidase assays, RNA was simultaneously 
extracted from the M. tuberculosis H37Rv wild-type and rpoB mutants harbouring the 
pMV306promolacZ vector cultures at the 24 hour time point using the RNA ProBlue kit. 
Two RNA extractions were done in parallel from each culture. 
 
The Experion RNA StdSens Analysis kit (Bio-Rad) was used to determine the RNA 
concentration and purity according to the manufacturer‟s instruction. Briefly, the kit reagents 
(RNA stain, RNA loading buffer and RNA gel) were equilibrated to room temperature and 
the RNA gel was filtered. The Experion electrode was cleaned with electrode cleaner 
followed by two rinsing steps with water. RNA stain (1 µl) was added to filtered gel (65 µl) 
and will subsequently be called the gel stain solution. The chip was primed with gel stain 
solution. The gel stain solution, filtered gel and loading buffer were loaded into the wells of 
the chip. The RNA samples (2 µl) and the RNA ladder (2 µl) were denatured for 2 min at  
70°C and placed on ice immediately afterwards. RNA samples and RNA ladder were loaded 
into the appropriate wells. The chip was vortexed for 10 seconds and placed in the Experion 
electrophoresis station (Bio-Rad). Experion software (Bio-Rad) was used for analysis. 
 
7.2.2 cDNA synthesis 
 
Reverse transcription was done using three gene specific primers that reverse transcribe sigA, 
Rv1258c and whiB7 using the MTB-sigA-RT, Rv1258c-RT and whiB7-RT primers 
respectively (Table 3.4). cDNA synthesis was carried out using the Transcriptor First Strand 
cDNA Synthesis kit (Roche Applied Sciences) according to the manufacturer‟s instructions. 
Firstly, RNA (1,500 µg) was added to a final concentration of 2 µM of each of the MTB-
sigA-RT, Rv1258c-RT and whiB7-RT primers and made up to a final volume of 13 µl with 
water. The RNA primer mix was denatured for 10 min at 65°C in a heated thermal block 




inhibitor (20 U), dNTP (final concentration of 1 mM each) and transcriptor reverse 
transcriptase (10 U) were added (making the total volume of each cDNA synthesis reaction 
20 µl). After mixing, the samples were incubated at 55°C for 30 min in a thermal block 
cycler. Inactivation of the enzyme was done by incubating at 85°C for 5 min. The cDNA was 
stored at -20°C until later use for qRT-PCR.  
 
7.2.3 DNA dilutions for standard curve 
 
Genomic DNA from the M. tuberculosis H37Rv Sasetti strain was provided by M. Williams. 
The concentration of the DNA was determined using the Nanodrop and gel quantification. In 
order to prepare a standard curve, a dilution was made with a final concentration of 10
7
  
M. tuberculosis genome copies per 2 µl. The concentration of DNA that represents 107  
M. tuberculosis genome copies per 2 µl was determined as illustrated in Addendum C. The 
dilution of 10
7









The FastStart Universal SYBR Green Master (Rox) kit (Roche Applied Sciences) was used 
for qRT-PCR according to the manufacturer‟s instructions. The standard curve method for 
relative quantification of Rv1258c and whiB7 expression relative to the sigA gene was used. 
Three mixes, each containing the set of primers for one of the genes were prepared. The final 
mixes contained: 1× FastStart Universal SYBR Green Master (Rox) mix, 300 nM forward 
and reverse primers (MTB-sigA-F1 and MTB-sigA-R1 or Rv1258c-F1 and Rv1258c-R1 or 
whiB7-F1 and whiB7-R1) in a total reaction volume of 50 µl. 
 
The reaction mixes were prepared and aliquoted into a MicroAmp® Optical 96-Well 
Reaction Plate (100 µl) (Applied Biosystems) and the wells were closed with strip caps 
(Applied Biosystems). The plate was covered with paper towel and kept on ice until used. 
The genomic DNA (10
7





). This dilution range was previously determined to fit onto the linear 
range. The cDNA samples were defrosted on ice. Dilutions (tenfold and 100 fold) of the 
cDNA were also prepared in order to ensure that the samples‟ cycle threshold (Ct) values 




cDNA (2 µl) were added to their respective wells. Each sample was read in technical 
duplicate. Three independent experiments representing three biological replicates were done. 
Melting curve analysis was also done. 
 
The qRT-PCR was done on an Applied Biosystems StepOnePlus Real-Time PCR machine 
(Applied Biosystems) and using the StepOne software (Applied Biosystems). The run 
protocol was as follows: Activation of FastStart Taq DNA polymerase for 10 min at 95 °C, 
followed by 40 cycles of denaturation for 15 s at 95 °C and annealing and elongation at 61 °C 
for 60 s. The Ct values of the DNA dilution series was plotted against the log genome copy 
number for the sigA, Rv1258c and whiB7 genes. A trend line was set to the values which fall 
within the linear range for each gene. The gradient of the trend line was used to determine the 
log copy number using the average Ct values of each of the technical duplicate cDNA 
samples. The copy number was determined from the log copy number. The copy numbers 
determined for the Rv1258c and whiB7 genes were divided by the copy numbers of sigA in 
the same sample. The results for three independent experiments or biological triplicates were 
averaged and the standard deviation determined. The expression levels of Rv1258c and 
whiB7 normalised to sigA expression were compared between the wild-type, S531L and 




The levels of the native Rv1258c gene expression at transcript level were compared between 
the wild-type and rpoB mutants using qRT-PCR in order to determine whether the results 
obtained during β-galactosidase assays were representative of the abundance of native gene 
transcripts. The effects of rpoB mutations on whiB7 expression were also determined using 
qRT-PCR. 
 
7.3.1 RNA concentration determination using Experion RNA StdSens Analysis kit 
 
Since the RNA concentration determined using the Nanodrop might not be accurate, the RNA 
concentration and purity was determined using the Experion RNA StdSens analysis kit (Bio-















Figure 7.1. Representative Experion RNA gel. Lane (1) RNA ladder, lanes (2-7) 




The expression of sigA in the wild-type and rpoB mutants was investigated first in order to 
determine whether the expression of sigA between the strains were comparable and could be 
used as housekeeping gene. There was no difference in the sigA transcript copy numbers 
between the wild-type and rpoB mutants (Table 7.1). This means that sigA could be used as 
housekeeping gene. 
 
Table 7.1. Number of transcript copies of sigA in the wild-type and rpoB mutants. The 
values represent the average of three independent experiments ± standard deviation. 
Strain Transcript copies of sigA 
Wild-type 352,175±217,374 
rpoB S531L mutant 323,936±130,614 
rpoB H526Y mutant 381,921±117,149 
 
The innate Rv1258c gene expression at transcript level was investigated using qRT-PCR. The 
expression levels of whiB7 were also investigated using qRT-PCR in order to determine the 
















The differences in Rv1258c expression was not significant but was only marginal with a 
similar trend to those seen with the promoter reporter studies. The S531L mutant showed 
marginally lower expression and H526Y mutant marginally higher expression than the wild-
type. Expression of whiB7 in the rpoB mutants did not differ significantly from those 
observed for the wild-type. However, whiB7 expression did show a similar trend to the trend 
observed in Rv1258c transcript levels and promoter activity, as the expression tended to be 
lower in the S531L mutant and higher in the H526Y mutant compared to the wild-type. The 
expression of whiB7 in the S531L mutant was significantly lower than that of the H526Y 
mutant (p=0.0129).  
 
Table 7.2. The relative expression levels of Rv1258c and whiB7 relative to sigA in the 
pMV306promolacZ transformed M. tuberculosis H37Rv wild-type and rpoB mutant 
strains. The values represent the average of three independent experiments ± standard 
deviation. Significant differences in expression are indicated by * representing p<0.05. 
  Expression levels of transcript relative to sigA 
Strain Rv1258c whiB7 
Wild-type 0.59±0.24 1.00±0.19 
rpoB S531L mutant 0.56±0.27 0.71±0.04 




Although differences were not significant, Rv1258c transcript expression followed the same 
trend as those obtained for the β-galactosidase assay as there was a marginally lower Rv1258c 
transcript level in the S531L mutant than in the wild-type while the Rv1258c transcript level 
was marginally higher in the H526Y mutant. The differences in Rv1258c expression levels 
appeared to be much bigger (significant differences observed) when measured as promoter 
activity in β-galactosidase assays than it appeared at transcript level during qRT-PCR (no 
significant differences observed). This could be because any small differences in expression 
are amplified in the β-galactosidase assays because of the nature of the assays. The use of β-
galactosidase assays could thus be advantageous in that any small differences in expression 






seemingly large difference observed during β-galactosidase assays might not actually 
represent a biologically significant difference in Rv1258c expression. 
 
Furthermore, whether the difference observed in the Rv1258c promoter expression between 
the rpoB mutants and wild-type during β-galactosidase assays are biologically significant is 
unknown. In order to determine whether the differences in Rv1258c expression between the 
rpoB mutants are biologically significant, one would need to prove that Rv1258c activity is 
decreased in the S531L mutant while Rv1258c activity is increased in the H526Y mutant. 
Doing this would however be impossible, as the activity of Rv1258c alone cannot be 
measured in a system where other efflux pumps are also present.  
 
It might be possible that the expression levels at promoter activity level for the Rv1258c 
promoter region fused to lacZ is not comparable to that of the native Rv1258c gene 
transcripts since the genes are in different contexts. It is also possible that mutating rpoB 
could change the structure of RpoB, which in turn could affect transcription of multiple 
genes. Differential expression of multiple genes could in turn affect the physiological state of 
the mutants, which in turn could indirectly alter the expression or regulation of Rv1258c. 
 
When comparing the transcript levels of whiB7 no significant difference between the wild-
type and rpoB mutants were observed. A similar trend to that observed for Rv1258c transcript 
levels and promoter activity was however observed as expression in the S531L mutant was 
lower and in the H526Y mutant was higher than that of the wild-type. Rv1258c expression 
might be altered by the differential expression levels of whiB7. The exact mechanism of this 






CONCLUSIONS AND FUTURE STUDIES 
 
During these past few years it has become clear that drug resistance in TB is more 
complicated than originally thought. It is generally believed that mutations in rpoB are 
associated with RIF resistance. However, there is now compelling evidence that efflux also 
plays an important role in determining the level of RIF resistance. The relationship between 
these mechanisms is not well understood. In this study it was hypothesised that rpoB 
mutations affect the expression of the Rv1258c efflux pump and the whiB7 gene. 
 
Promoter reporter assays are an established method for studying gene expression and we have 
taken advantage of this to investigate the effects of rpoB mutations on Rv1258c expression. 
The promoter region of Rv1258c was successfully cloned into an episomal vector and 
integrating vectors were also successfully constructed. The determined position of the 
transcriptional start site of Rv1258c, at six base pairs upstream of the annotated start codon, 
was questioned due to the apparent lack of a ribosomal binding site. As a future study, the 
vectors constructed in this study could be used to determine or confirm the position of the 
transcriptional start site determined in this study. This would involve mutagenesis of the 
Rv1258c promoter region which has been cloned into the reporter construct and from the 
promoter activity observed for the vector deducting whether the transcriptional start site is 
present or not. 
 
Mutations in the rpoB gene cause altered Rv1258c promoter activity in M. tuberculosis 
H37Rv in vitro generated mutants. No significant difference in Rv1258c and whiB7 transcript 
levels were however observed even though the same trend in expression as observed for the 
β-galactosidase assays was present. Whether the difference in Rv1258c expression between 
wild-type and rpoB mutants is biologically significant, remains to be determined. 
 
It is possible that the expression levels at promoter activity level for the Rv1258c promoter 
region fused to lacZ is not comparable to that of the native Rv1258c gene transcripts since the 
genes are in different contexts. It would therefore be interesting to examine the transcript and 
protein levels of the Rv1258c promoter fused to lacZ and see whether there are differences at 
transcript or protein level between the wild-type and rpoB mutants. It would also be 
interesting to determine and characterize the regulator of Rv1258c in order to understand the 




Exposure of the M. smegmatis and M. tuberculosis rpoB mutants to sub-inhibitory levels of 
RIF did not affect Rv1258c promoter activity. RIF does not affect the expression of Rv1258c 
in M. smegmatis possibly due to other mechanisms of resistance to RIF present in  
M. smegmatis or the RIF concentration not being high enough to induce Rv1258c expression 
in the M. smegmatis rpoB mutants. It is also possible that the concentration of RIF used  
(2 µg/ml) was not high enough to induce the expression of Rv1258c in M. tuberculosis since 
the MICs for the mutants were already so high. Alternatively, the expression of Rv1258c was 
already maximal and was thus not further induced.  
 
It is also possible that the MIC of the strain influences the induction of Rv1258c. The effects 
of RIF MIC on Rv1258c expression should be investigated. This could be done by using rpoB 
mutants which have the same rpoB mutation and no other difference in SNPs, but different 
MICs and comparing Rv1258c expression levels. Rv1258c expression levels should also be 
investigated in other rpoB mutants generated in this study to determine how other rpoB 
mutations affect Rv1258c expression. This will help establish a relationship between the type 
of rpoB mutation and the level of Rv1258c expression. 
 
The contribution of efflux, specifically Rv1258c expression, to the RIF MIC in the  
M. tuberculosis S531L and H526Y mutants could be assessed by adding efflux pump 
inhibitors to the MGIT cultures and determining the change in MIC. This would indicate 
whether efflux pumps contribute to a greater extent to the drug resistance (MIC) in the 
H526Y mutant than in the S531L mutant. The limitation of this approach is that there are 
many other MFS efflux pumps that might also be responsible for efflux of RIF, which will 
also be influenced by adding an efflux pump inhibitor. 
 
It might also be possible that the time of exposure to RIF was not sufficient for induction of 
the Rv1258c promoter activity and that Rv1258c expression at different RIF exposure time 
points should have been investigated. It would be interesting to monitor Rv1258c expression 
at different exposure times ranging from min to hours to days of RIF exposure. This would 
help to show whether the time of exposure to RIF influences the expression of the Rv1258c 
efflux pump.  
 
Since in previous studies Rv1258c was only upregulated upon exposure to RIF in some in 




others, the effects of other SNPs on Rv1258c expression also needs to be investigated. To do 
this Rv1258c expression levels between strains with different SNPs can be compared using 
the β-galactosidase assays as used in this study. The constructs generated in this study could 
provide a valuable tool for studying the expression of Rv1258c under various conditions and 
in various strains. However, one would need to be cautious when interpreting the results of β-
galactosidase assays since a seemingly big difference in Rv1258c expression might not be 
biologically significant.  
 
With drug resistance being such a major problem worldwide, new drug targets such as efflux 
pumps are needed. Efflux pumps are promising targets. When considering efflux pumps as 
targets for treatment, it needs to be taken into consideration that the expression of efflux 
pumps could be different because of differences in rpoB mutations present in drug resistant 
strains. With the increased occurrence of drug resistant M. tuberculosis, fighting back by 
using a combination of different mechanisms to acquire resistance, it is compulsory that we 
understand these mechanisms as well as their interconnectedness. This could provide us with 





SHORTCOMINGS OF THIS RESEARCH 
 
The position of the transcriptional start site for Rv1258c could not be definitely determined in 
the 5‟ RACE experiments done. This leads to uncertainty as to whether the promoter region 
cloned into the vectors contained the Rv1258c transcriptional start site. However, during the 
experiment there was an increase in β-galactosidase activity in the promoter region 
containing vectors, and this increase was different for the two rpoB mutants in both  
M. smegmatis and M. tuberculosis, which indicates that a promoter was present in the 
promoter region amplified from M. tuberculosis H37Rv. It was however questioned whether 
the promoter region was in fact that of the Rv1258c gene. To this we counter argue based on 
the layout of the genes surrounding the Rv1258c gene, the promoter region of Rv1258c 
should be present somewhere upstream of this gene and this gene is the only gene in the 
vicinity on the reverse strand. 
 
The lacZ gene and promoter fused to the lacZ gene were cloned into the integrating vector in 
a reverse orientation. These vectors were used in this study. Vectors in which the lacZ and 
promoter fused to lacZ gene were cloned co-directionally with the hygromycin cassette of the 
vector should also have been isolated and used in parallel to determine the influence of other 
vector elements on promoter activity. 
 
Since variation in the protocol and media might be present between different laboratories 
when determining the MIC of strains and a specific RIF MIC was not determined for the  
M. smegmatis mc2155 rpoB mutants (RIF MIC was determined to be somewhere between 
125 and 250 µg/ml), the RIF MIC for these strains should have been determined again in our 
laboratory. This would enable a more specific comparison of the RIF MIC of the  
M. smegmatis mc2155 rpoB mutants and could provide more information on a possible 
relationship between RIF MIC and Rv1258c expression. 
 
When investigating the growth of the transformed rpoB mutant strains in M. smegmatis and 
M. tuberculosis the measurement of colony forming units would have provided a more sound 
measure of growth than measuring OD, as was done in this study. The OD is not necessarily 
an indication of whether the bacteria are alive and culturable while the amount of colony 





The M. tuberculosis H37Rv wild-type strain and mutants generated in this study were not 
whole-genome sequenced. This leaves the possibility of other SNPs that might be present in 
the genome affecting the experimental results. 
 
Since the RIF MIC for the M. smegmatis and M. tuberculosis rpoB mutants were high, the 
effect of a few more concentrations of RIF (in addition to the 10 and 2 µg/ml RIF used 
respectively in this study) on Rv1258c expression should have been tested. The effect of 
different RIF concentrations on Rv1258c expression and whether different RIF concentrations 
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Determining the position of Rv1258c transcriptional start site using 5’ RACE: 
alignment results 
 
The position of the transcriptional start site was determined by doing 5‟ RACE using gene 
specific primers for the lacZ gene in the pJEM15promo vector and sequencing the product 
obtained. The alignment of the 5‟ RACE product to part of the pJEM15promo vector 
sequence is shown in Fig A1. The position of the transcriptional start site would be present 
immediately downstream of the polyT-tail of the oligo d(T)-anchor primer (Fig 4.1). The 
oligo d(T)-anchor primer and RACE2 SP3 primer are indicated in green (Fig A1; Table 3.4). 
The position of the transcriptional start of Rv1258c site is indicated in red (Fig A1) 
Transcriptional starts from an adenine (A) residue. The region from the immediately 
upstream of the start codon of Rv1258c up to the transcriptional start site (six nucleotides) is 
indicated in light blue (ATATTC) (Fig A1). The Asp718 cutting site (GGTACC) which is 
present in the pRv1258cpF primer used for the initial amplification of the Rv1258c gene 
(Table 3.4), is indicated in purple (Fig A1) and present immediately upstream of the Rv1258c 
promoter region as expected. The start codon of lacZ is indicated in orange and the lacZ 
fusion protein start codon in pink (Fig A1). 
 






Determining the protein concentration to be used for calculating the β-galactosidase 
activity 
 
The kinetic curve for M. smegmatis mc2155 rpoB H526Y (pJEM15promo) at a protein 
concentration of 19.2 µg/ml starts to flatten out 50 min into the enzyme reaction and reaches 
saturation at 55 min (Fig B.1A). The time points from 50 min onward for the 19.2 ng/µl 
protein concentration could thus not be used for the determining the promoter activity. When 
looking at the kinetic curve for the 4.8 ng/µl protein concentration, the readings at this protein 
concentration were still very low (Fig B.1C). The 9.6 µg/ml protein concentration kinetic 
curve was therefore chosen and the time point of 35 min as the enzyme reaction was not 
saturated yet at this time point (Fig B.1B). The same principal was used for the M. smegmatis 
strains transformed with the pMV306 integrating vectors and the protein concentration of  
153.6 µg/ml and 35 min exposure of the enzyme (β-galactosidase) to the substrate ONPG was 
chosen as the appropriate protein concentration and time point for calculating the β-
galactosidase activity (in Miller units) (kinetic curves not shown). Upon examining kinetic 
curves for M. tuberculosis, a protein concentration of 87.5 µg/ml was chosen for calculating 
the β-galactosidase value for the wild-type and S531L mutant and 43.75 µg/ml for the H526Y 







Figure B1. Kinetic curves for β-galactosidase assays in pJEM15 transformed  
M. smegmatis over time exposed to the substrate ONPG at a WCL concentration of (A) 









Figure B2. Kinetic curves of β-galactosidase over time exposed to the substrate ONPG 









Calculation of genomic DNA concentration to use for qRT-PCR 
 
The following calculations were done in order to determine the concentration of genomic 
DNA that represents a final concentration of 10
7
 M. tuberculosis genomes per 2 µl. This 
DNA would be used for the generation of a standard curve during subsequent qRT-PCR 
experiments. 
The M. tuberculosis genome size is 4,411,529 bp. The average weight of a bp is 650 Dalton. 
The molecular weight of one M. tuberculosis genome is thus 
                                               . 
This means that                                        
Thus 1 µg of genomic DNA =           genomes 
 
Therefore the weight of each genome is: 
                                            
 
A concentration of 10
7
 genomes per 2 µl was needed for the qRT-PCR experiment. 
                                             
Thus, 46.49 µg/ml in a total volume of 1 000 µl = 10
7
genome/µl 
A concentration of 23.25 µg/ml = 10
7
 genomes/2 µl. 
The genomic DNA was diluted to 23.25 µg/ml and this was aliquoted and used for 
preparation of the dilution range which was used to generate a standard curve.  
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